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The Polyomaviridae are a family of viruses which have several lifecycle requirements 
that have been poorly studied.  However, association of these viruses with disease in 
an immunocompromised host has been well documented.  The 2008 discovery of 
Merkel cell polyomavirus (MCPyV) as the causative agent in Merkel cell carcinoma 
(MCC) represented the first link of polyomavirus infection to cancer in humans.  
Further research identified the requirements of a truncation in the large tumour 
antigen (LT) and clonal integration of mutated viral genomes into the host genome.  
Despite truncation of LT being essential to MCPyV-positive MCC, the small tumour 
antigen (ST) has been implicated as the major oncogene that transforms the host cell 
and promotes several phenotypes associated with cancer. 
Previous publications in the Whitehouse laboratory have identified the requirement 
of ST in stimulating events that contribute to the highly metastatic nature of virus 
induced MCC.  ST facilitates microtubule destabilisation and filamentation of actin to 
prime the cellular cytoskeleton for movement, however despite identifying the 
essential interaction with the protein phosphatase 4 catalytic subunit (PP4C), the 
molecular mechanisms through which these changes are brought about have not 
been fully investigated.  In Chapter 5, we describe how ST activates the p38 mitogen-
activated protein kinase (MAPK) in a manner that is dependent upon PP4C 
perturbation.  Using chemical inhibitors, the activity of p38 is shown to be essential 
to the ability of ST to induce migratory phenotypes both in naïve cells and MCPyV-
positive MCC cell lines.  Therefore, we provide evidence of cellular mechanisms 
dysregulated by MCPyV ST to promote metastatic phenotypes, which may provide 
novel therapeutic targets to restrict MCC spread and improve patient prognoses. 
Intriguingly, MCPyV expresses only one minor capsid protein (VP) that is 
incorporated into the capsid, whilst the majority of polyomaviruses encode VP2 and 
VP3 which are both packaged.  Early events in the polyomavirus lifecycle are poorly 
understood in part due to lack of suitable systems.  In Chapter 3, we therefore 
produced new reporter systems, using MCPyV pseudoviruses to study events during 
entry and trafficking, and in Chapter 4 focus upon the role of ion channels.  




Ca2+ and K+ channels for MCPyV and a conserved broad Ca2+ channel dependency for 
both species.  This study highlights clinically available drugs that could potentially be 
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1.1.1 An introduction to polyomaviruses 
The Polyomaviridae is a family of small, non-enveloped viruses that package a circular 
double-stranded DNA (dsDNA) genome of approximately 5 kbp.  The family is 
composed of 4 genera with restricted host range and infect mammals, birds and fish.  
Polyomaviridae infections are generally acquired early in life, persistent and 
asymptomatic, however for a small number of polyomaviruses potentially life-
threatening diseases have been attributed to clinical manifestations in 
immunocompromised cohorts. 
The circular dsDNA genome of polyomaviruses (PyVs) can be split into three distinct 
regions: the non-coding control region (NCCR) which contains the origin of 
replication (Ori), the early transcript region which is alternatively spliced to produce 
the functional tumour antigens and the late transcript region which gives rise to the 
capsid proteins and, in some instances, additional auxiliary proteins. 
Polyomavirus virions are non-enveloped and typically around 45 nm in diameter.  The 
capsid itself is icosahedral and made up of 72 major capsid protein pentamers.  Under 
each pentamer sits a minor capsid protein, which links the capsid to the enclosed 
genome. 
1.1.2 History of polyomaviruses 
The accidental discovery of Murine PyV (MuPyV) by Ludwik Gross was first reported 
in 1953, who noticed the growth of tumours in mice whilst working with mouse 
leukaemia virus (Gross, 1953; Gross, 1976).  The name polyomavirus arose from this 
observation, with ‘polyoma’ a reference to the virus’s ability to cause many (poly) 
tumours (oma). 
Simian Virus 40 (SV40) was next identified in 1959 as a contaminant of poliovirus 
vaccines that were cultured in Rhesus monkey renal cells (Hilleman, 1998). The 
administration of the contaminated Salk poliovirus vaccine to an estimated 100 
million people in the US between 1955 and 1963, coupled with evidence that not 
only could SV40 infect humans but cause tumour formation in experimental animals, 




tumour virus.  However, more recent epidemiological studies have suggested there 
has been no increased incidence of cancer caused by SV40, with no conclusive link 
between administration of the vaccine and increased frequency of disease (Shah, 
2007). 
The first polyomaviruses to be identified as causative agents of disease in a human 
host were BKPyV and JCPyV, both independently isolated from urine samples in the 
early 1970s (Gardner et al., 1971; Hogan et al., 1980).  Despite adult seroprevalence 
of 90% (BKPyV) and 50-80% (JCPyV), progression of disease within healthy individuals 
is low, with an asymptomatic, latent infection typically observed.  However, in the 
case of an immunocompromised host the outcome of disease can be potentially 
fatal; with BKPyV a causative agent of renal transplant rejection by polyomavirus 
associated-nephropathy and haemorrhagic cystitis in bone marrow recipients, and 
JCPyV a precursor to progressive multifocal leukoencephalopathy (Gardner et al., 
1971; Padgett et al., 1971; Siguier et al., 2012). 
The third human polyomavirus was not identified until 2007, with the discovery of 
Karolinska Institute PyV (KIPyV) following technological advances in screening and 
detection of viral genomes (Allander et al., 2007).  Since 2007 however there have 
been a significant number of further additions to the human polyomavirus family, 
that currently contains 14 known members, which are summarised in Table 1.1. 
Of the recently discovered members of the human polyomavirus family, MCPyV in 
particular has received much attention due to its association as the first polyomavirus 





Table 1.1: Summary of the known human polyomaviruses.  (Decaprio and Garcea, 2013; Mishra et al., 2014; Gheit et al., 2017)
Polyomavirus Abbreviation Genus Source of identification Year Known associated diseases 
BK BKPyV Beta Urine 1971 Haemorrhagic cystitis and PyV-associated nephropathy 
JC JCPyV Beta Brain tissue 1971 Progressive multifocal leukoencephalopathy 
Karolinska Institute KIPyV Beta Nasopharyngeal tissue 2007 None 
Washington University WUPyV Beta Nasopharyngeal tissue 2007 None 
Merkel cell MCPyV Alpha Lesions 2008 Merkel cell carcinoma 
Human PyV 6 HPyV6 Alpha Healthy skin 2010 None 
Human  PyV  7 HPyV7 Delta Blood and lung 2010 None 
Trichodysplasia spinulosa TSPyV Delta Lesions 2010 Trichodysplasia spinulosa 
Human  PyV  9 HPyV9 Alpha Serum and skin 2011 None 
Malawi PyV HPyV10 Delta Stool and skin 2012 WHIM syndrome 
Saint Louis SLPyV Delta Stool and skin warts 2013 None 
Human  PyV 12 HPyV12 Alpha Gastrointestinal tract 2013 None 
New Jersey NJPyV Alpha Pancreas 2014 None 
Lyon IARC PyV LIPyV N/A Skin 2017 None 




1.1.3 Classification of polyomaviruses 
The International Committee on Taxonomy of Viruses (ICTV) has remodelled the 
classification of PyVs several times due to the ever-expanding list of known species.  
The initial Papovaviridae genus that previously encompassed both polyomaviruses 
and papillomaviruses due to comparable structural features, was split into the 
Polyomaviridae and Papillomaviridae in 2004 to reflect differences in genomic 
organisation (Mayo, 2005).   
The Polyomaviridae was again revised in 2011 in response to a burst of newly 
discovered PyVs, which gave rise to three separate genera: Orthopolyomavirus,  
Wukipolyomavirus and Avipolyomavirus (Johne et al., 2011).  As the name suggests, 
the Avipolyomavirus genus grouped species of PyVs that infect birds, whilst those 
that infect mammals were split between the remaining two genera dependent upon 
sequence divergence of the VP1-coding gene. 
In 2016, the ICTV again revisited the classification of PyVs, introducing new taxonomy 
that is currently in use today (Moens et al., 2017).  This led to four genera: 
Alphapolyomaviruses, Betapolyomaviruses, Gammapolyomaviruses and 
Deltapolyomaviruses.  As with previous classifications, avian polyomaviruses were 
grouped together and are contained within the Gammapolyomavirus genus using 
Avian PyV 1 as the type species.  The Alpha, Beta and Delta genera were used to 
categorise mammalian polyomaviruses based on amino acid sequence similarity 
between the large tumour antigens (LTs) of different species, with MuPyV, SV40 and 
HPyV6 used as type species, respectively.  There are currently 80 recognised PyVs, 
with 77 classified into a genus. 
1.2 The lifecycle of a polyomavirus 
The general lifecycle of PyVs is overall conserved between species, however 
individual mechanistic variations and requirements likely give rise to altered 
tropisms.  Figure 1.1 shows an overview of a PyV lifecycle.  Typically, PyVs bind to the 
host cell through interactions with glycans, before endocytic internalisation into the 
endo/lysosomal network (Tsai et al., 2003).  The use of PyV capsids containing non-




penetrate into a range of cell types, which suggests that tropism is not ultimately 
dictated by the availability of initial binding residues, although it most likely has some 
impact (Nakanishi et al., 2008).  Following penetration, the virion is then trafficked in 
an endosome that becomes acidic, promoting proteolytic rearrangement of the 
capsid before arriving at the endoplasmic reticulum (ER) (Qian et al., 2009).  Within 
the ER further processing occurs before trafficking to the nucleus where the genome 
is released (Jiang et al., 2009). 
A single early transcript is initially synthesised in the nucleus, which is alternatively 
spliced into transcripts encoding functional tumour  antigens (TAgs) (Decaprio and 
Garcea, 2013).  All PyVs encode the large tumour antigen (LT) and small tumour 
antigen (ST), in addition some PyVs encode additional early proteins.  The TAgs are 
the functional proteins that interact with a range of host cellular proteins to perturb 
pathways and promote an environment that promotes virus propagation whilst 
avoiding immune detection. 
Upon sufficient production of TAgs, LT with support from ST interactions, forms a 
helicase that binds to the NCCR and unwinds the genome to initiate genome 
replication and expression of a late viral transcript (Foster and Simmons, 2010). 
The late transcript is alternatively spliced to give rise to a variety of mRNAs that 
encode proteins which vary between PyV family members.  In all PyVs the major viral 
capsid protein 1 (VP1) and minor viral capsid protein 2 (VP2) are expressed 
(Schowalter and Buck, 2013).  Some PyVs are however capable of producing an 
additional minor viral capsid protein termed VP3 and/or auxiliary proteins that are 
not incorporated into the capsid such as VP4 and the viroporin agnoprotein (Daniels 
et al., 2007; Baez et al., 2017). 
Within the nucleus, newly synthesised virus genomes recruit host cell histones in 
order to form chromatin-like complexes, which interact with capsid proteins to 
produce infectious progeny (Coca-Prados et al., 1982; Dekeyser et al., 2015).  
Assembled capsids are either trafficked to the cell membrane where they are 
released by non-lytic exocytosis or lytic mechanisms (Clayson et al., 1989; Daniels et 






1.3 Early stages of the polyomavirus lifecycle 
1.3.1 Attachment 
The initial interaction of PyVs with the host cell varies between species and most 
likely has some influence upon tropism.  The majority of PyVs attach to the cell 
through VP1 capsomere interaction with sialic acid residues of glycans.  MuPyV, 
BKPyV and JCPyV require sialic acids during entry, as treatment with neuraminidase 
prevented the ability to agglutinate red blood cells and infect cells (Neu et al., 2009).  
Similarly SV40 interacts with GM1 gangliosides, however some confusion arose due 
Figure 1.1: Schematic representation the general polyomavirus lifecycle.  (1) The 
polyomavirus enters the cell via endocytosis (2) before trafficking to the nucleus 
via the endo/lysosomal network and ER (3).  Upon entry to the nucleus, 
transcription of the early tumour antigens is performed (4, 5).  DNA replication (6) 
and transcription of the late structural proteins (7, 8) is then initiated.  Virions are 




to neuraminidase resistance of GM1 and an inability of the virus to agglutinate red 
blood cells due to narrow specificity (Miller-Podraza et al., 1982; Clayson et al., 1989).  
SV40 has further been reported to require MHC class I molecules (MHC-1) to permit 
entry (Norkin, 1999).  Reports show that SV40 initially binds to MHC-1 before 
complexes migrate to lipid rafts (Stang et al., 1997).  Following arrival at lipid rafts, 
MHC-1 is degraded by metalloproteinases before interaction with GM1 gangliosides 
(Anderson et al., 1998).  In contrast, sucrose flotation assays identified that BKPyV 
utilises GD1b and GT1b receptors for initial binding (Low et al., 2006).  JCPyV is an 
example of a PyV that requires a secondary interaction for entry.  Initial binding is to 
lactoseries tetrasaccharide c (LST-c) which contains a terminal 2,6-linked sialic acid 
(Neu et al., 2010).  Following sialic acid interaction there is a secondary interaction 
with the serotonin (5-hydroxytryptamine) 2A receptor (5-HT2AR) to permit entry 
(Elphick et al., 2004; Neu et al., 2010). 
A dual entry mechanism is also employed by MCPyV, whereby initial attachment is 
via a sulphated glycosaminoglycan such as heparan sulphate or chondroitin sulphate, 
before a secondary interaction with sialylated glycans facilitates entry (Schowalter et 
al., 2011). 
1.3.2 Penetration 
Following attachment, PyVs penetrate the cell by endocytosis, however the 
individual mechanisms can vary.  SV40, BKPyV and MCPyV penetrate cells via 
caveolar- and lipid raft-mediated mechanisms (Gilbert and Benjamin, 2000; Eash et 
al., 2004; Moriyama et al., 2007; Becker et al., 2019).  SV40 and MCPyV were further 
confirmed to require dynamin, a GTPase that is responsible for endocytosis.  JCPyV 
utilises an alternative clathrin-mediated endocytosis mechanism that requires -
arrestin, with suggestion that this altered phenotype may contribute to its ability to 
infect cells in the central nervous system (CNS) (Mayberry et al., 2019). 
1.3.3 Trafficking to the nucleus 
Similarly to all DNA viruses, PyV replication occurs within the nucleus.  However, 




virion to reveal and release the contained genome so that the host cellular machinery 
can be utilised for replication. 
Following endocytosis, PyVs enter into the endo/lysosomal network (Engel et al., 
2011).  PyVs such as SV40, MCPyV and BKPyV that are endocytosed by caveolae-
mediated mechanisms enter into caveosomes.  These are proposed to be endosomes 
that are coated in caveolin-1 following budding from the plasma membrane although 
this concept is controversial (Nichols, 2003; Moriyama et al., 2007).  JCPyV, on the 
other hand, is endocytosed in a clathrin-dependent manner and enters directly into 
early endosomes (Maru et al., 2017). 
For SV40, caveolar tyrosine kinases promote trafficking along the cytoskeleton to 
early endosomes through recruitment of actin and dynamin II in a manner assisted 
by Rab5 and Arf1 (Mercer et al., 2010; Engel et al., 2011).  The SV40 virion is retained 
in the maturing endosome, with increasing acidity observed as progression into late 
endosomes and eventually endo/lysosomes continues.  During this process it is 
believed that the virion undergoes rearrangements that make it more susceptible to 
further processing by cellular proteins (Kuksin and Norkin, 2012a).  Throughout these 
stages the virion maintains an interaction with the initial GM1 receptor used for 
penetration, which through an unknown mechanism mediates budding of the virion 
from the endo/lysosome to escape lysosomal enzyme degradation.  Virus containing 
vesicles are then trafficked to the ER independently of the trans-Golgi network (TGN) 
(Pelkmans et al., 2001; Engel et al., 2011).  Within the ER the virion is recognised by 
the ER associated degradation system (ERAD) as a misfolded protein.  In response to 
identification as misfolded, disulphide bonds that are required for VP1 pentamer 
stability are reduced by peptide disulphide isomerase and ER protein 57 exposing the 
previously contained VP2 and VP3 (Schelhaas et al., 2007).  The presentation of the 
hydrophobic N-terminus sequence of VP2 anchors the virion to the membrane of the 
ER and the partially degraded virion once reduced also interacts with the lumenal 
chaperone BiP to prevent aggregation (Nishikawa et al., 2001).  An essential 
interaction between glutamic acid residues at position 17 of exposed VP2 with 
positive charges of the third transmembrane domain of BAP31 and the homologous 




a platform through which the partially disassembled virion can pass into the 
cytoplasm. 
Following release from the ER the heavily degraded capsid is further destabilised by 
changes in physiological conditions, most notably low Ca2+ concentrations, and 
remaining VP1 pentamers are stripped away by cellular chaperones (Li et al., 2003; 
Kuksin and Norkin, 2012b).  This then presents C-terminal nuclear localisation signals 
(NLSs) located on VP2 and VP3, enabling an interaction with  / importins for 
translocation into the nucleus via the nuclear pore (Clever et al., 1993; Yamada and 
Kasamatsu, 1993; Nakanishi et al., 2002; Nakanishi et al., 2007). 
The trafficking events of BKPyV are less studied than that of SV40.  Given that entry 
mechanisms are conserved, it is unsurprising that inhibitor studies support 
comparable requirements to that of SV40, although it should be noted that the body 
of work relating to post penetration events in the lifecycle of BKPyV is much smaller 
(Bennett et al., 2012). 
MCPyV also enters the cell by caveolar-mediated endocytosis and Becker et al. 
observed similar requirements to that of SV40 and BKPyV during trafficking (Becker 
et al., 2019).  Interestingly, electron microscopy data in this study did however 
suggest that MCPyV virions may potentially acquire a lipid-membrane coat whilst in 
endosomal compartments.  How or why coating occurred was not investigated, 
however suggestions were made that this is potentially to avoid immune detection 
or simply an unknown aspect or variance from prototypic PyV infection. 
As previously stated, the entry of JCPyV differs to SV40, BKPyV and MCPyV in that 
endocytosis is clathrin dependent.  As is the norm with clathrin-mediated 
endocytosis, following penetration in clathrin-coated pits, JCPyV localises to Rab5-
positive early endosomes (Querbes et al., 2004).  However, during trafficking JCPyV 
does not appear to follow the canonical Rab5-endocytic route.  At later time points 
the virus fails to localise to Rab7-positive vesicles, which would be the natural 
progression into the endo/lysosomal network, but instead localises to cholera toxin 
B, a routine marker of caveolar/lipid raft-mediated endocytosis (Querbes et al., 




those previously described for SV40, BKPyV and MCPyV suggesting that post-
penetration, PyVs have comparable requirements for trafficking through the 
endo/lysosomal network, ER and nuclear entry (Ferenczy et al., 2012; Bennett et al., 
2012; Toscano and de Haan, 2018; Becker et al., 2019). 
1.4 The prototypic polyomavirus genome 
The circular genome of PyVs is made up of dsDNA and despite some slight variation 
between species is approximately 5 kbp in size.  The genomic organisation and 
structure of PyV genomes is overall comparable and a schematic representation of 
the prototypic SV40 genome is shown in Figure 1.2.  The genome has a bipartite 
composition with the early and late coding regions (ECR and LCR, respectively) 
encoded on opposing DNA strands (Cantalupo et al., 2017).  The 5’ ends of both the 
early and late coding regions are separated by the NCCR, which contains the origin 
of replication required to drive sequential gene expression. 
Following infection and trafficking to the nucleus, transcription of the ECR is initiated 
by RNA polymerase II, producing a single mRNA that is subsequently alternatively 
spliced to generate mRNAs that encode the TAgs (Spurgeon and Lambert, 2013).  All 
PyVs express LT and ST, which are responsible for priming the cell for replication and 
production of viral progeny.  Some PyVs, namely MCPyV, SLPyV and MuPyV, also 
encode additional early proteins that are alternatively spliced such as 57 kT, 229T 
and middle TAg (MT), respectively (Shuda et al., 2008; Lim et al., 2013).  There is 
however no current evidence of an equivalent to MuPyV MT encoded by other 
mammalian PyVs that has unique functionality (Zhou et al., 2011). 
Later during infection there is a switch in transcription, initiated by TAgs binding into 
and unwinding the NCCR, leading to expression of the LCR transcript alongside 
replication of the DNA genome.  Arguably the largest variation between genome 
organisation and expression profiles of PyVs relates to late proteins.  All PyVs have 
conserved expression of the structural VP1 and VP2 which appear to be the minimum 
requirement for a PyV to infect a cell, however beyond this, there can be many 




The prototypic SV40 produces the greatest number of proteins, with four ‘VPs’ and 
the additional auxiliary agnoprotein (Vilchez and Butel, 2004).  BKPyV and JCPyV both 
encode three VPs and agnoprotein, but do not express the non-structural VP4 
(Ferenczy et al., 2012; Panou et al., 2018).  At the more simple end of the spectrum 
lies MCPyV, which is a member of a clade of PyVs that only express VP1 and VP2 from 
















1.4.1 The genomic organisation of MCPyV 
The genome of MCPyV diverges quite significantly from the prototypic SV40.  
Through comparison of the genomic maps of SV40 (Figure 1.2) and MCPyV (Figure 
1.3) it can be noted that MCPyV encodes additional early, and fewer late proteins.  
Information regarding 57 kT is sparse, with knowledge that it shares interactions 
comparable to expressed domains of ST and LT, however it is not believed to have 
Figure 1.2: Schematic representation of the SV40 genome.  Shown is 
representation of the SV40 genome containing the non-coding control 
region (NCCR); the early proteins LT, ST and 17 kT; and the late proteins 









































additional functionality in a manner equivalent to MuPyV MT (Spurgeon and 
Lambert, 2013).  Another early protein is ALTO (Alternate frame of the Large T Open 
reading frame), which currently has no known function and is instead considered to 
be an early example of viral evolution (Carter et al., 2013). 
The LCR of MCPyV is more restricted in comparison to that of SV40, as only VP1 and 
VP2 are expressed.  The genome does not encode an agnoprotein or VP4.  There is a 
reading frame that is consistent with VP3, however the highly conserved N-terminal 
Met-Ala-Leu motif required for translation is lacking, leading to loss of expression 




Figure 1.3: Schematic representation of the MCPyV genome.  Shown 
is the non-coding control region (NCCR); the early proteins LT, ST, 57 
kT and ALTO (alternate frame of the LT open reading frame); and late 
proteins VP1 and VP2.  The location of the MCPyV precursor miRNA is 




1.5 Polyomavirus early proteins 
The expression of LT and ST is ubiquitous amongst PyVs and both are essential for 
manipulation of the host cell, to avoid apoptosis, create an environment that is 
favourable for viral replication and orchestrate the sequential steps of the lifecycle 
(Stakaityte et al., 2014).  As previously described, TAgs are produced from one 
transcript through alternative splicing and proteins in addition to LT and ST are 
produced by some PyVs.  An overview of the MCPyV ECR and protein variants is 
shown in Figure 1.4.  Both LT and ST share the first 75-80 amino acids at the N-
terminus encoded by the first exon (Decaprio and Garcea, 2013).  ST mRNA is 
produced by read-through of the first splice donor site into a unique region that is 
bypassed by LT.  A stop codon within the ST unique region, coupled with use of the 
LT splice acceptor leads to production of ST mRNA transcripts.  MCPyV is an example 
of a PyV that encodes an additional early protein, which is termed 57 kT.  This protein 
shares common features with LT, however additional splicing leads to the loss of a 
large portion of residues towards the C-terminus. 
 
Figure 1.4: Mapping of the MCPyV tumour antigens to highlight 
major known binding regions and splice sites.  The regions of the 
MCPyV ECR responsible for functional activity are shown in the context 
of the full gene alongside the LT, ST and 57 kT proteins that are 
expressed following alternative splicing.  Abbreviations annotated 
upon the schematic represent the DnaJ domain (J), retinoblastoma-
associated binding domain (LXCXE), threonine-proline-proline-lysine 
motif (TPPK), nuclear localisation signal (NLS), origin binding domain 
(OBD), helicase/ATPase domain (helicase), host range and adenovirus 




1.5.1 The large tumour antigen 
LT is a complex, multi-functional protein that has a range of activities within the cell.  
The ability of the protein to dysregulate the cell cycle to promote transformation led 
to a body of early work in SV40, however many of the functions remain conserved 
between species and are applicable in the context of HPyVs (Van Ghelue et al., 2012; 
An et al., 2012).  To this extent, PyV LTs share a wide range of common features 
including the DnaJ domain, origin-binding domain, zinc-binding domain and 
helicase/ATPase domain, the location of which are highlighted in Figure 1.4.  The 
ability of LT to dysregulate several aspects of the host cell lifecycle to promote viral 
replication is due to interaction with endogenous proteins, some of which are 










1.5.1.1 DnaJ domain 
The DnaJ domain of LT, which is also shared with ST, is responsible for binding to the 
cellular chaperone and transcriptional repressor heat shock chaperone 70 (HSC70).  
The DnaJ domain is essential for cellular transformation and viral replication in a 
range of PyVs (Berjanskii et al., 2000; Whalen et al., 2005; Kwun et al., 2009; An et 
al., 2012).  In addition to promoting viral replication, LT binding of HSC70 activates 
the chaperone’s ATPase activity, leading to the dissociation of pRb from its complex 
with E2F (Sheng et al., 1997; Harris et al., 1998).  In the case of the HPyVs BKPyV, 
JCPyV and MCPyV the DnaJ domain also contains a pentapeptide CR1 LXXLL motif, 
Figure 1.5: LT interactions with cellular proteins required to promote 
the viral lifecycle.  Highlighted are important protein interactions in 
the lifecycle of PyVs.  Interaction of hVam6P is unique to MCPyV which 




which is proposed to assist in pRb/E2F disruption in a manner comparable to 
adenovirus E1A (Yaciuk et al., 1991; Sheng et al., 1997; Spurgeon and Lambert, 2013). 
1.5.1.2 Retinoblastoma binding domain 
The retinoblastoma-associated protein (pRb) binding site (LXCXE) cooperates with 
the DnaJ domain to perturb pRb/E2F interactions to promote cell cycle progression 
(Stubdal et al., 1997).  Following HSC70-mediated pRb/E2F disruption, the LXCXE 
domain binds to the tumour suppressor pRb as well as the Rb related proteins p130 
and p107.  In turn this releases the transcription factor E2F to promote progression 











The majority of PyV LTs can also interact with Bub1 via a WXXWW motif that is 
conserved between species and located between the DnaJ domain and pRb binding 
motif (Cotsiki et al., 2004).  Bub1 is a serine-threonine protein kinase that acts as a 
mitotic checkpoint; however, it is believed that binding by LT leads to chromosomal 
instability.  Given that MCPyV is the only HPyV that is currently known to cause 
cancer in humans and that chromosomal instability is a hallmark of cancer, it is 
intriguing that the Bub1-binding motif is not present in the genome of MCPyV (Baez 
et al., 2017; Vargas-Rondón et al., 2018).  Instead, MCPyV contains the MCPyV TAg 






Figure 1.6: Schematic representation of LT disruption of the Rb/E2F 
complex.  LT destabilises p130 interaction with the transcription factor 
E2F before binding the former and sequestering its activity as a 
repressor of E2F.  E2F can then initiate transcription of genes 










nucleus (Liu et al., 2011).  This disrupts lysosomal clustering and is suggested to 
potentially contribute to egress of virions. 
The ability of SV40 LT to induce immortalisation and transformation of rodent cell 
lines was shown to require residues 69-83, which interact with Cullin 7 (CUL7) (Kasper 
et al., 2005).  CUL7 acts as a scaffold to organise an E3 ubiquitin ligase composed of 
FBXW8, Skp1 and the ROC1 RING finger protein (Hartmann et al., 2014).  Interaction 
of LT with CUL7 therefore prevents ligase activity responsible for insulin receptor 
substrate 1 (IRS1) degradation, promoting downstream signalling pathways that 
include phosphatidylinositol-3 kinase/protein kinase B (PI3K/Akt) and extracellular 
signal-related kinase (ERK) mitogen-activated pathway kinase (MAPK) (Hartmann et 
al., 2014). 
Despite latency being commonplace for viruses to avoid immune detection and await 
host conditions that are more suitable to propagation such as immunosuppression, 
little is known about how small DNA viruses facilitate long-term persistence.  
However, MCPyV LT contains several phosphorylation sites that are constitutively 
recognised by the cellular SCF E3 ubiquitin ligases FBXW7, Skp2 and TrCP to 
facilitate degradation of LT (Kwun et al., 2017).  In particular alanine mutation of S220 
and S239 led to increased LT stabilisation, a phenotype that could also be induced 
through knock down of any of the ligases.  
1.5.1.3 TPPK domain 
The TPPK domain is a classic cdc2/CDK1 consensus sequence found in MCPyV LT 
(T299) and SV40 LT (T124).  Studies that prevented phosphorylation of these residues 
identified that phosphorylation was essential for viral Ori interaction, further 
highlighting the requirement of LT for initiation of viral replication (Diaz et al., 2014). 
1.5.1.4 Origin binding domain 
The Ori of PyVs contains a central palindrome consisting of four 5’-GAGGC-3’ repeats 
which interacts with LT (Dean and Hurwitz, 1991; Bochkareva et al., 2006).  The origin 
binding domain of LT is largely composed of positively-charged residues that interact 
with the negatively-charged viral DNA.  Specific residues important for this 
interaction are K331 and R380 for MCPyV LT binding and R154 and R2024 for SV40 




1.5.1.5 Helicase domain 
In order for PyVs to initiate replication, the genome firstly needs to be unwound prior 
to recruitment of the cellular DNA polymerase -primase (PRIM), replication protein 
A (RPA) and DNA polymerase  (POLA) to the origin binding domain (Sowd and 
Fanning, 2012).  This is achieved through the binding of two LT hexamers that 
opposingly twist to reveal the genome.  Following initiation the two hexamers then 
move apart to permit bidirectional DNA replication (Yardimci et al., 2012).  
Recruitment of topoisomerase 1 (TOP1) is also essential to viral propagation, with 
interactions required to relieve stress ahead of the replication fork prior to initiation 
of replication (Khopde and Simmons, 2008; Mahon et al., 2009; Nukuzuma et al., 
2016). 
The majority of PyVs bind p53 through the opposing surface of the helicase domain 
to prevent gene expression in response to DNA damage (Lilyestrom et al., 2006).  
However, this is not the case for MCPyV LT, which despite being able to significantly 
reduce p53 transcription activity was shown to not directly interact with the protein 
(Borchert et al., 2014).  In addition to p53, SV40 LT also interacts with the 
transcriptional co-activators CREB-binding protein (CREBBP) and histone 
acetyltransferase p300 (EP300) (Poulin et al., 2004).  This study identified that 
acetylation of LT was dependent upon binding of p53 as well as CREBBP suggesting 
this may provide a regulatory mechanism for binding to additional cellular factors.  
The study further noted that both BKPyV and JCPyV displayed conserved acetylation 
and that this may therefore be a requirement of several PyVs (Poulin et al., 2004). 
1.5.1.6 Host range and adenovirus helper domain 
The roles of the host range and adenovirus helper (HR-AH) domain have only been 
characterised in the context of SV40.  Additionally HPyVs, with the exception of 
BKPyV and JCPyV, do not possess the same length or homology of the final C-terminal 
domain suggesting that the interactions may be specific to SV40 or that HPyVs 
compensate through alternative interactions (Decaprio and Garcea, 2013).  The 
requirement of the SV40 LT C-terminus in determination of host range has been 
known for several years, however it was not until more recently that interaction with 




replication, was identified as the essential requirement (Pipas, 1985; Fine et al., 
2012).  The study by Fine et al. showed that loss of FAM111A interaction led to a loss 
of viral replication, host range restriction and loss of helper functions in promotion 
of adenovirus replication in monkey cell lineages.  Subsequent depletion of FAM111A 
led to recovery of viral phenotypes associated with full length LT, highlighting the 
necessity of this interaction to expand the host range of SV40.  A more recent study 
has suggested that FAM111A, which normally localises to the nucleoli in a cell cycle 
dependent manner, is recruited by LT to replication centres to promote DNA 
replication (Tarnita et al., 2018). 
The C-terminus of SV40 LT, when phosphorylated at T701, also acts as a 
phosphodegron decoy for the cullin RING ligase substrate adaptor FBXW7 (Welcker 
and Clurman, 2005).  This interaction interferes with FBXW7 mediated degradation 
of G1-S specific cyclin E1 and MYC to promote cellular growth and proliferation. 
1.5.2 The small tumour antigen 
All PyVs express ST alongside LT.  This small protein of approximately 17 kDa retains 
the DnaJ domain and functionality relative to LT, which has been previously 
described.  However, by reading through the LT splice junction of mRNA, ST possesses 
a unique carboxy-terminus (Shuda et al., 2011).  A schematic representation of ST 










Figure 1.7: Schematic representation of a Polyomavirus ST and 
known interacting partners.  A general overview of a PyV ST.  The 
protein is composed of two domains, the DnaJ domain, which is 
conserved with LT and the unique zinc finger domain (Zn Zn).  Shown 
are known interacting partners.  ST interaction with PP4C has to date 
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The unique region of ST contains two zinc fingers that interact with protein 
phosphatases to manipulate several cellular events.  Several PyVs have been shown 
to bind with subunits of the major cellular serine/threonine protein phosphatase 2A 
(PP2A) (Chen et al., 2007; Uhn et al., 2007; Bollag et al., 2010; Kwun et al., 2015).  
MCPyV ST has further been shown to interact with the protein phosphatase 4 
catalytic subunit (PP4C) and regulatory subunit 1 (PP4R1) (Griffiths et al., 2013; 
Stakaitytė et al., 2017; Abdul-Sada et al., 2017). 
1.5.2.1 ST-mediated LT stabilisation 
MCPyV ST stabilises and in turn increases the amount of LT  within the cell (Kwun et 
al., 2013; Dye et al., 2019).  There is conflicting evidence as to how this is brought 
about.  Kwun et al. identified that LT is targeted for proteasomal degradation by SCF 
E3 ligase FBXW7, however binding of the ligase by ST in the LT stabilisation domain 
(LSD), which spans residues 91-95 on the opposite molecular face to which PP2A 
interacts, prevents LT degradation.  ST binding further stabilises other cellular 
proteins such as c-Myc and cyclin E that would otherwise be degraded by FBXW7 to 
promote transformation.  Dye et al. confirmed that ST increased the quantity of LT 
within the cell via the LSD, however found no evidence to support ST interaction with 
FBXW7.  It was therefore suggested that ST interaction with ubiquitin ligases were 
not required, however no alternative hypothesis was presented. 
1.5.2.2 ST interaction with PP2A 
Within a cell, regulation of nearly one third of proteins is performed through 
differential phosphorylation, which in turn controls a vast array of biological 
functions (Seshacharyulu et al., 2013).  PP2A forms a heterotrimeric holoenzyme 
composed of the horseshoe-shaped scaffold protein (subunit A), a catalytic protein 
(subunit C) and a regulatory protein (subunit B) (Cho and Xu, 2007).  Subunits A and 
C both have two different isoforms that may be incorporated into the holoenzyme, 
whilst the regulatory B subunit is more variable, with four different classes made up 
in total of 16 different isoforms.  The four B subunit classes are termed B (PR55), B’ 
(B56/PR61), B’’ (PR72) and B’’’ (PR93/PR110).  Whilst subunit C and A/C dimer may 
have limited activity, specificity of PP2A is predominantly regulated by the variable 




and Goris, 2001).  Interaction of PyV STs with subunit A isoforms varies.  SV40 ST only 
interacts with PP2A A, whereas MuPyV and MCPyV interacts with both PP2A A 
and A (Zhou et al., 2003; Stakaitytė et al., 2017). 
PP2A is normally associated with regulating several cellular processes including cell 
cycle progression and apoptosis through dephosphorylation of signalling proteins 
such as Akt, p53, c-Myc and -catenin and as such is considered a tumour suppressor 
(Baez et al., 2017). It is therefore unsurprising that PP2A dysregulation is associated 
with a progression of cancer (Ruvolo, 2016). 
ST is able to alter substrate specificity of PP2A through competitive binding of subunit 
A/C dimers, which displaces and prevents the binding of the regulatory B subunit 
(Figure 1.8) (Pallas et al., 1990; Pallas et al., 1992).  This interaction inhibits 
dephosphorylation of a range of proteins which subsequently leads to continuous 
activation of pathways related to cellular transformation (Baez et al., 2017).  ST-PP2A 
interaction prevents the dephosphorylation of the CDK inhibitor p27 leading to its 
degradation and transition from G1-S phase of the cell cycle.  S-phase entry is further 
promoted through expression of cyclin A/CDK2 and cyclin E/CDK2 (Schüchner and 
Wintersberger, 1999; Skoczylas et al., 2005).  The ability of SV40 ST-PP2A binding to 
transform the host cell has been further described, as CDK2 activation and induction 
of DNA synthesis mediated by ST-PP2A was sufficient to transform human fibroblasts 










Figure 1.8: Schematic representation of the competitive binding of ST 
to PP2A.  ST acts as a competitive inhibitor of PP2A subunit B, 
preventing binding to the A/C dimer. 
ST 
ST 







SV40 ST interaction with PP2A has also been shown to activate ERK signalling to 
upregulate cyclin D1, which in turn enhances proliferation through phosphorylation 
of pRb to release E2F (Frost et al., 1994).  TSPyV ST also phosphorylates ERK and c-
Jun via a mechanism dependent upon MEK1/2, although confirmation of PP2A 
interaction was not performed (Wu et al., 2016). 
Increased c-Myc stabilisation is associated with a loss of PP2A-mediated phospho-
degradation which further enhances tumorigenesis due to subsequent increased 
expression of telomerase and cyclin D1 (Klucky and Wintersberger, 2007; Kwun et 
al., 2013). 
1.5.2.3 Interaction of ST with protein phosphatase 4 subunits 
SV40 ST upregulates antiapoptotic targets of nuclear factor kappa B (NF-B) 
signalling (Sablina and Hahn, 2008).  However, the mechanisms behind ST-mediated 
NF-B manipulation have only been deciphered in relation to MCPyV ST.  ST-
mediated inhibition of NF-B signalling prevents anti-viral responses and promotes 
expression of pro-inflammatory cytokines through the formation of a complex with 
PP4C and PP4R1 (Abdul-Sada et al., 2017). The ST-PP4 complex modulates NF-B 
signalling through an interaction with the NF-B essential modulator (NEMO) 
adaptor protein, inhibiting IB kinase  (IKK)/IKK-mediated phosphorylation 
(Griffiths et al., 2013).  This restricts translocation of the NF-B heterodimer to the 
nucleus preventing transcriptional activity associated with the innate immune 
response. 
MCPyV interaction with PP4C promotes a range of phenotypes that are associated 
with increased cellular migration and motility.  MCPyV ST interaction with PP4C leads 
to dephosphorylation of stathmin, which in turn prevents acetylation of tubulin and 
destabilisation of microtubules (Knight et al., 2015).  PP4C manipulation by MCPyV 
ST also leads to alterations in the actin cytoskeleton, promoting actin filamentation 
and filopodia formation to enhance motility (Stakaitytė et al., 2017).  Although the 
mechanism responsible was not fully elucidated, PP4C-mediated dephosphorylation 
of 1 integrin and subsequent activation of the Rho family GTPases cdc42 and RhoA 




1.5.2.4 Protein phosphatase independent ST activities 
Whilst most activities associated with PyV STs are mediated through manipulation of 
protein phosphatases, there is also evidence that some pathways are independently 
activated.   
MCPyV ST can induce cellular proliferation through hyperphosphorylation of 
initiation factor 4E-binding protein 1 (4E-BP1) and cap-dependent translation, via a 
mechanism that is independent of upstream mTOR pathway activation and PP2A 
interaction (Shuda et al., 2011).  Activity of 4E-BP1 was shown to be indispensable 
for ST-mediated anchorage- and contact-independent growth, transformation and 
serum free proliferation of rodent fibroblasts. 
Expression of the cellular sheddases A disintegrin and metalloproteinase (ADAM) 10 
and 17 is also induced by MCPyV ST, which act to break down cell-cell junctions to 
promote cell dissociation, which is an essential step for initiation of metastasis 









1.5.3 Species-specific additional early proteins 
In addition to LT and ST, some PyVs encode extra early proteins.  To date however, 
MuPyV MT is the only protein that has unique functionality in respect to cellular 
transformation. 
MT is the essential oncogene of MuPyV-induced tumour formation and is capable of 
inducing tumours in certain animal models independent of other TAgs (Treisman et 
ST 
Figure 1.9: Schematic representation of ST-mediated dissociation 
induced by ADAM 10 and ADAM 17 expression.  ST induces ADAM 10 
and ADAM 17 expression on the cell surface which disrupts cell-cell 




al., 1981).  The protein contains the full-length ST, however through splicing has a 
unique C-terminus that includes a membrane anchor that can tether the protein to 
the cell membrane and intracellular membranes (Fluck and Schaffhausen, 2009).  The 
transforming ability of MT is attributed to several interactions.  Similarly to PyV STs, 
MT interacts with PP2A, which results in displacement of the regulatory B subunit.  
MT also possesses a tyrosine-phosphorylated motif that can interact with the 
phosphotyrosineinteraction/phosphotyrosinebinding domain of Shc to enhance 
transformation, with overexpression of Shc sufficient to block transformation (Blaikie 
et al., 1997).  MT induced cellular transformation is also dependent upon the activity 
of the p110 isoform of phosphatidylinositol 3-kinase (Utermark et al., 2007).  
MuPyV also expresses tinyT, which is terminated prior to the LT splice site, 
maintaining DnaJ activity (Riley et al., 1997). 
MCPyV encodes two additional proteins termed 57 kT and ALTO, which are shown in 
Figure 1.3.  57 kT is produced through additional splicing of LT, resulting in the loss 
of the majority of the helicase and OBD (Kwun et al., 2009).  ALTO is produced 
through gene overprinting (Carter et al., 2013).  Although ALTO is evolutionary 
related to MuPyV MT, it has no influence upon the viral lifecycle and is considered to 
represent an example of viral evolution. 
SV40 expresses 17 kT, a protein that shares the initial exon with LT but through 
removal of a 746 bp intron and frame shifting contains four unique C-terminal amino 
acids (Comerford et al., 2012). 
BKPyV expresses truncated TAg (truncT), which is produced in a similar manner to 
SV40 17 kT in that a second intron leads to additional C-terminal amino acids (Abend 
et al., 2009). 
JCPyV encodes three additional TAgs termed T’165, T’136 and T’135 which again 
share a conserved sequence with LT but an additional intron leads to differential C-
terminal amino acids (Trowbridge and Frisque, 1995). 
A protein termed 229T was also identified in SLPyV, however no studies have been 
performed to determine whether this has any influence during the viral lifecycle  (Lim 




1.6 Polyomavirus microRNAs 
RNA interference (RNAi), through non-coding RNAs, plays an important role in many 
host processes. The enzymatic and regulatory functions of these molecules, coupled 
with a role in defence against viral infection, make these short (about 22 nucleotide) 
RNAs important targets for many viruses in order to avoid detection within infected 
host cells. miRNAs have been identified in all studied metazoan and although their 
functions are poorly characterised, a role in animal development and physiology has 
been proposed (Ambros, 2004). miRNAs specifically regulate gene expression and are 
initially transcribed as an imperfect hairpin structure that is around 70 nucleotides in 
length. Processing by Dicer produces the mature miRNA, which can 
posttranscriptionally regulate gene expression through binding of 3’-untranslated 
regions (3’-UTRs) (Doench et al., 2003).  
PyVs are known to encode one microRNA (miRNA) on the late strand that interacts 
with early mRNAs through binding the LT sequence (Imperiale, 2014).  The miRNA of 
MCPyV and MuPyV recognises the 5’ region of the second LT exon, the 
complementary region of MCPyV is highlighted in Figure 1.3.  The miRNA encoded by 
SV40, BKPyV and JCPyV in contrast is complementary to the 3’ end of LT.  There is 
currently little known about the functions of PyV miRNAs within the cell, but binding 
to LT mRNA leads to degradation, restricting the ability of the virus to replicate (Seo 
et al., 2009).  MCPyV miRNA-M1 has been implicated in immune evasion through 
modulation of SP100, which prevents CXCL8 secretion and subsequent viral 
identification by neutrophils (Akhbari et al., 2018). 
1.7 Late stages of the polyomavirus lifecycle 
1.7.1 Genome replication 
Genome replication has been identified as a block to replication in non-permissive 
cells and is a major contributor to limited host range (Ferenczy et al., 2012). 
As had been previously described, LT is essential for viral replication through 
formation of a double hexamer at the NCCR and recruitment of a range of host 




Binding of LT to the NCCR represses the early promoter and interaction with 
transcription-enhancing factor 1 (TEF1) prevents suppression of the late promoter to 
permit the initiation of viral replication in a bidirectional manner (Berger et al., 1996).  
Components of the DNA damage response (DDR) colocalise to viral replication 
centres and are required to promote replication (Tsang et al., 2014).  Newly 
synthesised viral DNA then recruits host cellular histones to form the 
minichromosome that is subsequently packaged into the virion (Tan, 1977). 
1.7.2 Late protein expression and capsid assembly 
The production of the late transcript that codes for the structural ‘VPs’ and any 
auxiliary proteins begins following initiation of DNA replication (Cubitt, 2006).  
Following translation, the structural proteins traffic into the nucleus due to the NLS 
region of the VPs which is also purported to be essential during initial infection.  The 
ability of VPs to translocate across the nuclear membrane does however vary 
between species and ultimately is dependent upon the presence of an NLS.  All SV40 
VPs contain an NLS and are therefore able to shuttle into the nucleus independently 
(Ishii et al., 1994).  Mutational analysis further showed that mutation to the NLS of 
VP1 or VP2/3 did not perturb nuclear localisation when co-expressed, indicating that 
pentamer and minor capsid interaction occurs within the cytoplasm prior to nuclear 
import.  JCPyV VP1 does not contain an NLS and therefore requires an interaction 
with VP2/3 to enter the nucleus and in contrast MuPyV VP2/3 requires the NLS-
containing VP1 (Forstová et al., 1993; Shishido-Hara et al., 2000). 
VP1 pentamers that make up the capsid share almost identical conformations, with 
C-terminal alteration in the ‘arms’ that reach out and insert into the cores of 
neighbouring pentamers to stabilise the capsid (Liddington et al., 1991; Stehle and 
Harrison, 1997).  In the case of BKPyV, interpentameric interactions are further 
stabilised through incorporation of Ca2+ ions which facilitate correct assembly (Li et 
al., 2003). 
The minor capsids proteins VP2 and VP3 (if expressed) share a common C-terminus, 
whilst a longer N-terminus of VP2 gives rise to a difference in size between the 
proteins.  One minor capsid protein binds to the axial cavity of each VP1 pentamer 




minor capsid proteins also contain a DNA binding domain which links the viral 
minichromosome to the capsid.  The additional N-terminal region of VP2 contains a 
myristoylation site which, when mutated, reduces the efficiency of infection 
(Krauzewicz et al., 1990). 
1.7.3 Late auxiliary proteins 
Several PyVs including SV40, BKPyV and JCPyV express agnoproteins (agno), which 
are encoded 5’ of the VPs, display a highly conserved sequence and have been 
implicated in a range of functions to enhance the efficiency of viral production (Royle 
et al., 2015). 
JCPyV agno is a viroporin that localises to the ER to dysregulate Ca2+ homeostasis 
(Suzuki et al., 2010).  This has been suggested to generate Ca2+ ions that are 
incorporated into the viral capsid and disrupt the plasma membrane to facilitate viral 
egress.  BKPyV that lacks agno is still able to form complete capsids that are retained 
within the cell, suggesting that the requirement of Ca2+ dysregulation is to facilitate 
release (Panou et al., 2018).  Interaction of BKPyV agno with -soluble N-
ethylmaleimide sensitive fusion attachment protein (SNAP), a component of the 
SNARE complex, could also facilitate release via a non-lytic mechanism of 
endocytosis. 
JCPyV agno also interacts with heterochromatin protein 1, causing its dissociation 
from lamin B receptors to destabilise the nuclear envelope to assist exit from the 
nucleus (Okada et al., 2005). 
SV40 also expresses the non-structural VP4 protein, which has been suggested to act 
as a viroporin to disrupt membranes and facilitate lytic release of progeny (Raghava 
et al., 2011).  An alternative study however suggested that VP4 had no role in the 
release of SV40 (Henriksen et al., 2016). 
1.7.4 Polyomavirus egress 
The mechanisms by which PyVs are released from the cell remain poorly 
characterised and, in the case of VP4, controversial.  Studies have shown, as 
highlighted previously, that agno is required for the release of some PyVs, but for 




mechanism to compensate.  BKPyV requires anion homeostasis to facilitate non-lytic 
release from cells (Evans et al., 2015).  This study further suggested that virions were 
trapped within LAMP-1 coated, acidic compartments, consistent with release 
through the endo/lysosomal network. 
1.8 Viruses and cancer 
The dynamic transformation of healthy tissue into a neoplastic state is determined 
by a complex series of events leading to the manipulation of several intracellular and 
extracellular functions to enhance cancerous phenotypes.  It is suggested that four 
to six fundamental modifications in cell physiology, known as the hallmarks of cancer 
(summarised in Figure 1.10), lead to the ability of cancerous cells to replicate 
uncontrollably.  The mechanistic strategy of individual tumours may however vary 
(Rubin, 1994; Hanahan and Weinberg, 2000).  Entry of a cell into a maintainable 
neoplastic state relies upon evasion of apoptosis, self-sufficiency in growth signals, 
insensitivity to anti-growth signals, tissue invasion and metastasis, limitless 
replicative potential and sustained angiogenesis.  In most if not all cases of cancer, 
fulfilment of the listed criteria is deemed essential for progression of disease, which 
given the complexity of required changes infers why the development of malignant 







Due to the similarities between the hallmarks of cancer and the host systems that 
are hijacked by pathogens, it is not surprising that viral infection is attributed to 15-
20% of the global cancer burden (Liao, 2006; Parkin, 2006).  Both DNA and RNA 
tumour viruses have been implicated as causative agents of cancer in humans.  
However, the minimal number of cases relative to the number of infected individuals, 
coupled with requirement of additional events such as immunosuppression, somatic 
mutations, genetic predisposition or exposure to carcinogens highlights the 
inefficiency of progression from viral infection to cancer development (Liao, 2006).  














Figure 1.10: Schematic representation of the six fundamental 
hallmarks of cancer. Sustained growth of the tumour 
microenvironment requires the dysregulation of at least six cellular 
processes.  Cells through mutation and/or pathogenic intervention are 
capable of evading apoptosis, self-sufficiency in growth signals, 
insensitivity to anti-growth signals and limitless replication.  Stromal 
cells react to the tumour microenvironment by causing inflammation, 
which in turn facilitates sustained angiogenesis which provides the 
microenvironment with sufficient nutrients and oxygen for growth, 
and metastasis is initiated through degradation of the extracellular 
matrix and promotion of anchorage-independent growth.  Adapted 




infected host, with expression of oncogenes leading to the immortalisation and 
transformation of the infected cell, priming it for virus replication and preventing 
apoptosis (Carrillo-Infante et al., 2007). 
To date there are seven viruses that have been associated with cancer formation and 
progression, which are summarised in Table 1.2 (Brechot et al., 1980; Dupin et al., 
2000; Schiffman et al., 2007; Klein et al., 2007; Boxus and Willems, 2009; Lei et al., 







Table 1.2: A summary of the seven viruses that are implicated in human cancers.  The classification of virus is in accordance with the Baltimore 
virus classification system. 






Hepatitis C HCV Hepaciviridae 
IV ((+)ssRNA) 
 






1980 Adult T-cell leukaemia 
Hepatitis B HBV Hepadnaviridae 
VII (ss+dsDNA) 
 
1965 Some hepatocellular carcinomas 
Epstein-Barr EBV Herpesviridae 
I (dsDNA) 
 
1964 Burkitt's lymphoma, nasopharyngeal carcinoma 
Human papillomaviruses 










1994 Kaposi's sarcoma and primary effusion 
lymphoma 
Merkel cell polyomavirus MCPyV Polyomaviridae 
I (dsDNA) 




1.8.1 Merkel cells and Merkel cell carcinoma 
Merkel cells were first identified in 1875 by Friedrich Sigmund Merkel.  They are 
found around hair follicles, certain mucosal tissues and in their largest quantities in 
touch-sensitive basal layers of the epidermis (Figure 1.11) (Spurgeon and Lambert, 
2013).  They are specialised sensory receptor cells of epithelial origin that are 
important for recognition and neural relay of somatosensory stimuli relating to a light 
touch (Morrison et al., 2009). 
MCC (Figure 1.12) is a rare but aggressive neoplasm that typically affects white, 
elderly and/or immunocompromised patients, who often have a history of sun-
exposure related diseases.  The significant features of MCC are summarised by the 
acronym AEIOU: asymptomatic, expanding rapidly, immune suppression, older than 
50 years, and ultraviolet exposed site on a person with fair skin (Heath et al., 2008).  
Due to a lack of distinguishing lesion features and challenging diagnosis, MCC is often 
not identified early in development with detection in localised lymph nodes a 
common staging procedure (Gupta et al., 2006; Lemos et al., 2010).  
Immunohistochemistry is commonly required in addition to clinical examination, 
with cytokeratin (CK) 20 a positive marker utilised alongside others including CK8, 
CK18, CK19 and huntingtin-interacting protein (HIP1) (Drusio et al., 2019).  MCC may 
be CK20 negative (<10% of cases), which is usually attributed to high mutational 
burden in virus negative tumours and may complicate diagnosis.  In the case that 
MCC is diagnosed, lymph node biopsies may be performed to identify the staging of 
disease. 
The incidence of MCC is believed to be around 50-fold lower than that of melanoma, 
with 0.6, 1.6 and 0.3 incidences per 100,000 people in the United States, Queensland 
(Australia) and Sweden, respectively, and average onset of disease in the age range 
of 75-80 years (Youlden et al., 2014; Zaar et al., 2016; Drusio et al., 2019).  In England 
the incidence rate has increased from 0.1 to 0.2 per 100,000 people between 1999 
and 2008 (Schadendorf et al., 2017). 
With no current specific treatment for MCC and poor prognosis for patients with 
advanced carcinomas, there is a need to better identify the causative agents of 




2012).  In particular, a correlation between metastasis and lowered survival rate has 
been identified.  Table 1.3 describes the current staging system for patients with 
MCC.  A review of an MCC database identified that the 5-year disease-specific 
survival rate was 64% (Allen et al., 2005).  The stage of cancer progression was also 
found to be of significance to prognosis with 5-year survival based upon disease stage 
found to be: stage I, 81%; stage II, 67%; stage III, 52%; stage IV, 11%.  One study 
concluded that between 1986 and 2011 the mortality rate of MCC has risen by more 
than 333% in the United States, however the contribution of better diagnostics 



















C A B 
Figure 1.12: Clinical example of MCC.  MCC typically progresses in sun 
exposed areas of the skin.  The images show MCCs that have 
developed on the eyelid (A), hand (B) and forearm (C).  Adapted from 
Heath et al. 2008. 
Figure 1.11:Diagrammatic representation of Merkel cell location 
within skin.  Merkel cells (shown in blue), which are located in the 
basal layer of the epidermis at the terminal of nerves and the bulge 




Table 1.3: Staging system for patients with MCC. 
Stage 
Primary tumour 





I No Negative No 
II Yes Negative No 
III Any Positive No 
IV Any Any Yes 
 
1.8.2 Treatment of MCC 
Following identification of MCC, wide local excision of the primary tumour is the 
standard of care (Lebbe et al., 2015; Bichakjian et al., 2018).  However, surgery is not 
always a feasible solution given the typically advanced age of patients and risks 
associated with extensive surgery under general anaesthetic, coupled with the 
functional and cosmetic consequences of tissue removal in sun-exposed regions such 
as the face and neck.  In cases where surgery is plausible, any positive lymph nodes 
would also be removed.  Following surgery daily wide-field adjuvant radiotherapy of 
the primary tumour site and, where applicable, draining lymph node basin is 
commonly performed for a period of 4-5 weeks post-surgery. 
Immunotherapy targeting the immune blockade checkpoint between programmed 
cell death protein 1 (PD1) and its ligand (PDL1) to activate immune responses against 
MCC has recently showed promising results (Giraldo et al., 2018; Miller et al., 2018; 
Del Marmol and Lebbé, 2019).  Treatment with the anti-PD1 antibody 
pembrolizumab led to a response in 56% of patients with advanced-stage MCC which 
led to progression-free survival of 67%, which was compared with chemotherapy 
progression-free survival of 24% (Iyer et al., 2016; Nghiem et al., 2016; Nghiem et al., 
2017).  Avelumab, an antibody targeting PDL1 also showed similar results, with 82% 







1.8.3 MCPyV and Merkel cell carcinoma 
MCPyV has been attributed to the causation of MCC due to the detection of clonally 
integrated viral DNA in 80-95% of patients, suggesting that the disease may be of an 
infectious origin (Feng et al., 2008).  The identification of MCPyV relied on a novel 
method termed digital transcriptome subtraction.  RNA extracted from tumours was 
reverse transcribed, before sequencing of the resulting cDNA.  Following subtraction 
of human transcripts, novel sequences were aligned using a BLAST homology search 
to identify polyomavirus-like sequences. 
With MCC being extremely rare within the population and clonal integration not 
solely responsible for the onset of disease, it is not surprising that MCC induced by 
MCPyV infection requires a secondary event.  Through comparison of MCC tissues 
with healthy tissues infected with MCPyV, it was discovered that mutations in the 
ECR were always evident (Shuda et al., 2008).  These mutations result in the insertion 
of a premature stop codon, leading to truncations of LT.  Therefore, for the 
development of MCPyV-induced MCC, it was assumed that a two-step process 
occurred; firstly, MCPyV has to become integrated into the host genome before 
subsequent mutations that are beneficial to transformation, but detrimental to the 
completion of the viral lifecycle occur. 
A more recent publication has provided evidence to the contrary of this hypothesis 
in that MCPyV mutation precedes integration events, summarised in Figure 1.13 
(Schrama et al., 2019).  This study identified that the viral genomes integrated into 
several MCPyV-positive MCC cell lines were concatemers containing the same 
genome mutation.  It is therefore suggested that mutation occurs in the presence of 
full-length LT which can initiate rolling circle replication of a mutated genome.  This 
concatemer then becomes integrated into the host genome and following WT LT 




















1.8.4 Truncated large tumour antigen 
Genomic sequence analysis of MCPyV positive MCCs identified mutations leading to 
premature stop codons within LT are present within the clonally integrated viral 
genome (Shuda et al., 2008; Spurgeon and Lambert, 2013).  Previous studies have 
shown that the subsequent truncated LT (tLT) proteins are still able to bind with pRb 
but lack the helicase activity of the C-terminus that is necessary for viral DNA 
replication.  The fact that truncations of LT in MCPyV positive MCCs all appear 
downstream of the LXCXE motif, with upstream functions preserved, suggest that the 
N-terminal domains are essential in the transformation of healthy tissue into a 
neoplastic state.  Direct comparisons of MCPyV LT, 57 kT and tLT identified that tLT 
is more effective at promoting growth of human and mouse fibroblasts (Cheng et al., 
2013).  Biochemical analysis has also found that while neither tLT nor LT are capable 
of binding p53 directly, the latter is able to reduce p53-dependent transcription in 
reporter assays (Borchert et al., 2014).  Furthermore, tLT is expressed at a higher 
level than the full length equivalent, possessing a greater affinity for Rb binding. 
Figure 1.13: Schematic representation of the sequential mutation 
and clonal integration of MCPyV genomes that leads to MCC.  UV-
mediated mutagenesis of replication competent viral genome leads to 
truncation of LT and loss of the helicase domain.  The replication 
incompetent virus then integrates into the host genome where 
continuous TAg expression leads to MCC. 
Loss of Clonal 
Human genome 






Phosphorylation at Serine 816 of LT has also been shown to arrest cell growth and 
induce cellular apoptosis (Li et al., 2015).  This could therefore provide further 
evidence to support the hypothesis that tLT is directly responsible for MCPyV-
induced MCC, as truncated proteins lack the required phosphorylation site for 
induction of apoptosis. 
In rare cases, tLT can also lose the NLS that spans amino acids 277-280 (Nakamura et 
al., 2010).  This infers that the NLS is not necessarily required for the progression of 
disease.  However the interaction with hVam6p is always preserved (Liu et al., 2011).  
LT interacts with and translocates hVam6p from the cytoplasm into the nucleus 
disrupting lysosomal clustering.  Interestingly, in the case of tLT that lack the NLS, 
localisation to hVam6p still occurs, suggesting that translocation is not required in 
the early stages of the MCPyV lifecycle.  As such, the hijacking of lysosomes may be 
implicated in endocytosis and virion egress, a process that is not associated with 
MCC. 
1.9 Ion channels 
Membrane proteins account for approximately 30% of the total proteome, 50% of 
which comprise ion channel subunits (Yu et al., 2005).  Pore-forming ion channels are 
transmembrane proteins through which inorganic ions selectively pass down 
electrochemical gradients at rates faster than diffusion (106-8 ions/second), that is 
independent of metabolic energy.  Over 400 putative ion channels  are now thought 
Membrane proteins account for approximately 30% of the total proteome, 50% of 
which comprise ion channel subunits (Yu et al., 2005).  Pore-forming ion channels are 
transmembrane proteins through which inorganic ions selectively pass down 
electrochemical gradients at rates faster than diffusion (106-8 ions/second), that is 
independent of metabolic energy.  Over 400 putative ion channels  are now thought 
to be expressed in mammals (O’Connell et al., 2002; Alberts et al., 2003; Bagal et al., 
2013; Wu et al., 2016).  Ion channels are present at membranes and intracellular 
organelles in nearly all animals, plants and bacterium, as ionic homeostasis is 
responsible for a wide array of physiological activities (PASSANO, 1963; Booth, 2003; 




cells where they shape action potentials through gating (activating) the flow of ions.  
However, channels also play a role in non-excitable cells where they regulate 
numerous basic cellular processes, including cell proliferation, differentiation and 
apoptosis (Prevarskaya et al., 2010; Bates, 2015). 
Channels consist of a number of transmembrane and pore domain subunits that 
create a central pore and selectivity filter.  They are categorised by the stimulus that 
gates them, the number of transmembrane domains (TMDs), or the specific ion it 
conducts.  Examples of stimuli that activate channels and their mechanisms are 
highlighted in Figure 1.14.  The selectivity filter is the most narrow point of the pore 
that selects which ions are conducted, with K+ channels for example having 10,000-
fold greater selectivity for K+ ions that Na2+ ions due to the signature TVGTG 
selectivity filter sequence (Alberts et al., 2003).  Cl- channels comprise channels that 





































1.9.1 K+  channels 
K+ ion channels are the most diverse class of membrane proteins expressed within 
the cell (Grizel et al., 2014).  There are four classes of K+ ion channel that are 
ubiquitously expressed across nearly all kingdoms of life: (1) voltage-gated (KV) (six 
TMDs); (2) inwardly rectifying (KIR) (two TMDs); (3) tandem pore domain (K2P) (four 
TMDs) channels and (4) Ca2+-activated K+ channels (KCa) (6 TMDs) (Zhong et al., 2013; 
Kuang et al., 2015).  K+ channel classifications are summarised in Figure 1.15. 
Open 
Closed 
+ + + 
+ + + + + + 
+ + + 
- - - - - - 
- - - - - - 
Ligand-gated Tension-gated Voltage-gated 
Figure 1.14: Schematic representation of ligand-, tension- and 
voltage-gated channel activation in response to stimuli.  The 
interaction of a ligand with the ion channel it gates leads to opening of 
the channel and passage of ions.  Tension-gated (or mechanosensitive) 
channels are activated in response to environmental changes such as 
increased tension or stretching of the cell.  Voltage-gated channels are 
activated by changes in membrane potential to permit rapid ionic flow 
and cellular depolarisation.  Red balls depict ligands interacting with 






K+ channels, with the exception of K2p channels, are composed of four monomers 
that each contain one pore-forming domain (Kuang et al., 2015).  The carbonyl 
oxygens of threonine residues in the selectivity sequence (TVGYG) provide oxygen 
layers to which four K+ ions interact.  The arrangement of oxygen around the ion 
mimics hydrated K+, resulting in low transfer energy and near diffusion rate 
conduction.  Interaction of K+ ions within the filter stabilises the pore providing 












1.9.1.1 KV channels 
KV channels are gated by voltage sensors that respond to depolarisation of the cell to 
repolarise the membrane potential (O’Connell et al., 2002).  When inactive, the pore 
is shielded by closing of the selectivity filter (C-type inactivation), closing of the 
intracellular entrance (S6 gated) or S6 gate blocking by the N-terminus (N-type 
inactivation) (Yellen, 2002).  In excitable cells KV channels repolarise the cell after 
action potential firing, in non-excitable cells KV channels mediate an array of cellular 
functions including cell volume regulation, acidification and apoptosis. 




















































1.9.1.2 KIR channels 
KIR channels in contrast to other channel types facilitate the movement of K+ ions at 
membrane voltages negative to the K+ equilibrium and therefore inwardly.  This is 
achieved not through channel activity but channel blockage (Nichols and Lopatin, 
1997).  Within the cell Mg2+ ions and polyamines block KIR pores in a voltage-
dependent manner to restrict the leakage of K+ ions out of the cell and promote 
inward conduction. 
Kir channels are grouped into seven subfamilies that are classified into four 
functional groups: classical KIR channels (KIR2.x) which are constitutively active, G-
protein KIR channels (KIR3.x) that are regulated by G-protein coupled receptors, ATP-
sensitive channels (KIR6.x) which are linked to cellular metabolism and K+ transport 
channels (KIR1.x, KIR4.x, KIR5.x and KIR7.x) (Hibino et al., 2010). 
1.9.1.3 K2p channels 
K2p channels are unique when compared to most K+ channels as the transmembrane 
subunit contains two pore loops that structurally resemble two inward rectifier  
subunits and form dimers in the membrane.  Another unique feature is that they are 
not voltage-gated, instead responding to stimuli including pH, membrane stretch, 
polyunsaturated fatty acids and heat to slowly leak K+ outwardly to regulate resting 
potential (Piechotta et al., 2011; Braun, 2012).  An extracellular cap structure 
protrudes from TM1 helix and covers the pore to prevent vertical ion efflux and this 
restricts blockage of the channel with peptide toxins and some small molecule 
inhibitors. 
1.9.1.4 KCa channels 
KCa channels are activated by Ca2+.  Three KCa subfamilies exist that are divided on the 
concentration of Ca2+ required for activation termed large conductance (BKCa), 
intermediate conductance (IKCa) and small conductance (SKCa) (Guéguinou et al., 
2014).  BKCa channels are activated by membrane depolarisation, whilst IKCa and SKCa 






1.9.2 Ca2+ channels 
Ca2+ channels are predominantly voltage-gated and act as second messengers to a 
range of downstream signalling pathways associated with muscle contraction, gene 
transcription, hormone secretion, neurotransmitter release, cell cycle regulation, 
and apoptosis (Berridge et al., 1998; Tyson and Snutch, 2013). 
The pore of voltage-gated Ca2+ channels is formed by an 1 subunit of which 10 
isoforms are expressed in the mammalian genome (Dolphin, 2016).  Long-lasting (L-
type, CaV1.1-1.4, high-voltage activated) and transient (T-type, CaV3, low voltage 
activated) are widely distributed, whilst purkinje, neural and residual (P/Q-, N- and 
R-type channels, respectively, CaV2.1-2.3) are located in the brain and nervous 
system. 
Ligand-gated Ca2+ channels include IP3 receptor channels, ryanodine receptor 
channels and the NAADP-activated two-pore channels (TPCs) (Zhu et al., 2010). 
1.9.3 Na+ channels 
Na+ channels are associated with the propagation of action potentials in excitable 
cells, and in non-excitable cells regulate proliferation, migration, differentiation, 
phagocytosis and endosomal acidification (Catterall, 2000; Roger et al., 2015).  
Following depolarisation, Na+ channels are inactivated in milliseconds to ensure 
unidirectional propagation of action potentials.  To date nine functional NaV isoforms 
have been identified.  However as the channels have similar activities and high 
degree of amino acid conservation between  subunits there has been difficulty in 
distinguishing individual function (Catterall, 2000; Yu and Catterall, 2003).  Treatment 
with tetrodotoxin (TTX) and saxitoxin (STX) has revealed differences between some 
isoforms, with single amino-acid variation in the pore region conferring differential 
resistance to inhibition (Satin et al., 1992; Sivilotti et al., 1997).  The principal cardiac 
isoform NaV1.5 is 200-fold less sensitive to TTX following mutagenesis of a Phe 
residue is to Cys.  The corresponding residue in NaV1.8 and NaV1.9 is Ser and these 






1.9.4 Cl- channels 
Cl- channels are a poorly understood family of ion channels that transport anions in 
a process that is less specific than cation channels.  As such these, channels transport 
a range of ions including Cl-, HCO3-, I-, and NO3-; and have roles in the excitation of 
excitable cells, cell volume regulation, cell motility, the acidification of endosomes, 
cell cycle regulation and apoptosis (Anon, 2009; Stakaityte et al., 2018).  Cl- channels 
are grouped into: Cl- intracellular-channels (CLIC), cystic fibrosis transmembrane 
conductance regulator (CFTR), cAMP-, Ca2+-, stretch-, swelling-, and voltage-
activated channels (Baumgarten et al., 2005; Suzuki et al., 2006).  The structure of Cl- 
channel types varies as they may possess between 1 and 12 transmembrane 
segments. 
1.10 Endosomal ion channels 
The endo/lysosomal network consists of a series of intracellular organelles that 
dynamically interconvert as cargo is trafficked into and out of the cell (Hu et al., 
2015). There is a long-standing acceptance that the acidification of maturing 
endosomes and lysosomes is due to the flux of H+, which whilst true, only reflects a 
part of the dynamic ionic flux that regulates pH within these compartments.  There 
is an emerging field that identifies ions including K+, Na+, Ca2+, and Cl- in altering pH 
across the endo/lysosomal network that are summarised in Figure 1.16. 
Vacuolar-type H+-ATPase (V-ATPase) activity is essential for proton translocation into 
endosomes, however this action alone would quickly lead to self-limiting 
electrochemical gradients preventing further acidification.  To bypass this issue 
significant flux in the concentration of various ions (summarised in Figure 1.16B) 
create an environment whereby the H+ equilibrium is shifted to permit further 
translocation and lowering of intracompartmental pH (Hara-Chikuma et al., 2005; 






























Figure 1.16: Schematic representation of ionic flux in vesicles 
trafficking through the endo/lysosomal network.  (A) Representation 
of endo/lysosomal channels that regulate a range of functions 
including pH.  (B) Representation of ionic concentration and pH across 
early endosomes, late endosomes and lysosomes.  Solid colour 
represents known changes whilst dashed lines represent hypothesised 
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Endosomal Ca2+ flux is mediated by mucolipins and TPCs.  There are three mucolipins 
(TRPML1, TRPML2 and TRPML3) which are members of the transient receptor 
potential (TRP) superfamily and are primarily located to late endosomes and 
lysosomes (Cheng et al., 2010).  The role of TRPMLs is poorly understood, however 
they are believed to leak Ca2+ to prevent lysosomes from becoming too acidic and 
regulate trafficking and fusion.  More recently TPC1 and TPC2 have been identified 
to have endo/lysosomal functionality (Wang et al., 2012; Cang et al., 2013; Cang et 
al., 2014).  The role of TPCs in acidification is somewhat controversial and unclear, 
however activity in response to the second messenger nicotinic acid adenine 
dinucleotide phosphate (NAADP) is required for fusion to membranes including the 
ER and release of Ca2+ from endo/lysosomal stores (Galione et al., 2009; Sakurai et 
al., 2015; Grimm et al., 2017). 
Endo/lysosomal membranes also contain a range of proton exchangers with CLICs, 
Na+-proton exchangers (NPEs) and K+-proton exchangers (KPEs) all able to shift 
equilibrium and regulate pH by transporting Cl-, Na+, and K+ into endosomes at the 
expense of H+, respectively (Scott and Gruenberg, 2011). 
1.11 Ion channels and disease 
Given that ion channels are ubiquitously expressed across all cells and are involved 
in a range of developmental and cellular functions, their association with human 
disease, termed channelopathies is unsurprising (Kasianowicz, 2012). 
The dysregulation of ion channels, the activity of which are essential for correct 
neuronal signalling, have been linked with a range of neurological disorders including 
Alzheimer’s, Parkinson’s, epilepsy and neuropathic pain (Lemoine et al., 2012). 
Channelopathies are not restricted to excitable cells, with cystic fibrosis a well-
studied example.  The single amino acid F508 deletion in the chloride-sensitive CFTR 
channel prevents channel folding, impairing transepithelial transport and mucus 
fluidity, that in turn leads to chronic mucus obstruction, neutrophilic inflammation 
and respiratory infection (Mall and Hartl, 2014).  Hypoglycaemia in infants due to the 




abnormal Na+ channel turnover are just two further examples (Eaton et al., 2006; 
Martin et al., 2013). 
Due to their association with a  wide range of diseases, drugs that modulate channels 
have been well documented in therapeutic treatment.  L-type Ca2+ channel 
inhibitors, including verapamil and nifedipine were clinically approved for the 
treatment of hypertension in the late 1970s/early 1980s (Bagal et al., 2013).  Further 
examples are the Na+ channel inhibitors lidocaine, which is used as a local anaesthetic 
since 1949, and phenytoin and retigabine in the treatment of epilepsy since 1953 and 
2011, respectively. More recently conotoxins, which are small peptide channel 
inhibitors produced by cone snails, have been identified as potential therapeutics in 
the treatment of a several conditions including chronic pain, stroke, schizophrenia, 
epilepsy, and neuromuscular disorders (Layer and McIntosh, 2006).  Ziconotide is a 
clinically available example of a synthetically produced conotoxin that has analgesic 
properties through selective targeting of N-type Ca2+ channels in the spinal cord to 
interrupt pain signalling (McGivern, 2007). 
1.12 Ion channel manipulation by viruses 
Given the vast array of cellular processes that are regulated by ion channels, it is 
unsurprising that viruses manipulate and/or mimic channel function to favour their 
replicative cycle. 
1.12.1 Viroporins 
Viroporins are small (<120 residue) hydrophobic proteins that adopt transmembrane 
oligomeric structures, mimicking the functions of ion channels to regulate ionic 
homeostasis and manipulate pathways relating to autophagy, trafficking, 
inflammation, transformation, cell survival, and virus assembly and release (Royle et 
al., 2015).  Viroporins are encoded by a wide range of viruses that typically contain 
RNA genomes including poliovirus (2B), HCV (p7), human immunodeficiency virus 1 
(HIV-1) (Vpu) and Influenza A virus (M2); whilst in humans the dsDNA viruses BKPyV 
and JCPyV encode agnoproteins, whilst HPV-16 encodes E5 (Scott and Griffin, 2015).  
The role of PyV agnoproteins has previously been described (The production of the 




following initiation of DNA replication (Cubitt, 2006).  Following translation, the 
structural proteins traffic into the nucleus due to the NLS region of the VPs which is 
also purported to be essential during initial infection.  The ability of VPs to translocate 
across the nuclear membrane does however vary between species and ultimately is 
dependent upon the presence of an NLS.  All SV40 VPs contain an NLS and are 
therefore able to shuttle into the nucleus independently (Ishii et al., 1994).  
Mutational analysis further showed that mutation to the NLS of VP1 or VP2/3 did not 
perturb nuclear localisation when co-expressed, indicating that pentamer and minor 
capsid interaction occurs within the cytoplasm prior to nuclear import.  JCPyV VP1 
does not contain an NLS and therefore requires an interaction with VP2/3 to enter 
the nucleus and in contrast MuPyV VP2/3 requires the NLS-containing VP1 (Forstová 
et al., 1993; Shishido-Hara et al., 2000). 
VP1 pentamers that make up the capsid share almost identical conformations, with 
C-terminal alteration in the ‘arms’ that reach out and insert into the cores of 
neighbouring pentamers to stabilise the capsid (Liddington et al., 1991; Stehle and 
Harrison, 1997).  In the case of BKPyV, interpentameric interactions are further 
stabilised through incorporation of Ca2+ ions which facilitate correct assembly (Li et 
al., 2003). 
The minor capsids proteins VP2 and VP3 (if expressed) share a common C-terminus, 
whilst a longer N-terminus of VP2 gives rise to a difference in size between the 
proteins.  One minor capsid protein binds to the axial cavity of each VP1 pentamer 
through a common C-terminus hydrophobic interaction (Chen et al., 1998).  The 
minor capsid proteins also contain a DNA binding domain which links the viral 
minichromosome to the capsid.  The additional N-terminal region of VP2 contains a 
myristoylation site which, when mutated, reduces the efficiency of infection 
(Krauzewicz et al., 1990). 
Late auxiliary proteins). 
1.12.2 Viral persistence 
In addition to its viroporin p7, HCV non-structural protein 5A (NS5A) inhibits liver 




preventing reactive oxygen-species-mediated p38 phosphorylation of KV2.1 at 
Ser800, that would reduce intracellular K+ to trigger caspase-mediated apoptosis 
(Mankouri et al., 2009; Norris et al., 2012).  The flux of anions facilitated by CLIC 
channels (CLIC-1, CLIC-5 and CLIC-7) are essential for HCV lifecycle progression, with 
inhibition or genetic depletion of these channels leading to loss of viral replication 
(Igloi et al., 2015). 
HIV-1 negative regulatory factor (Nef) and the surface subunit of the envelope 
protein gp120 have been shown to affect K+ channel activity to regulate virion release 
(Choi et al., 2008; Herrmann et al., 2010).  Gp120 interacts with the KV channel brain-
specific ether-a-go-go-like channel 1 (BEC1) to repress its activity and inhibit virion 
release.  In contrast, Nef indirectly modulates K+ channel activity to enhance 
replication and cell death in a manner that may compensate for the regulatory roles 
of other viral proteins including gp120. 
MCPyV-positive MCC is known to be highly metastatic due to ST-mediated migratory 
phenotypes.  ST enhances the expression of CLIC1 and CLIC4 to promote anion flux, 
with depletion of the channels resulting in reduced motility and invasiveness of ST 
expressing cells (Stakaityte et al., 2018). 
1.12.3 Viral trafficking 
The entry stages of the Filoviruses Ebola virus (EBOV) and Marburg virus require Ca2+ 
channel activity (Gehring et al., 2014; Hover et al., 2017).  During EBOV entry, virus-
containing endosomes fuse with the ER and the inhibition of TPC1 and TPC2 is 
sufficient to prevent docking and virion release from the endosomal network 
(Sakurai et al., 2015).  This study identified that the Ca2+ channel inhibitors verapamil 
and tetrandrine restricted the ability of EBOV to traffic through the endosomal 
network.  RNAi-mediated knock-out of TPC1 and TPC2 showed that these channels 
were required to facilitate docking of endosomes to the ER and by blocking this 
process entry could not be achieved (Figure 1.17A).  
Several members of the Bunyaviridae have been shown to require K2P channel 
activity during trafficking through the endosomal network and it has further been 




Bunyavirus (BUNV) entry (Figure 1.17B) (Hover et al., 2016; Hover et al., 2018).  HIV 
requires KIR channels, in particular G-protein-regulated channels, ATP-sensitive-
channels (KATP+), and KIR1.1 inhibition was shown to restrict entry and to inhibit virus 
production and release (Dubey et al., 2019).  In both cases, results indicated that 
membrane depolarisation was required to favour viral lifecycle progression. 
Entry of herpes simplex virus 1 (HSV1) can be inhibited through Cl- channel blockage 
(Zheng et al., 2014).  Manipulation of anion homeostasis has also been implicated in 
the non-lytic release of BKPyV (Evans et al., 2015).  Treatment with the anion 
exchange inhibitor DIDS led to accumulation of virions within LAMP-1 positive 
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Figure 1.17: Predicted entry mechanisms of EBOV (A) and BUNV (B).  
(A) Following entry via macropinocytosis, EBOV traffics through the 
endosomal network.  Within late endosomes NAADP-mediated 
activation of TPC1 and TPC2 releases Ca2+ to facilitate fusion with the 
ER.  (B) Following entry, BUNV traffics through the endosomal network 
where increasing acidity and K+ concentration cause structural 
changes in the viral glycoproteins to facilitate release  of 




1.13 Mitogen-activated protein kinases 
The mitogen-activated protein kinases (MAPKs) are a highly conserved class of 
serine/threonine protein kinases that form a complex signalling network in all 
eukaryotic cells (Figure 1.18).  Extracellular stimuli that activate MAPKs may include 
UV exposure, growth factors, proinflammatory cytokines, osmotic shock and heat 
shock, which ultimately regulate cellular functions including cell differentiation, 
















































Growth factors, osmotic shock, inflammatory cytokines, 
TNF, UV exposure, heat shock 
Gene expression, cell cycle progression, cell differentiation, 
motility, apoptosis 
Figure 1.18: Overview of the four MAPK signalling cascades: ERK1/2, 
p38, JNK and ERK5.  A range of stimuli activate MAP3Ks which in turn 
activate their MAPK cascade.  A range of phenotypic outcomes may 




The canonical activity of MAPKs relies upon a three-tiered cascade whereby the 
downstream kinase serves as a substrate for the upstream activator, with MAPK 
kinase kinase (MAP3K, MEKK) phosphorylation and activation of a MAPK kinase 
(MKK, MEK, MAP2K) which in turn phosphorylates and activates the MAPK, with each 
step amplifying the signal.  The active MAPK is then able to translocate into the 
nucleus to phosphorylate and modify the activity of downstream targets which may 
include kinases, transcription factors, cytoplasmic enzymes, phospholipids and 
structural proteins (Chang and Karin, 2001; Yang et al., 2003; Yoon and Seger, 2006). 
MAPK signalling is not a straight forward cascade, with several MAP3Ks able to 
phosphorylate each of the MKKs which may engage in cross-talk to activate more 
than one MAPK (Chang and Karin, 2001).  Scaffold proteins and distinct docking 
interactions ensure that signal specificity is maintained and downstream cellular 
responses are regulated (Whitmarsh and Davis, 1998; Van Drogen and Peter, 2002; 
Tanoue and Nishida, 2003; Morrison and Davis, 2003; Raman et al., 2007). 
There are four distinct MAPK pathways within mammalian cells: extracellular signal-
regulated kinases (ERK) 1/2, c-Jun NH2-terminal kinases (JNK) 1/2/3, p38 and ERK5 
which is also termed big MAPK-1 (BMK1).  Activation of these kinases requires 
phosphorylation of threonine and tyrosine residues in the activation loop T-X-Y motif, 
where X represents a glutamic acid in ERKs, a proline in JNKs and a glycine in p38 
(Widmann et al., 1999).  Dual phosphorylation of the activation loop leads to 
conformational reorganisation to relieve steric hinderance of the active site and 
permit substrate interactions. 
1.13.1 p38 MAPK 
The p38 MAPK pathway is predominantly associated with response to stress, 
however it can also have roles in immune response, survival, differentiation and 
invasion and metastasis (Cuadrado and Nebreda, 2010; Barrantes and Nebreda, 
2012). p38 (p38, MAPK14) was named following its identification as a 38 kDa 
protein and subsequent studies have identified three additional genes that express 
isoforms with approximately 60% identical amino acid sequence, termed p38 




(MAPK12, SAPK4) (Mertens et al., 1996; Jiang et al., 1996; Goedert et al., 1997).  An 



































Figure 1.19: Overview of the p38 MAPK pathway.  In response to 
stimuli MAP3Ks are phosphorylated and activated, which in turn 
phosphorylate and activate MAP2Ks, with either canonical p38 
signalling via MKK3/6 or non-canonical signalling via MKK4, 
phosphorylating and activating p38.  p38 then translocates into the 
nucleus where it phosphorylates and activates a range of targets.  For 
simplicity only the transcription factors ATF2 and MSK1, alongside the 
kinase MK2 are shown.  Following activation, MK2 translocates into 
the cytoplasm where it can regulate a range of activities including 




p38 is ubiquitously and highly expressed in most cell types, whereas other isoforms 
are expressed in a tissue specific manner: p38 in the brain, p38 in skeletal muscle 
and p38 in endocrine glands (Cuadrado and Nebreda, 2010).  Whilst MAPKs 
generally have overlapping functionality and targets, there are examples whereby an 
individual p38 isoform is more efficient in activating a downstream target, such as 
p38 activation of MAPK activated protein kinase 2 (MK2, MAPKAPK2) (Sudo et al., 
2005). 
The p38 pathway may be activated by a wide range of environmental stimuli 
including oxidative stress, inflammatory cytokines, UV irradiation, hypoxia, ischemia, 
interleukin 1 (IL-1) and tumour necrosis factor  (TNF) (Cargnello and Roux, 2011).  
Recruitment of TNF receptor associated factors (TRAFs) by TNF and IL-1 stimulate 
MAP3K to activate p38 isoforms.  G-protein coupled receptors (GPCRs) and the Rho 
GTPase family members Rac and cdc42 may also activate p38-related pathways 
(Bagrodia et al., 1995; Goldsmith and Dhanasekaran, 2007).  These stimuli may 
activate a plethora of MAP3Ks, including MEKK1-3, MLK2/3, ASK1, Tpl2, TAK1 and 
TAO1/2 (Cuadrado and Nebreda, 2010).  It is often the case that stimuli that activate 
p38 will have a similar effect upon the JNK pathway. 
There are three MKKs that are capable of activating the p38 pathway.  MKK3 and 
MKK6 are the canonical and highly specific activators of p38 isoforms, with the 
former able to activate all four isoforms and the latter able to activate all but p38; 
additionally JNK-associated MKK4 can also phosphorylate p38 (Doza et al., 1995; 
Enslen et al., 1998; Alonso et al., 2000; Brancho et al., 2003). 
p38 effects a plethora of proteins localised both in the cytoplasm and the nucleus.  
In the cytoplasm p38 may phosphorylate cPLA2, MNK1/2 MK2/3, HuR, Bax and Tau, 
whilst in the nucleus phosphorylation of ATF1/2/6, MEF2, Elk-1, GADD153, Ets1 and 
MSK1/2 may occur giving rise to a range of different cell fates and phenotypic 
alterations (Cuadrado and Nebreda, 2010). 
1.13.2 p38-association with metastasis 
Metastasis is the general term used to summarise the multistage spread of a primary 




associated deaths (Norman, 1952).  Mechanistically metastasis is poorly understood, 
however the process can be defined by several discrete steps: the loss of cell 
adhesion, gain of cellular motility and invasion of localised tissue which are 
summarised as epithelial-mesenchymal transition (EMT), degradation of the 
extracellular matrix (ECM) and entrance into the vascular and lymphatic systems, 
survival during circulation and colonisation of distant secondary sites (Lambert et al., 
2017; Chitty et al., 2018).  Following colonisation tumour cells often undergo 
metastatic latency, where the cells become dormant for a period of months or years, 
facilitating immune evasion prior to resumed proliferation via unknown mechanisms 
(Malladi et al., 2016; Pollard, 2016). 
It is proposed that tumour cells interact with the surrounding environment, immune 
cells and secreted signalling molecules including transforming growth factor  
(TGF), vascular endothelial growth factor (VEGF), TNF and cytokines such as IL-6 
to promote several processes associated with the metastatic cascade (Joyce and 
Pollard, 2009).  Given that the p38 MAPK pathways respond to such stimuli, it is 
plausible that p38 activity may contribute to metastatic processes.   
1.13.3 EMT 
The ability of a cell to undergo EMT relies upon the upregulation of a range of 
different genes, most notably Snail, Slug, Twist and Zeb1 which repress E-cadherin 
(Thiery, 2002; Kalluri and Weinberg, 2009; Nieto et al., 2016).  p38-mediated 
phosphorylation of Twist at Ser68 stabilises the protein and enhances its ability to 
induce EMT and invasiveness, whilst p38 activation has also been linked with Snail 
expression (Hipp et al., 2010; Hong et al., 2011).  TGF and epidermal growth factor 
(EGF) mediated activation of p38 led to metastatic progression of breast cancer cells, 
with the former enhancing lung metastasis (Parvani et al., 2011).  p38 can activate 
hypoxia-inducible factor 1 (HIF-1) through stabilisation of the -subunit to 
promote growth factors and cytokines such as VEGF and TGF, in addition to EMT-
associated transcription factors Snail and Twist (Emerling et al., 2005; López-Nouoa 
and Nieto, 2009).  Inhibition or RNAi depletion of p38 in head and neck squamous 




transcripts, further highlighting the role of p38 in promoting EMT markers (Lin et al., 
2016) 
Whilst most evidence supports the role of p38 in EMT it is however not absolute, 
with evidence that p38 activation may promote E-cadherin expression and 
suppress TGF-activated kinase 1 (TAK1, MAP3K7) phosphorylation restricting EMT 
in human peritoneal mesothelial cells.  This suggests that p38 may have a cell type 
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Figure 1.20: Reported roles of p38 in metastasis.  p38 activity leads to the 
upregulation and stabilisation of several proteins that are associated with 
EMT, which facilitate invasion and migration.  p38 is inhibited during 
circulation to avoid anoikis, before activation to promote extravasation.  
Dormancy and progression of secondary tumours have both been associated 
with p38 activity.  Stages that require activated p38 are highlighted in red, 
whilst stages requiring inactivation of p38 are in black.  Adapted from del 




1.13.4 Enhanced migration and invasion 
The ability of a cancerous cell to migrate and invade distant tissues requires 
remodelling of the cytoskeleton and secretion of proteins to degrade the ECM. 
The dynamic and rapid polymerisation of globular monomeric actin (G-actin) into a 
filamentous form (F-actin) initiates morphological changes within the cell, priming it 
for migration (Figure 1.21) (Gardel et al., 2010).  Subsequent actin filaments can then 
form into lamellipodia, filopodia or stress fibres dependent on the presence of actin-
associated proteins which either enhance or perturb filament bundling (Yamaguchi 
and Condeelis, 2007; Mattila and Lappalainen, 2008).  Lamellipodia spread over a 
large area in a quasi-two-dimensional actin mesh, whilst filopodia contain bundled 
filaments that form antennae-like protrusions from the lamellipodia that push 
forward the leading edge of the cell.  In a motile cell, filaments may bundle together 
to form stress fibres that become polarised towards the leading edge, with 
retrograde recycling of trailing edge actin to drive migration (Snider and Omary, 
2014).  Activated p38 phosphorylates MK2 which in turn phosphorylates HSP27, 
initiating loss of F-actin cap binding and polymerisation of filaments (Laferrière et al., 
2001; Xu et al., 2006).  p38 also activates LIM domain kinase 1 (LIMK1), which in turn 
phosphorylates cofilin to initiate actin polymerisation at the leading edge and 
supports contractility through depolymerisation and recycling of F-actin at the 















The ability of tumour cells to degrade the ECM and invade secondary sites is also 
essential for metastasis.  These processes are mediated by secretion of matrix 
metalloproteinases (MMPs), for example ADAMs (Deryugina and Quigley, 2006; 
Mochizuki and Okada, 2007).  P38 activity is essential for expression of MMP1, 
MMP2, MMP9 and MMP13 in a range of cancers including bladder, breast, liver, skin 
keratinocytes and prostate to promote tumorigenesis (Johansson et al., 2000; Xu et 
al., 2006; Hsieh et al., 2010; Kumar et al., 2010; Park et al., 2011).  Expression of 
MMP1 and MMP13 in HNSCC progression is regulated by p38; and p38 is required 
in cooperation with c-Jun to facilitate K-Ras mediated MMP9 expression and breast 
cancer metastasis (Junttila et al., 2007; Meng et al., 2011). 
1.13.5 Viral manipulation of p38 MAPK 
MAPKs are responsible for altering a wide range of cellular processes and it is 
therefore unsurprising that a wide range of viruses manipulate these signalling 
cascades to promote several aspects of the viral lifecycle.  HCV non-structural protein 
3 (NS3) enhances hepatocellular carcinoma invasion through an ERK/p38/NF-B 
signalling cascade leading to increased expression of MMP9 and cyclooxygenase-2 
(Figure 1.22A) (Lu et al., 2015).  Encephalomyocarditis virus (ECMV) activates p38 to 
Figure 1.21: Schematic representation of actin rearrangements to 
drive cellular motility.  G-actin is polymerised to form F-actin and drive 
morphological changes in the actin cytoskeleton.  Actin filaments 
move the leading edge of the cell forward through formation of 




enhance translation of viral RNAs, HSV1-mediated inhibition of the innate immune 
central adaptor stimulator of interferon genes (STING) requires ubiquitin specific 
peptidase 21 (USP21) phosphorylation by p38 (Figure 1.22B), and Reovirus activates 
p38 via Ras to dictate host cell permissiveness (Figure 1.22C) (Hirasawa et al., 2003; 
Norman et al., 2004; Chen et al., 2017).  Swine influenza virus activates p38 to 
enhance inflammation, with mouse model data indicating that inhibition of p38 is 




















Figure 1.22: Schematic representation of p38 pathway activation by 
HCV NS3 (A), HSV-1 (B) and reovirus (C).  (A) HCV NS3 activates NF-B  
via p38 resulting in expression of MPP9 which contributes to invasion.  
(B) HSV1 activates USP21 via p38.  USP21 interacts with and 
deubiquitinates STING preventing IRF3-mediated IFN expression and 
subsequent activation of the innate immune system.  (C) Reovirus 
activates Ras which activates the guanine nucleotide-exchange factors 
(GEFs) for the small G protein Ral (RalGEFs) which in turn activate p38.  






























1.14 Thesis aims 
This thesis describes investigation into two different aspects of the polyomavirus 
lifecycle, with a focus upon MCPyV.   
Following internalisation, trafficking events during PyV entry are poorly defined.  
Although pseudovirus assays have previously been described, they have seldom been 
used to study trafficking events, which is in part due to laborious and difficult 
detection that is synonymous with studying early PyV events (Buck and Thompson, 
2007; Schowalter et al., 2012; Gee et al., 2013).  We therefore considered novel 
approaches to quantification using GFP reporter vectors coupled with Incucyte 
imaging and analysis.  SV40, which structurally differs from MCPyV in that two minor 
viral capsid proteins can be incorporated into the capsid compared with the VP3-less 
MCPyV, is the most studied of the PyVs.  As such, infection studies using SV40 are 
well documented, but similar to MCPyV end-point analysis has been somewhat 
restrictive to deciphering early events.  Chapter 3 describes the optimisation of 
MCPyV pseudovirus (PsV) production using reporter vectors and how they can be 
coupled with automated fluorescence detection and fluorescence microscopy to 
study trafficking events.  A novel, rapid method for the quantification of SV40 
infected cells using immunofluorescent detection of SV40 LT coupled with 
automated Incucyte imaging and analysis is also described. 
PyVs are known to traffic through the endosomal network to the ER, before release 
into the cytoplasm and transport to the nucleus (Kuksin and Norkin, 2012a; Kuksin 
and Norkin, 2012b; Becker et al., 2019).  The requirement of acidification to initiate 
proteolytic rearrangements of the capsid whilst within endosomes is well 
established, however the mechanisms that are responsible for acidification had not 
been investigated.  There is an emerging field that identifies the essential role of ion 
channels to translocate ions to facilitate continued compartment acidification (Scott 
and Gruenberg, 2011).  Using a panel of ion channel inhibitors, the requirement of 
channel activity during entry of MCPyV and SV40 was therefore investigated using 
the systems of detection and quantification previously described, leading to 
identification that Ca2+ channel activity is required for efficient entry of both MCPyV 




further characterised.  Ion channel targeting is a long-established method in the 
treatment in a range of diseases and as such there are a wide array of clinically 
available drugs that may be utilised.  By identifying conserved requirements between 
different polyomavirus species there is the potential that a common inhibitor may be 
found to treat a range of polyomavirus infection associated diseases. 
MCPyV ST, like other PyV STs, is known to interact with cellular protein phosphatases, 
namely PP2A and PP4 (Kwun et al., 2015; Abdul-Sada et al., 2017).  Despite this 
knowledge and the known link to of protein phosphatases with dephosphorylation, 
there had been little investigation as to whether kinases were important.  It was 
therefore proposed that through the use of phospho-kinase arrays, cellular kinases 
that were differentially activated following the expression of ST could be identified 
and any interesting hits could be further investigated.  Building upon previous 
publications from the Whitehouse laboratory that showed MCPyV ST induces the 
expression of ADAM10 and ADAM17, induces microtubule destabilisation and 
stimulates actin rearrangements to enhance filopodia formation via Rho-GTPase 
activity, particular focus was placed upon signalling pathways that could potentially 
dysregulate and enhance migratory phenotypes.  Results show that the p38 MAPK 
pathway is activated by ST in a manner independent of extracellular stimuli to 
enhance migratory phenotypes.  Inhibition of p38 using chemical inhibitors is shown 
to be sufficient to restrict ST-induced wound healing and MCPyV-positive MCC cell 
line migration during transwell assays.  Aligned with previous results, it is identified 
that PP4C is essential for the phosphorylation and activation of p38 and therefore 
further highlights the essential nature of ST interactions with protein phosphatases 
to enhance oncogenic phenotypes. 
In summary, these findings highlight the importance of ion channels and p38 
signalling pathways in MCPyV infection and tumorigenesis.  Importantly, they 
provide new avenues for potential drug targets to restrict MCC progression and the 














Chapter 2  





2.1 Laboratory consumables 
2.1.1 Chemicals and solvents 
All chemicals and solvents were purchased from Sigma-Aldrich® Fischer Scientific® 
and Melford Laboratories Ltd. Unless otherwise stated. Where applicable reagents 
were sterilised using a 0.22 m filter or by autoclaving (121 oC, 30 mins, 15 psi).  
Water for general laboratory experiments was deionised using an ELGA PURELAB 
ultra machine (ELGA).  Water for DNA experiments was ultrapurified using a Milli-Q® 
water purification system (Merck).  Nuclease-free water (New England Biolabs) was 
used for PCR and cloning. 
2.1.2 Chemical inhibitors 
The active p38/ inhibitor SB202190, non-active structural analogue SB202474 and 
MEK1/2 (indirect ERK1/2) inhibitor U0126 were purchased from Cambridge 
Bioscience and resuspended in DMSO. 
Inhibitors targeting ion channels and trafficking are summarised in Table 2.1 with 







  Table 2.1: Ion channel inhibitors used during experiments. 
Compound Abbreviation Solvent Target  Additional inhibitory information 
Verapamil hydrochloride Ver H2O Ca2+ L- and T-type channels 
Nifedipine Nif DMSO Ca2+ L-type channels 
Nitrendipine Nit DMSO Ca2+ L-type channels 
5-Nitro-2-(3-phenylpropylamino)benzoic Acid NPPB DMSO Cl- Broad spectrum 
Tetraethyl ammonium TEA H2O K+ Broad spectrum, K+ ion mimic 
4-aminopyridine 4AP H2O K+ Non-selective voltage gated (Kv) channels 
Quinine hydrochloride dihydrate Qn 
 
H2O K+ 
Non-specific channel inhibitor with unknown 
mechanism of action 
Potassium chloride KCl H2O K+ Imbalances ion gradients 
Potassium sulphate K2SO4 H2O K+ Imbalances ion gradients 
Procainamide hydrochloride Pro H2O Na+ Broad spectrum – Class IA antiarrhythmic 





Clustering of acidified late endosomes and 
lysosomes 
Barium chloride BaCl2 H2O K+ KIR channels 
Ruthenium red RR H2O Ca2+/K+ K2P channels 
Margatoxin Mgtx H2O K+ Specific KV1.3 inhibitor 
Mibefradil HCl Mib DMSO Ca2+ T-type channels 





Antibodies used in Western blotting and immunofluorescence microscopy are 
described in Table 2.2.  The 2T2 hybridoma used to detect MCPyV LT/ST was a kind 
gift from Dr Christopher Buck (NIH, Bethesda, USA) and hybridoma medium was 
diluted as described.  The (pAb)108 hybridoma used to detect SV40 LT/ST was a kind 
gift from Daniel DiMaio (Yale Cancer Centre, Connecticut, USA) and hybridoma 
medium was diluted as described.  Purified MCPyV VP1 (clone 9B2) antibody was a 
kind gift from Patrick Moore and Yuan Chang (University of Pittsburgh, Pennsylvania, 
USA). 
Species specific secondary HRP-conjugated antibodies for use in Western blotting 
were purchased from Cell Signaling Technologies (CST) (Rabbit, catalogue number 
7074, used diluted 1:2,000) or Agilent (Mouse, catalogue number P044701-2, used 
diluted 1:5,000).  Species specific secondary Alexa Fluor-conjugated antibodies for 

















Table 2.2: Primary antibodies used for Western blotting and immunofluorescence 
microscopy.  Specific phosphorylation sites for each antibody are shown in brackets 
in the target column.  Antibody dilutions are shown in brackets under the usage 





pcDNA6 MCV sTco was a gift from Patrick Moore (Addgene plasmid # 40201 ; 
http://n2t.net/addgene:40201 ; RRID:Addgene_40201).  pcsNUC, pwM, pwM2m and 
ph2m were kind gifts from Dr Christopher Buck.  ST-eGFP was created by Dave 
Griffiths in the Whitehouse laboratory using cDNA extracted from an MCPyV-positive 
MCC tumour.  pEGFP-C1 and pEGFP-N1 were available within the laboratory.  The ST-
eGFP mutants R7A, 100-103, R102A and F103A were produced by Hussein Abdul-
Sada in the laboratory of Dr Andrew Macdonald, University of Leeds. 
 
 
Target Species Usage Company Product 
code 
Flag tag R WB (1:5,000) Sigma F7425 
GAPDH M WB (1:10,000) Abcam 8245 
HA tag R WB (1:10,000) Sigma H9658 
LAMP2 M IF (1:50) Santa Cruz Sc-18822 
MCPyV LT/ST M WB (1:5) Gift 2T2 
MK2 R WB (1:1000) CST 3042 
P-ATF2 (T71) R WB (1:1000) CST 5112 
P-ERK (T202/Y204) R WB (1:2,000) CST 4370 
P-MK2 (S257) R WB (1:1000) CST 3041 
P-MKK3/6 (S189)/(S207) R WB (1:1000) CST 12280 
P-MKK4 (S257) R WB (1:1000) CST 4514 
P-MSK1 (T581) R WB (1:1000) CST 9595 
P-p38 (T180/Y182) R WB (1:1,000) CST 4511 
p38 R WB (1:1,000) CST 9212 
SV40 LT/ST  M IF (1:200) Gift (pAb)108 




2.2 General methods 
2.2.1 Nucleic acid concentration determination 
The concentration of DNA and RNA samples was performed using a NanoDrop™ 2000 
(Thermo Scientific™) by calculation of absorbance at 260 nm.  The ratio of 
absorbance at 260 nm and 280 nm was used to confirm the purity of samples with a 
ratio of >1.8 and >2.0 deemed acceptable for DNA and RNA, respectively. 
2.2.2 Significance value calculation 
Significance values (p values) were calculated using GraphPad Prism 7 software.  
Analysis was performed using an unpaired parametric t test. P values are represented 
upon graphs using a star system (*), whereby *= ≤0.05, **= ≤0.005, ***= ≤0.0005 
and ****= ≤0.00005. 
2.2.3 Production of schematics 
Schematics were produced using BioRender and Motifolio Biology Bundle in 
Microsoft PowerPoint. 
2.3 Bacterial cell culture 
2.3.1 Growth medium and agar plates 
Premixed Luria Broth (Miller’s LB Broth Base) was purchased from Invitrogen™ and 
used as recommended by dissolving 25 g/L in deionised water before autoclaving.  LB 
as described was used for all antibiotics with the exception of zeocin, which due to 
inactivity at high salt concentration, required a low salt LB medium containing 10 g/L 
tryptone soya broth, 5 g/L yeast extract and 5 g/L NaCl.  For the production of LB agar 
(LBA) plates, 3% (w/v) agar was added to the Luria Broth mix before autoclaving. 
2.3.2 Transforming competent E. coli cells for DNA expression 
Plasmids were transformed into DH5 competent E. coli for bulking of DNA stocks.  
50 ng of plasmid or 5 l of a ligation mixture was added to 50 l of DH5 cells before 
incubation on ice for 30 mins.  Cells were then heat shocked at 42 oC for 30 seconds 
before a further 5 mins on ice.  950 l of LB media was added to the cells before a 1 




spread onto LBA plates made up with appropriate antibiotic for selection, before 
overnight incubation at 37 oC.  The next day, colonies were picked and added to 10 
ml of LB media containing appropriate antibiotic, before overnight incubation at 37 
oC with shaking.  500 l of culture was added to 500 l of 50% glycerol and stored at 
-80 oC.  To ensure successful transformation, Sanger sequencing was performed 
following DNA extraction. 
2.3.3 Bacterial DNA extraction and purification 
DNA was extracted and purified from bacterial culture using kits purchased from 
QIAGEN as per manufacturer recommendations.  For small scale DNA extraction from 
10 ml of culture the QIAGEN Plasmid Mini Kit was used, whilst for greater quantities 
of DNA extraction the QIAGEN Plasmid Midi Kit was used with 100 ml of bacterial 
culture. 
2.4 Mammalian cell culture 
2.4.1 Cell culture medium and supplements 
Unless specified, all cell culture medium and supplements were purchased from 
Gibco™ (Life Technologies™).  Unless otherwise stated, 10% (v/v) foetal bovine serum 
(FBS) was added to all medium.  Complete medium was stored at 4 oC and 
equilibrated at 37 oC before use. 
Dulbecco’s modified eagle’s medium (DMEM) was supplemented with high glucose 
(4,500 mg/L) and L-glutamine (580 mg/L). 
Roswell Park Memorial Institute 1640 medium (RPMI) was supplemented with 300 
mg/L L-glutamine, 10% (v/v) FBS and 50 U/mL penicillin and streptomycin 
(pen/strep). 
Opti-MEM® reduced serum media (Opti-MEM) was used during transfection as the 
medium in which DNA and transfection reagents were initially incubated to allow 
complex formation before addition to cells grown in appropriate complete medium. 
1X Dulbecco’s phosphate buffered saline (PBS) without Ca2+ or Mg2+ was purchased 




Passaging of cells was performed using trypsin.  10X (2.5% (w/v)) trypsin was 
aliquoted and stored at -20 oC.  1X trypsin (0.25% (w/v)) was made up using PBS and 
stored at 4 oC.  1X trypsin was equilibrated to 37 oC before use. 
2.4.2 Cell lines and maintenance 
Human embryonic kidney 293 (HEK293) cells are a foetal kidney cell line, which was 
originally immortalised through transformation with sheared Adenovirus 5 DNA.  
HEK293 cells were purchased from Thermo Scientific™ and maintained in DMEM 
supplemented with 100 g/mL zeocin. 
HEK293TT (293TT) cells were a kind gift from Christopher Buck (NIH, Bethesda, USA).  
This cell line expresses high levels of both SV40 ST and LT, is derived from the 293T 
cell line and is comparable to the commercially available HEK293 FT cell line sold by 
Thermo Scientific™.  This cell line was generated to aid pseudovirus production using 
plasmids containing an SV40 promoter.  293T cells contain clonally integrated SV40 
genome, but typically express very low levels of LT due to splicing bias that favours 
ST production.  Therefore, stable introduction of a second plasmid that solely 
expresses SV40 LT leads to a high level of SV40 ST and LT expression.  This in turn 
facilitates high expression of plasmid DNA that is transfected into 293TT cells.  293TT 
cells were maintained in DMEM containing 250 g/mL Hygromycin B (Invitrogen™). 
For experimentation using HEK293 and 293TT cell lines, unless otherwise stated, 
plates were pre-treated with poly-L-lysine to facilitate adherence.  Wells were coated 
with Poly-L-lysine and washed twice with PBS before seeding of cells. 
Vero cells are an African green monkey kidney epithelial cell line that is continuous 
and aneuploidy.  Vero cells were a kind gift from Andrew Macdonald (University of 
Leeds) and maintained in DMEM supplemented with 50 U/mL penicillin and 
streptomycin (pen/strep). 
WaGa, PeTa, MKL-2 and MS-1 cell lines are all MCPyV-positive MCC cell lines that 
were a kind gift from James Boyne (University of Bradford) and originally provided 
by Adam Grundhoff (Heinrich Pette Institute, Leibniz Institute for Experimental 




from Sigma-Aldrich®.  All MCC lines were grown in RPMI containing 50 g/mL 
pen/strep. 
With the exception of cell lineages grown in pen/strep, antibiotic selection was 
removed prior to experimentation with appropriate medium supplemented with 
only 10% (v/v) FBS used throughout. 
2.4.3 Cryogenic storage and recovery of cell lines 
Cell lines were frozen in appropriate medium supplemented with 10% (v/v) DMSO to 
prevent ice crystal formation.  1X106 cells were suspended in 1 mL of freeze-down 
medium and aspirated into cryotubes.  Cryotubes were stored in cryogenic freezing 
containers for 48 hours, whereby the temperature was steadily reduced at a rate of 
1 oC/minute.  Cryotubes were transferred to liquid nitrogen for long term storage. 
Cell lines were raised rapidly through addition of cryotubes from liquid nitrogen to a 
water bath at a temperature of 37 oC.  Once thawed, cells were pelleted by 
centrifugation at 300 g for 3 minutes before resuspension in appropriate medium 
that was pre-warmed to 37 oC.  Cells were then aspirated into T75 flasks and left for 
48 hours to recover and adhere before medium was replaced to remove any dead 
cells.  Cells were passaged for a minimum of 1 week before used for experimentation. 
2.4.4 Cell line passaging 
Passaging of adherent cell lines was performed by trypsin protease cleavage and 
dissociation of cells.  Growth medium was removed from cells before a wash with 
PBS to remove residual medium.  Cells were then incubated at 37 oC in 1X trypsin PBS 
solution until cells had dissociated.  Detached cells were then resuspended in 
appropriate medium before seeding into vessels for continued passaging or 
experimentation as required. 
MCPyV-positive MCC cell lines do not adhere and therefore grow in suspension.  
Growth medium in which MCPyV-positive MCC cell lines were growing was 
transferred into a Falcon tube before pelleting of cells through centrifugation at 300 
g for 3 minutes.  WaGa and PeTa  cells were resuspended in growth medium and 




and therefore following pelleting cells were washed with PBS and briefly trypsinised 
to dissociate cells prior to seeding. 
2.4.5 Cytotoxicity assay 
To evaluate potential cytotoxicity induced by addition of chemical inhibitors during 
cell-based experimentation the CellTiter 96® AQueous One Solution Cell Proliferation 
Assay was performed.  This colorimetric assay relies upon the bioreduction of the 
tetrazolium compound 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium (MTS) to formazan which can be detected by 
measuring absorbance at 490 nm and is directly proportional to the number of living 
cells. 
5X104 HEK293 cells were seeded into 96 well plates in 100 L of growth medium and 
left overnight to settle.  The next day growth medium was removed and replaced 
with a range of drug dilutions as appropriate in 100 L fresh medium.  Cells were 
then incubated for a period of time relative to intended experimentation, with 
addition of 20 L of MTS reagent for the final hour.  Plates were briefly vortexed to 
ensure produced formazan compound was evenly distributed and absorbance at 490 
nm determined using a microplate reader.  Untreated cells were used as a positive 
control against which viability was determined based upon untreated cells 
representing a 100% viable sample.  Medium only wells were used as a negative 
control to account for background fluorescence and subtracted from each reading.  
All conditions were evaluated using triplicate experimental repeats. 
2.4.6 Transfection of mammalian cell lines 
Transfection of HEK293 and 293TT cell lines was performed using Lipofectamine® 
2000 (Thermo Scientific™).  Described is the protocol used for transfection of a 6 well 
plate.  All concentrations were adjusted for different sized plates based on surface 
area.  2 g DNA was mixed by brief vortexing in 100 l of Opti-MEM.  6 l of 
Lipofectamine® 200 was added directly to the DNA mix, before brief vortexing and a 
20 minute incubation to allow complexes to form.  DNA complexes were then added 




hours with complexes before the medium was replaced with fresh DMEM 
prewarmed to 37oC. 
2.4.7 Harvesting of cells for lysis 
For experimentation with evaluation by Western blotting cells were washed with PBS 
before lysis using Leeds lysis buffer consisting of 25 mM glycerol phosphate, 20 mM 
Tris, 150 mM NaCl, 1 mM EDTA, 1% (v/v) Triton X-100, 10% (v/v) glycerol, 50 mM 
sodium fluoride and 5 mM sodium pyrophosphate which was adjusted to pH 7.4 
using HCl.  Roche cOmplete™ protease inhibitor cocktail (Sigma-Aldrich™) and 
phosphatase inhibitor cocktail set II (Sigma-Aldrich™) were added at the 
recommended concentration to inhibit cellular proteases and phosphatases, 
respectively.  Cells were scraped into lysis buffer and resuspended by vigorous 
pipetting to ensure homogenisation.  Samples were incubated on ice for 30 minutes 
before sonication 30 seconds on/off three times to shear cellular DNA.  Cells were 
returned to ice for a further 30 minutes before centrifugation at 12,000 g for 10 
minutes at 4 oC to pellet insoluble material.  Supernatant was aspirated and stored 
at -20oC. 
2.4.8 Protein standardisation 
Protein standardisation was performed using the bicinchoninic acid (BCA) assay 
(Thermo Scientific™) as per manufacturer specifications.  The BCA assay permits 
quantification of total protein concentration through colorimetric detection of Cu1+ 
following reduction by protein in an alkaline medium. 
10 l of protein sample was incubated with 100 l of working reagent for 30 minutes 
to 1 hour at room temperature in a 96 well plate reading absorbance at 562 nm using 
a microplate reader.  All samples were set up in duplicate.  BSA standards at 
concentrations ranging from 25 g/mL to 2,000 g/mL made up in lysis buffer were 
used to create a calibration curve against which protein sample concentration was 
determined. 
2.4.9 Sodium dodecyl sulphate polyacrylamide gel electrophoresis  
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) separates 




medium, with SDS present to denature and solubilise proteins and create a negative 
net charge leading to migration under electrophoretic conditions.  The Bio-Rad Mini-
PROTEAN Tetra Cell system was used for all SDS-PAGE applications. 
SDS-PAGE gels were made in house using a final percentage of acrylamide 
appropriate for the protein of interest and ranged from 8-15%.  30% (w/v) 
acrylamide concentrate with an acylamide:bis-acrylamide ratio of 37.5:1 was 
purchased from Severn Biotech Ltd®.  Stocks and dilution of reagents for stacking 
and resolving solutions to make two SDS-PAGE gels are shown in Table 2.3 and 
Table 2.4, respectively. 
Table 2.3: Recipe to make stacking solution for two SDS-PAGE gels. 
Component Stock Volume Final concentration 
Tris-HCl pH 6.8 1 M 250 L 62.5 mM 
Water N/A 3 mL N/A 
Acrylamide 30% (w/v) 660 L 5% 
SDS 10% (w/v) 80 L 0.1% 
APS 10% (w/v) 80 L 0.1% 
TEMED N/A 20 L 0.5% 
Total volume  10 mL  
 
Table 2.4: Recipe to make resolving solution for two SDS-PAGE gels. *Volume of 
water and 30% acrylamide were adjusted dependent upon the final acrylamide % 
required, with water used to make the solution up to 10 mL total volume. 
Component Stock Volume Final concentration 
Tris-HCl pH 8.8 1.5 M 3.75 mL 375 mM 
Water N/A 3.75-6.9 mL* N/A 
Acrylamide 30% (w/v) 4.05-7.5 mL* 8-15% 
SDS 10% (w/v) 100 L 0.1% 
APS 10% (w/v) 100 L 0.1% 
TEMED N/A 25 L 0.25% 




SDS-PAGE gels were run at 180 V until samples were approaching the end of the gel 
as indicated by the bromophenol blue indicator loaded into each well.  Precision Plus 
Protein™ Dual Color Standard (Bio-Rad) was loaded onto each gel as a reference of 
migration and consisted of proteins of known molecular weight from 10-250 kDa. 
2.4.10 Protein loading dye 
Protein samples that were resolved by SDS-PAGE were diluted 1:1 with 2X loading 
dye prior to loading onto gels.  2X protein loading dye was composed of 100 mM Tris-
HCl pH 6.8, 2% (w/v) SDS, 20% (v/v) glycerol, 0.1% (w/v) bromophenol blue and 5% 
(v/v) -mercaptoethanol. 
2.4.11 Western blotting 
To identify specific proteins from whole cell lysates Western blotting was performed. 
Following separation of protein samples by SDS-PAGE, proteins were transferred 
onto Amersham 0.45 m nitrocellulose (GE Healthcare) using a Trans-Blot® Turbo™ 
Transfer System (Bio-Rad).  SDS-PAGE gel and nitrocellulose were sandwiched 
between extra thick blotting paper (Bio-Rad) that were pre-soaked in Bjerrum Shafer-
Nielsen buffer.  A 10X Bjerrum Shafer-Nielsen buffer stock was made with 250 mM 
Tris and 1.92 M glycine, with a pH of 9.2 which was not corrected.  When required, 
10X buffer was diluted to 1X (25 mM Tris and 192 mM glycine) with water and 
addition of 20% (v/v) methanol.  The pre-set Bio-Rad transfer protocol was followed, 
with 25 V for 30 minutes applied. 
Following protein transfer, nitrocellulose membranes were blocked for 1 hour at 
room temperature in Tris-buffered saline with 0.1% (v/v) Tween-20 (TBS-T) 
containing 5% non-fat milk (Marvel).  TBS was made as a 10X stock consisting of 500 
mM Tris and 1.5 M NaCl and was pH adjusted to 7.6 using concentrated HCl.  1X 
working TBS-T consisted of 50 mM Tris, 150 mM NaCl and 0.1% (v/v) Tween-20. 
Primary antibody was diluted in TBS-T containing either 5% (w/v) non-fat milk or 5% 
(w/v) BSA as per manufacturer guidelines.  If TBS-T containing 5% (w/v) BSA was 
used, membranes were washed 3 times with TBS-T prior to addition of primary 
antibody solution.  Primary antibody was incubated with the membrane for 1 hour 




with TBS-T before incubation with a primary species-specific HRP-conjugated 
secondary antibody made up in TBS-T containing 5% (w/v) non-fat milk for 1 hour at 
room temperature. 
Following secondary antibody incubation cells were washed 3 times with TBS-T 
before application of ECL Western Blotting Substrate (Promega).  Chemiluminescent 
signal was detected by exposure of Amersham Hyperfilm ECL (GE Healthcare) to the 
membrane for an appropriate period of time. 
All membranes were probed for GAPDH to confirm equal loading and in the case of 
phosphoproteins, total protein expression may have been determined.  In the event 
of a membrane been probed multiple times for proteins of a similar molecular 
weight, it was required for stripping of the membrane to remove previous antibodies.  
This was achieved using Restore Western Blot Stripping Buffer (Merck Millipore) 
following manufacturer guidelines.  Membranes were washed once with TBS-T 
before application of new primary antibody solution and Western blotting protocol 
was followed as previously described. 
2.4.12 Human Phospho-MAPK array 
The Phospho-MAPK array was purchased from R&D Systems (catalogue #ARY002B) 
and experimentation was performed as per manufacturer guidelines.  Briefly, 5x105 
HEK 293 cells were plated into a 6-well plate and incubated overnight.  The next day 
cells were transfected with ST-GFP or GFP as a control and fresh growth medium was 
added after 6 hours.  Following a further 18 hour incubation serum free medium was 
added for 22 hours before a 2 hour serum boost using growth medium containing 
10% FBS (v/v).  Cells were then lysed using the provided buffer and a BCA assay 
performed to confirm equal loading.  Differences in concentration were corrected 
using lysis buffer.  The manufacturer provided protocol was then followed to 
immobilise and detect phospho-MAPKs using Amersham Hyperfilm with a range of 
exposure periods.  Quantification was performed by densitometry using ImageJ. 
2.4.13 Silver staining 
To identify the presence of VLPs in fractions following ultracentrifugation and 




SDS-PAGE was performed as previously described, however due to assay sensitivity 
the protein standard ladder was used 100-fold more dilute than recommended. 
All steps described were performed at room temperature with gentle agitation.  
Solution recipes to make 100 mL used during the silver staining protocol are 
described in Table 2.5. 
 
Table 2.5: Solution recipes for use in silver staining of SDS-PAGE resolved protein 
samples. 
Solution Contents 
A 50% (v/v) ethanol, 10% (v/v) acetic acid 
B 5% (v/v) ethanol, 1% (v/v) acetic acid 
C 0.2 g sodium thiosulphate 
D 10 mL solution C 
E 0.2 g silver nitrate, 75 L formaldehyde 
F 6 g sodium carbonate, 50 l formaldehyde, 0.2 mL solution C 
G 5% (v/v) acetic acid 
 
Following separation of protein samples by SDS-PAGE the gel was fixed by incubation 
in a solution A for 30 minutes.  The gel was then incubated in a solution B for 15 
minutes before 3 5-minute washes with deionised water.  Solution D was then added 
for 1-2 minutes before 3 30-second washes with deionised water.  The gel was then 
incubated in a solution E for 20 minutes before 3 20-second washes.  The gel was 
developed in solution F until protein bands were visible before the reaction was 
stopped with incubation in solution G until effervescing yielded.  The gel was stored 
in deionised water and imaged using a G:BOX XX9. 
2.4.14 Fixation of cells 
Cells to be used for immunofluorescence microscopy (IF) were washed once with PBS 
before incubation with ice-cold 4% (w/v) paraformaldehyde (PFA) for 15 minutes.  




produced through addition of 10 g PFA powder to 200 mL of boiling water in a fume 
hood.  Once cooled, 25 mL 10X PBS was added and the solution made up to 250 mL 
using deionised water and stored at 4oC. 
2.4.15 Immunofluorescence staining 
Following fixation with PFA, samples were prepared for IF through permeabilization 
with 0.1% (v/v) Triton X-100 in PBS for 15 minutes.  Samples were then washed 2 
times with PBS before blocking using 1% (w/v) BSA in PBS (termed PBS blocking 
buffer (PBB)) for an hour at 37 oC or overnight at 4 oC.  Primary antibody was diluted 
appropriately in PBB and incubated on cells for 1 hour at 37 oC.  Cells were then 
washed 3 times with PBS before addition of species-specific Alexa Fluor conjugated 
secondary antibody, diluted 1 in 500 in PBB, for 1 hour at room temperature.  Cells 
were then washed 3 times with PBS.  Following staining of cells mounted upon 
coverslips, VECTASHIELD Antifade Mounting Medium containing DAPI (Vector Labs) 
was added prior to mounting upon slides.  For IF performed in plate-based assays, 
PBS was added to cells prior to imaging. 
2.4.16 MCPyV pseudovirus production and purification 
MCPyV pseudovirus (PsV) production and purification was performed following a 
publicly available revised protocol 
(https://home.ccr.cancer.gov/Lco/production.asp) and has been previously utilised 
for production of PyV and HPV PsVs. 
MCPyV PsVs were produced using either GFP or NanoLuc reporter vectors.  For high-
throughput screening using inhibitors PsVs packaging a GFP reporter were used.  For 
production of PsVs to visualise intracellular localisation NanoLuc (secreted luciferase) 
reporter vectors labelled with EdU were used. 
All steps following transfection were performed using low-retention microcentrifuge 
tubes and low-retention filter tips. 
To produce MCPyV PsVs 7X106 293TT cells were seeded into a T75 flask 16 hours to 
transfection.  The next day, 18 g reporter vector, 15 g pwM2m (VP1 and VP2 dual 
vector) and 3 g ph2m (VP2 only vector) were mixed into 1 mL of opti-MEM and 




MEM and incubated for 5 minutes before combination with DNA mix.  Transfection 
mixtures were incubated for 20 minutes to allow complexes to form before addition 
to 293TT cells. 
For production of EdU labelled PsVs, growth medium was replaced after 6 hours with 
fresh growth medium containing 50 M EdU.  For production of GFP vector-
containing PsVs, growth medium was changed the next morning.  Cells were 
incubated for a total period of 48 hours post transfection before harvest. 
Supernatants were removed from the cells and adhered cells dissociated by 
trypsinisation.  Growth medium was used to inactivate trypsin and collected cells 
were added to the supernatant.  Flasks were washed with 2 mL of growth medium 
to collect any residual cells and added to harvested cells and supernatant.  Cells were 
then pelleted by centrifugation at 300 g for 5 minutes are room temperature.  
Supernatant was aspirated and cells resuspended by agitation in residual fluid.  Cells 
were transferred to a 1.5 mL microcentrifuge tube and pelleted (300 g, 5 minutes, 
room temperature) to remove residual fluid.  Cell pellets were resuspended in 1.5X 
pellet volumes PBS containing 9.5 mM MgCl2 and pen/strep.  Following resuspension 
1/20th volume 10% (v/v) Triton X-100, 1/1,000th volume RNase Cocktail™ Enzyme Mix 
(Ambion) and 1/40th volume 1 M ammonium sulphate, pH 9.0, were added and mixed 
by agitation.  Microcentrifuge tubes were then incubated in a 37 oC water bath for 
20-24 hours to allow maturation of PsVs. 
The next day PsVs were extracted from the matured lysate mix.  All centrifugation 
steps performed at 5,000 g for 5 minutes at room temperature and all supernatants 
were combined and retained.  Following removal from the water bath, lysates were 
chilled on ice before centrifugation to clarify the lysate.  Pelleted material was 
washed with 2X pellet volumes PBS and centrifugation followed by a wash with 1X 
pellet volume PBS and centrifugation 1X pellet volume PBS was then added before 
freeze thawing on dry ice and centrifugation.  A final wash was performed using 1X 
PBS containing 0.8 M NaCl before centrifugation. 
Pooled supernatants were then loading onto a 27-33-39% opti-Prep (iodixanol) 




ultracentrifuge tubes (Beckmann-Coulter) suitable for use in SW55 Ti ultracentrifuge 
buckets (Beckmann-Coulter).  Ultracentrifugation was then performed at 50,000 rpm 
(303,000 g) for 3.5 hours at 16 oC.  A medium acceleration speed and slowest brake 
setting (above coast) were used to avoid mixing of the gradient during 
acceleration/deceleration. 
Fractions were then collected initially by puncturing of the underside of the tube, 
however due to highly variable flow rates fraction by withdrawal from the top of the 
tube downwards was the preferred method.  Two 1.5 mL initial fractions were taken 
before subsequent 340 L fractions until all gradient had been aspirated.  Fractions 
were run by SDS-PAGE before Western blotting and silver staining to confirm 
successful purification PsVs and also purity, respectively.  BSA standards were also 
used for silver staining so that the mass of VP1 could be calculated.  Fractions were 
also used in reporter assays using 293TT cells to ensure that viable PsVs were 
produced. 
For confirmation of viable GFP reporter PsVs, 293TT were transduced for 2 hours 
before addition of fresh growth medium.  Cells were then imaged using an Incucyte 
ZOOM System (Essen Bioscience) 72 hours post transduction to determine the 
number of GFP positive cells. 
For confirmation of viable NanoLuc, EdU-labelled PsVs 293TT cells were transduced 
for 2 hours before addition of fresh growth medium.  Cells were incubated for 96 
hours before removal of growth medium.  Growth medium was then tested using the 
NanoGlo® Luciferase Assay System (Promega) to detect secreted luciferase according 
to manufacturer guidelines, with slight modification which is described.  25 L of 
growth medium was added in triplicate into wells of a white, opaque 96-well plate.  
Working substrate containing NanoLuc substrate diluted 1:50 in NanoLuc buffer was 
made up fresh at the time of use.  Due to high sensitivity and detection, working 
substrate was further diluted 1:8 using 10 L of working substrate and 70 L PBS.  
This mix was then injected into wells using a FLUOstar OPTIMA microplate reader 
(BMG Labtech) and luminescence was detected.  The provided FLUOstar OPTIMA 





2.4.17 MCPyV PsV GFP reporter assay 
PsV assays that used GFP for quantification were performed using 5X104 293TT cells 
seeded into wells of a poly-L-lysine treated 24 well plate 16 hours before addition of 
PsVs.  If required, pre-treatment with chemical inhibitors was performed for 1 hour.  
10 g VP1 equivalent of PsVs was pre-mixed in 300 L of growth medium (containing 
chemical inhibitor if required) and added to wells for 2 hour with gentle shaking every 
30 minutes.  Fresh growth medium was then added for and cells were incubated for 
72 hours before detection of GFP positive cells using an Incucyte ZOOM System.  
Analysis was performed using pre-set parameters to quantify the number of GFP 
positive cells.  Phase confluence was also determined to ensure that cells treated 
with chemical inhibitors continued to proliferate relative to untreated cells. 
2.4.18 EdU-labelled MCPyV PsV reporter assays 
EdU labelled PsVs contained a NanoLuc reporter to confirm viability.  This vector was 
preferred to GFP to ensure that there would be no potential of background 
fluorescence during microscopy. 
293TT cells were seeded into 24-well plates onto 12 mm coverslips that had been 
pre-treated with poly-L-lysine 16 hours before transduction.  Cells were transduced 
with 50 g VP1 equivalent of PsVs with pre-treatment and addition of chemical 
inhibitors as required.  Cells were fixed 48 hours post transduction using PFA as 
previously described.  Detection of EdU was performed using the Click-iT™ Plus EdU 
Alexa Fluor™ 488 Imaging Kit (Life Technologies) according to manufacturer 
guidelines.  Briefly, following fixation cells were washed 2 times using 3% (w/v) BSA 
in PBS.  0.5% (v/v) Triton X-100 was added before incubation at room temperature 
for 20 minutes before 2 further washes using 3% BSA (w/v) in PBS.  Complete Click-
iT® Plus reaction cocktail was added for 30 minutes with gentle rocking protected 
from light.  Cells were then washed with 3% (w/v) BSA in PBS before mounting onto 
coverslips or performing immunofluorescence staining as previously described. 
2.4.19 SV40 production 
A stock of SV40, kindly provided by Michelle Antoni (Macdonald group), was used to 




confluent at the time of infection.  1.5X106 infectious units were incubated on the 
cells for 2 hours with gentle rocking every 30 minutes before addition of fresh growth 
medium.  Cells were incubated for 7 days before the supernatant containing virions 
was harvested.  The supernatant was flash frozen in a dry ice bath containing 
isopropanol and stored at -80oC. 
2.4.20 Quantification of SV40 titre 
Quantification of SV40 titre was calculated by Incucyte ZOOM system analysis of cells 
stained using an SV40 T antigen specific antibody. 
5X103 Vero cells were plated into wells of a 96-well plate 16 hours before infection.  
Growth medium containing SV40 virions was flash-frozen and then defrosted to 
mimic storage conditions before supernatant was diluted 1:5 using fresh growth 
medium.  The 1:5 diluted stock was then serially diluted 2-fold to produce a dilution 
series.  100 L of diluted samples was added to wells and incubated for 2 hours with 
gentle rocking every 30 minutes.  Fresh growth medium was then added before a 
further 22-hour incubation.  Cells were then fixed using PFA and immunostained 
using a T antigen specific antibody and species-specific Alexa Fluor 488 secondary 
antibody.  Four images of each well were then taken using the Incucyte ZOOM system 
and analysed to determine the number of T antigen positive cells in each well for 
each dilution.  Dilution factors were then reversed to determine the total IU/mL for 
each dilution.  The data was then plotted on a graph to identify a plateau indicative 
of IU/mL and multiplicity of infection (MOI).  Each dilution was performed in triplicate 
so that error bars could identify hypervariability at higher dilution factors caused by 
amplification of slight changes in positive counts.  Samples with visible 
hypervariability were discounted from analysis. 
2.4.21 SV40 infection assays 
5x103 Vero cells were seeded into wells of a 96-well plate 16 hours prior to 
experimentation.  If required cells were pre-treated with chemical inhibitors for 1 
hour.  SV40 virions were diluted in growth medium (containing chemical inhibitors if 
applicable) to achieve an MOI of 1 relative to initial seeding and incubated on cells 




added before a further 22-hour incubation.  24 hours after initial infection cells were 
fixed and stained, before imaging and analysis using an Incucyte ZOOM System as 
previously described.  Chemical inhibitor effects were calculated through comparison 
to an untreated control which was arbitrarily used to represent 100% infection. 
2.4.22 Scratch assays 
Scratch assays were performed using an ST-inducible cell line that was under the 
control of a tetracycline promoter, termed i293-ST cells, in poly-L-lysine 24-well 
plates (Knight et al., 2015).  5X105 cells were seeded into each well and incubated 
until 90% confluent.  Expression of ST was induced through addition of 2 g/mL 
doxycycline hyclate, along with chemical inhibitors if appropriate.  Cells were 
incubated for a further 24 hours to permit ST expression and cell confluency to reach 
100%.  Scratches were then performed using a 50 L Clip Tip (Thermo Scientific) and 
wells were washed 1X using PBS to remove non-adhered cells before addition of 
fresh growth medium.  Images were taken at 1, 24 and 48 hours post scratch using 
an EVOS FL Auto 2 Imaging System (Invitrogen), before images were processed using 
ImageJ to determine wound closure.  
2.4.23 Transwell migration assays 
Transwell migration assays were performed using a CytoSelect 24-well Haptotaxis 
Assay as per manufacturer guidelines.  The assay was performed using the MCPyV-
positive MCC cell line PeTa. 
Briefly, 1x106 cells/mL were resuspended in serum depleted (0.5% v/v FBS) medium 
containing drug as appropriate and incubated for 24 hours.  Cytoselect plate 
membranes were rehydrated by incubating serum depleted medium in the upper 
chamber for 1-hour.  Medium was removed and 300 L medium containing cells 
added to the upper chamber.  500 L of serum enriched (20% v/v FBS) growth 
medium was added to each lower chamber before incubation for 48-hours.  Cells in 
each chamber were resuspended by pipetting and aliquots mixed with trypan blue 
before quantification of cell number using a Countess II FL Automated Counter.  The 
percentage of migrated cells for each condition was calculated and before 














Chapter 3  







Comparable with many other polyomaviruses, the lifecycle of MCPyV is poorly 
understood.  Assumptions are made that the virus will follow similar pathways to the 
prototypic and more widely studied SV40.  Binding of MCPyV to its cellular receptor 
has been characterised, however requirements post-attachment had not been 
investigated at the time that this study began (Schowalter et al., 2011; Neu et al., 
2012).  More recently Becker et al. have identified several aspects of MCPyV 
trafficking and host cellular mechanisms that are required during the early stages of 
infection (Becker et al., 2019). 
Many polyomaviruses bind cell surface sialic acid residues that are associated with 
glycolipids or glycoproteins, in contrast sialylated glycans are not required for MCPyV 
attachment (Schowalter et al., 2011).  Instead, attachment is dependent upon 
heparan sulphate interactions, before a secondary interaction with a sialylated 
cofactor permits entry into the cell.  Given that attachment is different to other 
studied polyomaviruses, it therefore suggests that MCPyV may not follow canonical 
polyomavirus routes of infection and there may be differences in other aspects of 
the lifecycle. 
It has been demonstrated that MCPyV enters the cell by caveolar/lipid raft mediated 
endocytosis and that following penetration, virions traffic to the ER via the 
endosomal network (Becker et al., 2019).  Similar to other polyomaviruses, 
acidification of endosomes and a functional redox environment are required whilst 
virus-containing endosomes are trafficked via microtubular transport to the ER. 
A significant issue challenging the ability to study MCPyV infection is that there are 
no easily reproducible systems to study the viral lifecycle.  Despite recent 
identification of dermal fibroblasts as a potential cell population that permit the full 
replication of MCPyV, these cells require substantial manipulation using enzymes, 
growth factors and chemical inhibitors to promote both infection and replication (Liu 
et al., 2016).  Given that MCPyV has been detected in a range of different tissues and 
is continuously shed from skin of a large cohort of healthy individuals, it may be that 




MCPyV has only been identified as a contributing factor in MCC development, which 
suggests that further factors such as clonal integration and UV exposure are required 
for MCPyV to promote oncogenesis.  Moreover, the inability to culture Merkel cells 
has further hindered attempts to conclusively identify connections between 
infection and disease.  
Previous studies have relied upon HEK293 cell-based infection methods, however 
due to inefficiencies/absence of replication, the ability to detect aspects of the viral 
lifecycle following native virion infection has remained difficult and provided little 
insight.  We therefore considered an approach using MCPyV PsVs containing reporter 
vectors to identify viral requirements of the host cell during entry and trafficking. 
In order to evaluate several aspects of the virus lifecycle two systems were developed 
so that penetration, trafficking and subcellular localisation could be assessed.  Firstly, 
an assay that utilised a GFP reporter and end-point Incucyte analysis was developed 
so that high-throughput drug screening could be performed, secondly a reporter that 
incorporated EdU was produced enabling penetration and subcellular localisation to 
be determined by click chemistry.  To compare MCPyV requirements to SV40, an 
immunofluorescent Incucyte assay was also developed to determine infection.  This 
also led to the production of a novel, rapid method to determine infectious titre of 
SV40 stocks. 
3.2 Method of PsV production 
Previous studies using MCPyV PsVs are limited, however recent publications have 
shown that a method for production of HPV PsVs can be adapted to a range of 
polyomaviruses (Buck and Thompson, 2007; Pastrana et al., 2009; Schowalter et al., 
2011). 
The production of MCPyV PsVs is a multi-step process that is summarised in Figure 
3.1.  Following transfection and incubation of 293TT cells for 48 hours, cells were 
incubated overnight in the presence of detergent to lyse cells and permit capsids to 
form before purification.  Whilst this is in essence simple, there are many small 




a preparation.  It was therefore required that several rounds of optimisation were 

















3.3 Expression of MCPyV capsid proteins 
It has been previously shown that the amount of VP2 expression can directly impact 
PsVs, with lower expression correlating with lower transduction efficiencies 
(Schowalter and Buck, 2013).  Whilst a VP2 expression vector was available and used, 
it was investigated whether the use of a vector that dually expressed VP1 and VP2 
would compromise VP1 expression alone.  293TT cells were transfected with 
constructs that solely expressed VP1 (pwM) or dually VP1/ VP2 (pwM2m) (Figure 
3.2).  Results showed that transfection with the dual expression vector had no impact 
Transfection 
293TT 
Harvest and maturation 
Purification 
Confirmation Experimentation 
Figure 3.1: Schematic representation of MCPyV PsV 
production.  293TT cells were transfected with VP1/VP2 and VP2 
expressing constructs along with the desired reporter vector.  
Cells were harvested after 48 hours and matured before 
purification using an iodixanol cushion gradient.  Successful 





upon the expression of VP1 and this was therefore taken forward into PsV production 










3.4 Confirming production of PsVs 
To identify the successful production and purification of PsVs following iodixanol 
cushion ultracentrifugation and fractionation a range of methods could be used.   
To evaluate fractions that potentially contained PsVs, silver staining of fractions was 
initially performed.  Figure 3.3 showed the bulk of cellular proteins were detected in 
fractions 1-3 which represented the ‘top’ of the tube and proteins that were unable 
to enter the iodixanol cushion.  As fractions proceeded further down the tube, less 
host cellular debris could be detected.  In fractions 8-10 (predominantly 9) a protein 
band was more prominent at approximately 50 kDa which corresponded to the 
molecular weight of VP1.  Whilst this band was distinct, there were also other bands 


















Figure 3.2: The use of a dual VP1/VP2 expression vector does not impact 
upon the amount of VP1 expressed.  293TT cells were transfected with 
VP1 only pwM or dual VP1/VP2 expressing pwM2m constructs for 48 hours 
before lysis.  Western blotting was performed to evaluate the quantity of 


















Due to the detection of potential contaminants, negative stain electron microscopy 
was performed to visualise peak fractions.  Imaging revealed that capsids had been 
successfully produced and purified, as indicated by the presence of spherical virion-
like structures of approximately 45 nm in size (Figure 3.4).  As indicated from the 
silver stain, contaminants were also identified surrounding the purified capsids.  It 
was not clear whether these contaminants were aggregated proteins or partially 
encapsidated chromosomal DNA, however given that these may have been 
detrimental to the transducibility of PsVs, slight variations in the method of 





Figure 3.3: Evaluation of fractions following iodixanol purification of a 
MCPyV PsV preparation.  Following ultracentrifugation, fractions were 
separated by SDS-PAGE before silver staining to visualise resolved 
































3.5 Optimised purification of PsVs 
Previously published protocols for the purification of PsVs relied upon puncturing the 
bottom of the ultracentrifuge tube with a needle and then collecting equivalent 
fractions based on the number of drops.  An issue with this method was that due to 
variations in flow rates, there was difficulty in collecting equal fractions.  By having 
to move the tube around quickly between collection tubes there was also the 
possibility of unintentionally mixing the remaining contents of the gradient leading 
to more dispersed contaminants and PsVs. 
To avoid potential detrimental effects upon the purity of fractions collected caused 
by this method, fractionation from the top of the tube to the bottom using aspiration 
with a pipette was performed.  Results showed that this method yielded preparations 
of high purity (Figure 3.5A).  Due to knowledge that capsids would migrate through 
the initial iodixanol cushion, two larger initial fractions (1 and 2) were taken to 
remove cellular supernatant, before smaller fractions were collected.  In comparison 
to Figure 3.3, this method yielded PsVs of higher purity with no obvious contaminants 
observed by silver staining in the peak fraction (fraction 7). 
Figure 3.4: Negative stain electron microscopy of PsV preparation.  
Following ultracentrifugation of MCPyV PsV, the peak fraction was 
imaged by uranyl acetate negative stain electron microscopy.  Scale 
bar 50 nm.  Preparation of grids and electron microscopy was kindly 




To further confirm that the observed band was indeed VP1, Western blotting of the 
fractions was performed.  Figure 3.5B showed that detection of VP1 correlated with 
the silver stained gel, with VP1 detected predominantly in fraction 7and to a lesser 
extent in fractions 5, 6 and 8.  Detection of GAPDH also confirmed that cellular 
proteins did not enter the iodixanol cushion, with signal predominantly in fraction 2 
which also correlated with the results obtained by silver staining. 
Negative stain electron microscopy was performed on peak fractions to identify 
whether any contamination was present.  Results supported the silver stain and 
Western blot data, showing spherical virions with considerably reduced background 














































Figure 3.5: Revised purification of MCPyV PsV visualised by silver 
staining and Western blot.  Visualisation of MCPyV fractions by silver 
stain (A) and Western blotting (B) following ultracentrifugation.  (A) 
fractions were resolved by SDS-PAGE before silver staining to determine 
purity and quantify the total mass of VP1 by comparison to a BSA 
standard curve produced using known concentrations that were resolved 
on the same gel.  Black arrow indicates the predicted molecular weight 
of MCPyV VP1.  (B) Western blotting for MCPyV VP1 to confirm that the 
viral protein was detected in peak fractions.  Western blotting for GAPDH 
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3.6 GFP PsV analysis using the Incucyte 
Previous studies have identified cell lines that are permissive to transduction through 
the use of MCPyV PsVs packaging a GFP reporter, with quantification by flow 
cytometry to determine the number of GFP-positive cells (Schowalter and Buck, 
2013).  Given that 293TT cells are one of a handful of cell lines known to be permissive 
to transduction, this cell line was considered for further experiments.  A caveat to 
the use of 293TT cells is that they poorly adhere to tissue culture plastic and will 
readily dissociate into growth medium, particularly at higher confluency.  To counter 
this, plates were treated with poly-L-lysine to promote attachment, although this in 
turn created an issue whereby there was great difficulty in detaching cells for fixation 
and further analysis by flow cytometry. 
We therefore tested an alternative method of analysis using an Incucyte ZOOM 
instrument (Incucyte).  An Incucyte is an automated microscope that will image tissue 
culture plates using defined bright field (phase), green fluorescence and red 
fluorescence parameters.  The Incucyte is also housed in a 37 oC, 5% CO2 incubator 
so that time-course experiments using live cells may be performed.  In comparison 
to other microscopy techniques which require manual counting, the Incucyte 
Figure 3.6: Negative stain electron microscopy of fractionation-
optimised PsV preparations.  Following ultracentrifugation of 
MCPyV PsV, the peak fraction was imaged by uranyl acetate 
negative stain electron microscopy.  Scale bar 200 and 100 nm for 
left and right micrographs, respectively.  Preparation of grids and 




incorporates an analysis suite that will autonomously evaluate samples using the 
same predefined processing definition across all samples, removing any potential 
human bias. 
To validate that GFP PsVs were viable, purified fractions were used to transduce 
293TT cells before incubation for 72 hours, correlating with the end-point used in 
previous publications.  After incubation, cells were imaged using the Incucyte to 
measure cell confluence and detect GFP positive cells (Figure 3.7).  Results clearly 
showed that PsVs were viable as GFP was detected in a large population of cells.  
Comparison between untransduced and transduced samples showed no change in 



































Figure 3.7: Transduction of 293TT cells using MCPyV PsVs.  293TT cells 
were incubated with MCPyV PsVs for 2 hours before replacement with 
fresh growth medium.  After 72 hours, plates were added to an Incucyte for 




Following confirmation that PsVs were viable, we explored the possibility of whether 
an earlier time point could be used in future experiments given that planned used of 
inhibitors may have led to increased cytotoxicity with longer incubations.  293TT cells 
were transduced as previously described and plates added to the Incucyte 24 hours 
post transduction for imaging.  Results showed that there was no observed detection 
of GFP at 24 hours, with only a small proportion of cells GFP positive at 48 hours 
(Figure 3.8).  Imaging at 72 hours post transduction revealed a much higher 
proportion of GFP positive cells.  This confirmed that it was not feasible to use an end 


















Figure 3.8: MCPyV PsV time course to evaluate optimal assay end 
point.  293TT cells were incubated with MCPyV PsVs for 2 hours 
before addition of fresh growth medium.  The same region of wells 
were imaged using an Incucyte at 24, 48 and 72 hours post 
transduction for phase and green fluorescence. 


















3.7 Analysis using EdU labelled PsVs 
In order to evaluate MCPyV penetration, trafficking and subcellular localisation a 
second PsV system that utilised an EdU labelled reporter DNA was produced.  This 
system is comparable to more traditional BrdU labelling approaches, however due to 
the bulky size of antibodies that are required to detect BrdU this was not suitable for 
detection of encapsidated DNA as the antibody would be unable to penetrate the 
fully formed capsid to access and bind to the incorporated BrdU.  In contrast to BrdU, 
detection of the thymidine analogue EdU relies upon click chemistry, where an Alexa 
Fluor dye is conjugated to an azide linker.  This is much smaller than an antibody 
based equivalent, allowing penetration of the capsid to access and react with the 
alkyne containing EdU via a copper catalysed covalent ‘click’ reaction.   
To remove any potential background fluorescence that may be attributed to GFP 
expression, a NanoLuc reporter was used rather than the previously described GFP 
reporter, however the method of PsV production was otherwise unaltered.  NanoLuc 
reporters encode a luciferase that is secreted from the cells, unlike a traditional 
luciferase which requires cell lysis.  Therefore, confirmation that viable PsVs were 
produced was performed using a luciferase assay with growth medium taken from 
the wells for analysis by a luciferase reporter assay.  Due to the slow speed at which 
MCPyV PsVs enter and traffic through the cell, coupled with not only the requirement 
of expression but also secretion, a later time point of 96 hours post transduction was 
used for evaluation.  Results showed that fraction 5 produced the highest amount of 
luminescence, which correlated with Western blot analysis on the fractions showing 





























As further confirmation of PsV production, negative stain electron microscopy was 
performed on the peak fraction 5 (Figure 3.10).  This showed that PsVs were formed 
and that the sample was of high purity.  To confirm that virion structure resembled 
that of a polyomavirus, approximately 300 particles were picked for 2D and 3D class 
averaging, yielding a structure with a resolution of 23 angstroms.  Whilst little 
information can be revealed with such low resolution, this analysis showed MCPyV 
PsVs retained the correct composition in relation to the pentameric VP1 heads 
Figure 3.9: Determining viable EdU labelled MCPyV PsV 
production and purification of peak fractions.  Following 
ultracentrifugation, EdU-labelled, NanoLuc expressing MCPyV 
PsVs were fractionated before quantification of luciferase 
activity (A) and quantity of MCPyV VP1 in each fraction (B).  (A) 
293TT cells were incubated with MCPyV PsVs for 2 hours before 
replacement with fresh growth medium.  Following 96 hours of 
incubation medium was taken and luciferase activity 
determined by NanoLuc luciferase reporter assay.  (B) fractions 
were resolved by SDS-PAGE before Western blotting for MCPyV 
VP1 to determine the presence of viral protein in each fraction.  
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present upon the surface of the capsid in comparison to other previously resolved 
polyomaviruses.  Unfortunately, given the low resolution it was not possible to 























Figure 3.10: Confirmation of EdU labelled MCPyV PsVs production by 
negative stain electron microscopy (A), with 2D (B) and 3D (C) class 
averaging.  EdU-labelled MCPyV PsVs were imaged by uranyl acetate 
negative stain electron microscopy to confirm the production and purity 
of PsVs.  Approximately 300 virus particles were picked for 2D and 3D class 
averaging, yielding a structure of approximately 23 angstroms (B and C).  
The resulting structure was colour coded to show radial distance from a 






3.8 Confirmation of EdU incorporation into encapsidated DNA 
Whilst the NanoLuc reporter assay and EM confirmed that viable PsVs were 
produced, it did not however provide evidence as to whether EdU had been 
successfully incorporated into packaged DNA.  To determine this, PsV stocks were 
serially diluted and 10-40 ng VP1 equivalent mass was added to wells for 48 hours 
before fixation.  A click reaction was then performed to covalently attach Alexa Fluor 
488 conjugated dye to EdU before visualisation by confocal microscopy (Figure 3.11).  
The mock control showed little if any signal, confirming that the click reaction did not 
lead to the detection of a non-specific signal.  Increasing the mass of PsVs incubated 
with cells correlated with an increase in the number of puncta within cells, consistent 












































Figure 3.11: Detection of EdU labelled MCPyV PsVs at a range of concentrations 
to confirm successful integration of EdU into PsVs.  MCPyV PsVs were diluted in 
growth medium to the desired concentration before addition to 293TT cells grown 
on coverslips.  Following a 48-hour incubation cells were fixed, and a click reaction 
performed to label EdU with Alexa Fluor 488.  Coverslips were mounted using 
mounting medium containing DAPI and imaged using a Zeiss LSM880 upright 






















































To further confirm that the reaction was specific, it was determined that the 
fluorescence observed was due to EdU detection within cells and not due to 
background artefacts.  In addition to detection of Alexa Fluor 488 labelled EdU, 
brightfield imaging was also performed to visualise the outline of cells.  Results 
showed that the detection of EdU was specifically within the boundaries of the cell 
(Figure 3.12).  This suggested that only PsVs that had bound to or penetrated the cell 
were detected and that there was no background signal produced by the click 
reaction. 
Together the data presented in Figure 3.11 and Figure 3.12 confirmed that NanoLuc 
reporter-containing MCPyV PsVs incorporated EdU which could be detected by click 

















Figure 3.12: Confirmation that EdU labelled MCPyV PsVs are detected 
within cells.  MCPyV PsVs were added to 293TT cells grown on 
coverslips.  Following a 48-hour incubation cells were fixed, and a click 
reaction performed to label EdU with Alexa Fluor 488.  Coverslips were 
mounted using mounting medium containing DAPI and imaged using a 
Zeiss LSM880 upright confocal microscope using pre-set filters for each 






3.9 Development of a high-throughput SV40 infection system 
Similar to MCPyV and other polyomaviruses, there are limited high-throughput 
assays available for drug screening following SV40 infection.  Current methods of 
detection typically rely upon Western blotting, however a recent example utilises 
flow cytometry which shortened assays to 48 hours.  Although in both cases these 
assays are laborious, time consuming and given inefficiencies in cell loss during 
washes and lysis require large amounts of reagents. 
Previous unpublished data obtained in the Macdonald group (University of Leeds) 
had successfully adapted an HCV protocol that used immunofluorescent staining 
coupled with Incucyte analysis to determine virus titre of BKPyV stocks, which has 
more recently been utilised to determine SV40 titre.  This protocol used 
immunofluorescent detection of the late structural protein VP1 in cells following 
fixation.  VP1 was chosen to visualise BKPyV infected cells due to an inability to detect 
early viral proteins following infection. 
Given the premise that the aim was to investigate early events in the lifecycle of 
polyomaviruses, VP1 did not represent an ideal target for evaluation as this could 
also encompass other aspects of the virus lifecycle, such as the switch between early 
and late expression and DNA replication.  We therefore decided to explore whether 
it would be possible to use immunofluorescent staining to perform SV40 infection 
studies using a T antigen antibody. 
Vero cells were infected with SV40 for 2 hours before addition of fresh growth 
medium and fixation after a 24-hour incubation.  Following immunostaining using LT 
antibody and an Alexa Fluor 488 conjugated secondary antibody, wells were imaged 
using an EVOS FL Auto 2 imaging System.  Given that the antibody had not been 
previously validated, a range of dilutions were tested.  Across the dilution series used 
no visible loss of detection was observed, shown in Figure 3.13 is the lowest 
concentration of antibody tested (diluted 1:200).  In comparison, the mock infected 
cells were incubated with antibody at the highest concentration used (diluted 1:20) 
but showed no sign of staining.  This confirmed that immunostaining for SV40 LT was 




enabled the volume of reagents and the time taken to complete an experiment to be 
significantly reduced compared to other previously utilised methods. 
Following validation that the LT antibody could be used for immunostaining infected 
cells, it was next determined whether Incucyte imaging could be performed.  Fixed 
and stained plates were therefore imaged using the Incucyte (Figure 3.14).  Results 
showed that SV40 LT immunostaining was successfully detected by Incucyte imaging 
and therefore confirmed that similarly to the previously described system for MCPyV, 





































DAPI LT Merge 
Figure 3.13: Evaluation of SV40 LT staining following infection of Vero cells.  
Vero cells seeded into 96 well plates were infected with SV40 for 2 hours at 
a MOI of 1.  Fresh growth medium was added, and cells fixed after 24 hours.  
Following permeabilization and blocking, SV40 LT antibody and a species-
specific Alexa Fluor 488 secondary antibody were sequentially used to stain 
LT.  During washes following secondary antibody incubation, DAPI in PBS 
was incubated with cells to stain nucleic acid.  Cells were imaged using an 




















3.10 A novel system for SV40 stock titre determination 
Following confirmation that Incucyte analysis was a viable method for determining 
infection, we explored the possibility of utilising this method for quantification of 
SV40 virus stock titre.  Stock titre is typically determined by hemagglutination assay, 
qPCR or plaque assay, which all have disadvantages.  A hemagglutination assay whilst 
relatively quick, does not provide information regarding how many capsids are 
viable.  Due to polyomaviruses readily encapsidating host genomic DNA in addition 
to viral genomes alongside ‘empty’ capsids, there is the potential of varied and false 
titres.  In contrast a plaque assay provides a more accurate measure of viable virions 
at the expense of time, with assays typically taking at least 2 weeks for the formation 
of small yet visible plaques. 



















Figure 3.14: Evaluation of SV40 LT staining of infected Vero cells by 
Incucyte analysis. Vero cells seeded into 96 well plates were infected with 
SV40 for 2 hours at a MOI of 1.  Fresh growth medium was added with cells 
fixed after 24 hours.  Following permeabilization and blocking, SV40 LT 
antibody and a species-specific Alexa Fluor 488 secondary antibody were 
sequentially used to stain LT.  The plate was added to an Incucyte before 





We therefore tested whether a previously published method of HCV quantification 
could be adapted to SV40.  A stock of SV40 provided by the Macdonald laboratory 
(University of Leeds) with a titre of approximately 7.5x105 infectious units/mL 
(IU/mL) was 2-fold serially diluted before incubation with Vero cells for 2 hours in 96 
well plates.  Fresh growth medium was then added before fixation 24 hours post 
infection.  Cells were permeabilised and stained using a LT specific antibody before 
secondary detection using a species-specific antibody conjugated to Alexa Fluor 488.  
The immunostained plate was then imaged using an Incucyte with four images taken 
per well.  Representative images of the serial dilution are shown in Figure 3.15.  As 
expected, the mock infected cells showed no detection of fluorescence.  Evaluation 
by eye revealed that there was little change in the number of positive cells in dilutions 
1:5 to 1:40, suggesting that at lower dilutions the system was saturated.  For higher 
dilutions, from 1:80 downwards, there was a step-wise reduction in the number of 
positive cells as would be expected.  Values for triplicate wells at each dilution were 
determined using the Incucyte analysis software (Figure 3.16A).  Values determined 
by the Incucyte showed that low dilutions produced raw reads around 1x104 LT 
positive cells/well, which given initial seeding of 5x103 Vero cells and an approximate 
doubling time of 24 hours in cell culture, is consistent with most cells been infected 
and saturation of the system.  For 1:40 dilutions onwards there is a steady sigmoidal 
decrease in the number of SV40 positive cells, with dilutions of 1:2560 and higher 
showing detection near to that of the negative mock. 
In order to determine IU/mL reciprocal values were calculated by reversal of dilution 
factors (Figure 3.16B).  Following reversal of dilution factors there was an initial linear 
positive phase, indicative of system saturation.  Highlighted in green is the plateau 
that is representative of IU/mL.  The plateau represents the region whereby the 
system is not saturated but before hypervariability induced by disproportional 
amplification of small variables in infected cell count (shown in red).  To calculate 
IU/mL from the plateau, an average between all values was found.  The example 
presented yielded a calculate 7.48x105 IU/mL which is directly comparable to the 
provided 7.5x105 IU/mL stock.  This therefore demonstrated that the system was a 


























































1:5 1:10 1:20 
1:40 1:80 1:160 
1:320 1:640 1:1280 
1:2560 1:5120 1:10240 
Figure 3.15: Incucyte imaging of Vero cells infected with serially diluted SV40.  
Vero cells plated into 96 well plates were incubated with serially diluted virus 
stocks for 2 hours before the addition of fresh growth medium before fixation 
after 24 hours.  Following permeabilization and blocking, SV40 LT antibody and 
a species-specific Alexa Fluor 488 secondary antibody were sequentially used to 
stain LT.  Plates were then imaged for phase and green fluorescence using an 
Incucyte, with four images taken of each well.  Each dilution was performed in 





























Figure 3.16: Quantification of SV40 stock titre using 
Incucyte detection and analysis.  Following imaging of wells 
using an Incucyte, a predefine processing definition was used 
to calculate the number of SV40 LT positive cells in each well 
(A).  IU/mL was then calculated by reversing dilution factors 
(B).  Green data points represent the plateau used to 
calculated IU/mL.  Red data points are indicative of 
hypervariability following slight fluctuation in positive cells 



















































































The poor characterisation of events during the lifecycle of MCPyV is due to several 
reasons, but predominantly due to a lack of systems available to study the virus.  Until 
recently there were no efficient methods to determine aspects of the viral lifecycle.  
Despite the identification of human dermal fibroblasts enabling complete 
replication, this system requires challenging conditions that are not easily 
reproducible (Liu et al., 2016).  To evaluate early events including attachment and 
entry, PsVs have therefore been utilised as initial infection itself does not appear to 
be the limiting factor during the viral lifecycle, with several cell types permissive to 
initial infection (Pastrana et al., 2009).  An added benefit of using alternative cell lines 
is the ability to move away from primary cell culture, which whilst an essential aspect 
of cellular biology, is less well suited to high-throughput experimentation due to 
increased sensitivity and requirements in comparison to easily cultured and more 
robust transformed cell lines.  Given that infection can be achieved in other 
transformed cell lines, this suggests that initiation of transcription and/or translation 
is most likely inefficient in primary cells and presents a key mediator of cellular 
tropism.  The use of PsVs however bypasses this issue through packaging of reporter 
vectors that utilise more efficient promoters, permitting the evaluation of early 
lifecycle events in more proficient systems.  Whilst previous methods to produce 
MCPyV PsVs have been well documented, use had until recently been limited to 
binding and initial entry, with subsequent events broadly encompassed by trafficking 
to the nucleus yet to be elucidated. 
Although the literature provided somewhat detailed protocols for production of 
PsVs, several areas still required optimisation.  Subtle alterations to the production 
and purification of MCPyV PsVs led to enhanced yield and in particular significant 
improvement in the purity of stocks.  Initial purification attempts resulted in large 
amounts of contaminants, which were assumed to be aggregated protein or large 
fragments of partially encapsidated DNA.  Through increasing the centripetal force 
applied during ultracentrifugation, better sample purity was achieved.  Given that 
there was increased detection by silver staining in the final fractions, it was believed 




gradient whilst PsVs were unable to penetrate the lower cushion.  Purity was further 
confirmed by electron microscopy, which showed that contamination was removed 
by increased centripetal force. 
An issue facing the use of PsVs in high-throughput assays was the ease at which 
experimentation could be performed.  Previously, GFP reporter constructs were used 
alongside flow cytometry to determine the number of infected cells, which was both 
time consuming and wasteful with reagents given that processing would require 
larger starting cell numbers.  A method of live cell detection using an Incucyte was 
therefore successfully adopted.  This system reduced the size and cost associated 
with each sample and also meant that a greater number of samples could be 
simultaneously processed, whilst maintaining unbiased analysis through automated 
computational quantification. 
To visualise the location of PsVs an alternative system that utilised EdU-labelled PsVs 
was produced.  EdU was used to label genomic content rather than the more 
tradition BrdU due to the method of detection.  BrdU relies upon antibody detection 
methods, which for most applications is straight forward and follows standard 
immunostaining protocols.  However, an issue arises when DNA is encapsidated 
inside a virion as the bulky antibodies used for detection cannot penetrate formed 
capsid shells.  In contrast, EdU reactions require a much smaller molecule conjugated 
to a fluorescent probe which can be covalently attached by click chemistry.  The size 
of the molecule is crucial, as this is small enough to pass through the small holes 
between VP1 pentamers that make up the virus capsid in order to label the contained 
vector and visualise subcellular localisation. 
In addition to methods described for the detection of MCPyV, a novel high-
throughput protocol to determine virus titre and in experimentation using SV40 is 
described. 
Determination of SV40 titre is typically performed by plaque assay, which given the 
speed of viral propagation generally requires several weeks of incubation before 
sufficient plaque formation.  In contrast, the described method used a 96-well plate 
format and an incubation of only 24 hours before fixation and immunofluorescent 




negates the requirement of manual counting, this had led to a novel method of 
detection that is significantly quicker than tradition alternatives whilst maintaining 
comparable accuracy. 
The use of immunostaining and Incucyte analysis has also permitted the 
development of a high-throughput screening method to evaluate inhibitor effects 
upon early lifecycle events.  Typically, Western blotting to determine whether T 
antigens are expressed has been used to investigate changes in infection.  This 
method provides reasonable information regarding the total amount of T antigen, 
but it fails to indicate whether less cells are infected or if replication is impeded, 
therefore immunostaining and manual cell counting is performed to determine 
which aspect of the early viral lifecycle is affected.  Whilst Incucyte analysis could also 
provide information regarding fluorescence intensity which would be indicative of 
total protein present, in this instance it was optimised in a binary manner whereby 
the number of infected cells was calculated to determine how many cells are virus 
positive.  This could permit high-throughput screening of inhibitor effects during 
SV40 infection in a 96-well plate format. 
In summary this chapter described the optimisation of MCPyV PsV production and 
how existing protocols were adapted to permit high-throughput assays to determine 
the effects of inhibitors upon early stages of the viral lifecycle.  In addition, a novel 
and rapid method for the quantification of SV40 viral titre was developed, which can 
be further utilised for inhibitor screening.  The described procedures were taken 
forward for use in experiments to determine polyomavirus host cell requirements 















Chapter 4  
Ion channels and polyomavirus 






The mechanisms by which polyomaviruses infect the host are mostly shrouded in 
uncertainty.   This is in part due to lack of appropriate systems but also limited studies 
have been performed to elucidate these early events.  Given that many diseases 
associated with polyomaviruses are generally due to persistent infections that lead 
to severe degradation of tissues, it is surprising that host factors required for 
infection of naïve cells have not been better studied.  Restriction of infection could 
be a viable option for therapeutic intervention and ultimately prevention of disease 
progression. 
SV40 is the most widely studied of the Polyomaviridae and the assumption is often 
made that other family members will follow similar routes of infection.  However, 
SV40 and MCPyV represent arguably one of the most variable compositions of the 
polyomavirus family.  Despite the principally similar composition of polyomavirus 
genomes, the encoding of an additional early protein for MCPyV (57 kT) and three 
additional late proteins for SV40 (agnoprotein, VP3 and VP4) there is the potential 
that variable entry mechanisms are required (Stakaityte et al., 2014; Moens et al., 
2017).  Whilst agnoprotein and VP4 are not incorporated into the capsid and are most 
likely required to assist viral egress, a major difference between MCPyV and many 
other polyomaviruses, including SV40, is that there is no expression of a second 
minor capsid protein (Schowalter and Buck, 2013).  The additional minor capsid 
protein present in VP3-containing virions is believed to facilitate secondary 
interactions and loss of either VP2 or VP3 leads to perturbation of JCPyV infection 
(Nelson et al., 2015).  In contrast, given that MCPyV infects the host without a 
secondary minor capsid protein suggests that this is dispensable, although it has 
been proposed that the presence of a larger VP1 could compensate for this loss.  
Differences in capsid composition could however mean differences in infection 
mechanisms.  This is highlighted by the observed differential cellular attachment and 
penetration between polyomaviruses which likely contributes to varied tropisms 
(Norkin, 1999; Decaprio and Garcea, 2013).  However, events following attachment 
and penetration have been less well studied and there is the potential that these 




within the host during stages, such as trafficking and genome release.  It has been 
well established that polyomaviruses traffic through the endo/lysosomal network 
and it is believed that acidification is required for initiation of capsid rearrangement 
and destabilisation facilitating genome release.  The mechanisms by which 
acidification occurs is currently unclear, however there is an emerging field that 
identifies ion flux to be important and these alterations are regulated by host cell ion 
channels. 
Specific requirements of ion channels during the lifecycle of polyomaviruses have 
previously been characterised (Evans et al., 2015; Stakaityte et al., 2018).  Within the 
Whitehouse group, CLIC channels have been shown to be important for MCPyV ST 
enhanced cellular motility and Evans et al. identified the importance of anion 
homeostasis during non-lytic virion release of BKPyV.  To date however, no studies 
have investigated the potential role of ion channels during early events of 
polyomavirus infection, despite identification of requirements for other viral 
families.  For example, K+ ions are required for acidification events during initial 
Bunyamwera infection and two pore Ca2+ channel inhibition severely restricts Ebola 
infection (Sakurai et al., 2015; Hover et al., 2016; Hover et al., 2018). 
Using systems described in Chapter 3, we investigated whether MCPyV required 
acidification of the endo/lysosomal network similarly to other polyomaviruses.  The 
requirement of ion channels during transduction of MCPyV and infection of SV40 was 
characterised, with identification of K+ ion channels as a novel requirement during 
MCPyV entry.  It was confirmed that the clinically available Ca2+ channel inhibitor 
verapamil could restrict both MCPyV and SV40 and that the T-type Ca2+ inhibitors 
mibefradil and flunarizine ablated MCPyV entry.  Therefore, Ca2+ channel inhibitors 
potentially represent candidate targets to restrict polyomaviruses that cause disease 
through a persistent, continuous infection that cause tissue degradation, particularly 
in an immunocompromised host. 
4.2 MCPyV PsVs appear to localise to vesicular structures 
During development of the previously described EdU system to visualise MCPyV PsVs 




To validate these observations, 293TT cells were incubated with PsVs for 48 hours 
before fixation and a click reaction performed to visualise PsVs.  Consistent with 
previous observations it was confirmed that the click reaction was highly specific and 








































Figure 4.1: MCPyV PsVs localise to spherical structures.  293TT cells 
were transduced with EdU-labelled MCPyV PsVs with fixation after a 
48-hour incubation.  Cells were permeabilised before a click reaction 
was performed to label PsVs with Alexa Fluor 488.  Cells were 
visualised using a ZEISS LSM880 upright confocal microscope and DAPI 




4.3 MCPyV traffics through the endosomal system 
Following penetration, polyomavirus virions traffic through the endosomal network 
before arriving at the nucleus, where the genome is released (Geiger et al., 2011; 
Kuksin and L. C. Norkin, 2012b).  Whilst this holds true for all tested polyomaviruses, 
whether this requirement would be conserved by MCPyV, given that the capsid is 
composed of only one minor capsid protein is unknown.  Therefore, it was 
determined whether MCPyV PsVs localised to endosomal compartments. 
293TT cells were transduced with EdU labelled PsVs, fixed at 48 hours and a click 
reaction performed.  Late endosomes/lysosomes were visualised using antibody 
detection of the lysosomal-associated membrane protein 2 (LAMP2).  Results 
showed that PsVs colocalised with LAMP2 coated vesicles (Figure 4.2).  This was 












































EdU labelled PsV LAMP2 
DAPI Merge 
Figure 4.2: MCPyV PsVs colocalise to vesicles coated with LAMP2.  
293TT cells were transduced with EdU-labelled MCPyV PsVs with 
fixation after a 48-hour incubation.  Cells were permeabilised before a 
click reaction was performed to label PsVs with Alexa Fluor 488.  
Following the click reaction, endo/lysosomes were labelled through 
immunostaining using a LAMP2 antibody, with a secondary species-
specific antibody conjugated to Alexa Fluor 546 used for visualisation.  
Cells were visualised using a ZEISS LSM880 upright confocal 






4.4 MCPyV requires an acidified environment during entry 
Polyomaviruses require an acidic environment during entry (Gilbert and Benjamin, 
2000).  It is thought that acidification is required to initiate proteolytic 
rearrangements of the capsid, destabilising the integrity to allow conformational 
shifting before further processing and ultimately release of genomic contents.  
Although, this had not been confirmed for MCPyV. 
To evaluate if acidification is required during MCPyV entry, 293TT cells were treated 
with ammonium chloride (NH4Cl) in the presence of GFP-reporter containing MCPyV 
PsVs.  NH4Cl can passively enter cells before accumulating in compartments of the 
endosome-lysosome system, where it deprotonates to neutralise pH preventing the 
acidification of endosomes and lysosomes. 
Results showed that treatment with NH4Cl significantly impeded MCPyV 
transduction at both 5 mM and 10 mM, with 66% and 87% reduction in average 
number of GFP positive cells relative to untreated, respectively (Figure 4.3).  This 
further suggested that MCPyV, like other polyomaviruses, shares a conserved 




















To confirm that NH4Cl treatment did not perturb penetration or GFP expression a 
range of control experiments were performed.  Firstly, EdU-labelled PsVs were used 
to transduce cells in the presence of 10 mM NH4Cl.  Imaging showed that in the 
presence of drug, PsVs still penetrated cells and displaying a comparable distribution 
to control cells (Figure 4.4A).  This confirmed that PsV penetration was unaffected by 
10 mM NH4Cl, suggesting that the effect was either upon trafficking or expression.  
To investigate whether 10 mM NH4Cl had a detrimental effect upon the expression 
of GFP, cells were transfected with vector and treated with 10 mM NH4Cl to 
determine whether any detrimental effect upon translation occurred.  Results 
showed that treatment with 10 mM NH4Cl had no effect upon expression of GFP 
(Figure 4.4B).  As a further test, cells were again transfected with GFP before Incucyte 
imaging and analysis was performed.  Using identical parameters of analysis that 
were defined for PsV assays, results showed that NH4Cl treatment had no effect upon 
Figure 4.3: MCPyV transduction is dependent upon endosomal 
acidification.  293TT cells were pre-treated with drugs for 1 hour prior 
to a 2-hour incubation with MCPyV GFP PsVs in the presence of drug.  
Fresh medium was then added before incubation and visualisation of 
GFP-positive cells after 72 hours using an Incucyte ZOOM instrument.  
Predetermined analysis parameters were used to identify the number 













































the number of GFP positive cells (Figure 4.4C).  Taken together these results showed 
that NH4Cl affected MCPyV trafficking events and was not related to cellular 























Figure 4.4: Treatment with NH4Cl does not affect PsV penetration or 
GFP expression.  (A) 293TT cells were transduced with EdU-labelled 
MCPyV PsVs with fixation after a 48-hour incubation.  Cells were 
permeabilised before a click reaction was performed to label PsVs with 
Alexa Fluor 488.  Cells were visualised using a ZEISS LSM880 upright 
confocal microscope and DAPI staining was used to identify nuclei.  
Scale bar 20 µm.  (B+C) 293TT cells were incubated with GFP containing 
transfection complexes for 6 hours.  Fresh growth medium containing 
drug was then added for a further 18 hours before lysis and Western 
blotting to detect the amount of GFP expressed (B) or evaluation of 




















































4.5 MCPyV PsVs enter acidified compartments 
In addition to preventing acidification, NH4Cl may have additional intracellular effects 
leading to vesicle swelling and reduced intralysosomal proteolysis.  Alternative 
classical inhibitors of endosomal trafficking and acidification including wortmannin, 
monensin and chloroquine diphosphate were therefore tested.  However, in all cases 
results showed that the inhibitors led to high rates of cell death at inhibitory 
concentrations and were therefore discarded (data not shown). 
An alternative approach was therefore adopted using EGA.  EGA is a drug that blocks 
a range of toxins from entering cells, including anthrax lethal toxin and diphtheria 
toxin (Gillespie et al., 2013; Schnell et al., 2016).  Whilst EGA targets endosomal 
trafficking pathways, the mechanism of action is vastly different to that of NH4Cl.  
EGA has no effect upon pH or acidification.  However, when an endosome or 
lysosome becomes acidified, EGA prevents target membrane docking and release of 
cargo, instead leading to sequestration and accumulation of vesicles.  Therefore, if 
MCPyV required and/or entered into acidified endo/lysosomes following 
penetration, virions would become trapped and unable to exit from the subsequently 
sequestered compartments. 
Results showed that treatment with 10 M and 25 M EGA severely impaired 
transduction of 293TT cells, with an average reduction in GFP positive cells compared 
to untreated controls of 84% and 81%, respectively (Figure 4.5).  This confirmed that 

























Similarly to NH4Cl, it was determined whether EGA had off-target effects upon 
penetration or GFP expression.  Firstly, EdU-labelled PsVs were utilised to show that 
penetration of the cell occurred  (Figure 4.6A).  Interestingly, in the presence of EGA, 
EdU puncta appeared larger and less dispersed in comparison to the solvent control.  
This observed phenotype supported the hypothesis that EGA leads to accumulation 
of acidified compartments into which MCPyV virions were sequestered.  Following 
transfection of GFP into cells, results showed that translation was not affected and 
no change in the detection of GFP positive cells was observed (Figure 4.6B and Figure 
4.6C, respectively).  This confirmed that MCPyV traffics through the endosomal 





Figure 4.5: Treatment with EGA inhibits MCPyV entry.  293TT cells 
were pre-treated with drugs for 1 hour prior to a 2-hour incubation 
with MCPyV GFP PsVs in the presence of drug.  Fresh medium was then 
added before incubation and visualisation of GFP-positive cells after 
72 hours using an Incucyte ZOOM instrument.  Predetermined analysis 
parameters were used to identify the number of GFP-positive cells for 






































































Figure 4.6: EGA does not affect MCPyV penetration or GFP 
expression.  (A) 293TT cells were transduced with EdU-labelled MCPyV 
PsVs with fixation after a 48-hour incubation.  Cells were 
permeabilised before a click reaction was performed to label PsVs with 
Alexa Fluor 488.  Cells were visualised using a ZEISS LSM880 upright 
confocal microscope and DAPI staining was used to identify nuclei.  
Scale bar 20 µm.  (B+C) 293TT cells were incubated with GFP 
containing transfection complexes for 6 hours.  Fresh growth medium 
containing drug was then added for a further 18 hours before lysis and 
Western blotting to detect the amount of GFP expressed (B) or 
evaluation of GFP positive cells using an Incucyte with predetermined 










































4.6 Manipulation of the endo/lysosomal network is time dependent 
Post penetration, polyomaviruses traffic slowly through the cytoplasm to the 
nucleus.  SV40 is the best characterised of the polyomaviruses and appears to be the 
most efficient in terms of entry and early protein production.  However, the required 
partial disassembly and presentation of VP2/3 in the ER does not occur until 6 hours 
post infection and subsequent release into the cytoplasm to continue trafficking to 
the nucleus may potentially take up to 12 hours or longer (Kuksin and L. C. Norkin, 
2012a).  Previous results in Chapter 3 showed that MCPyV PsVs typically require a 
minimum incubation of 72 hours, whilst following SV40 infection, early proteins 
could be detected at 24 hours.  Given that MCPyV appeared to traffic more slowly, a 
time-course using larger 24-hour intervals was therefore performed. 
293TT cells were pre-treated for 1 hour with 10 mM NH4Cl or 10 M EGA before 
addition of MCPyV PsVs.  Following removal of PsV containing medium, cells were 
incubated in either drug for a period of 24, 48 or 72 hours, with shorter time points 
washed with PBS and addition of medium without either drug for remaining time up 
to the 72-hour endpoint.  Drugs were also introduced after 24 and 48 hours to 
evaluate any effects occurring later during entry.  Results showed that inhibition of 
MCPyV transduction by both NH4Cl and EGA was time-dependent (Figure 4.7). 
Treatment with NH4Cl for 48 and 72 hours led to significant inhibition of transduction, 
with 84% and 85% reduction in GFP positive cells, respectively (Figure 4.7A).  
Interestingly, when NH4Cl was incubated with cells prior to addition of PsVs, a 166% 
increase in the number of GFP positive cells was observed, suggesting that shorter 
treatments may increase the efficiency of transduction.  The reasons for this 
unexpected phenotype were unclear, however possible explanations could range 
from increased endocytosis in response to loss of endo/lysosomal acidification or a 
response mechanism that following drug removal led to quicker acidification and 
trafficking. 
Treatment with NH4Cl for 24 hours showed only a 14% and insignificant change in 
the number of GFP positive cells compared to the control.  This suggested that either 




or that PsVs were held in vesicles awaiting acidification which following drug removal 
was permitted to proceed.  In contrast, NH4Cl treatment for 48 and 72 hours showed 
a comparable phenotype, with transduction greatly restricted.  Addition of NH4Cl 24 
and 48 hours post PsV exposure showed a time-dependent response which returned 
to control levels of GFP positive cells (35% and 5% reduction, respectively).  Given 
that 24-72-hour treatment led to a large increase in the number of GFP positive cells 
in comparison to treatment for the initial 48 hours, this suggested that the 
requirement of acidification for MCPyV occurs around 24 hours post penetration.  
Results also showed that 48-72-hour treatment had no detrimental effect upon 
transduction, which further indicated that the inhibitory effect of NH4Cl was during 
earlier stages of entry, when virions would still be expected to be in endosomal 
compartments. 
Results for EGA were comparable to that of NH4Cl, showing clear evidence of time-
dependency for drug effects (Figure 4.7B).  Unlike NH4Cl, EGA did not however cause 
an increase in transduction when incubated during initial attachment.  Instead, 
treatment during attachment led to a 35% reduction in the number of GFP positive 
cells compared to the control.  There is little data available regarding the mechanism 
of EGA and therefore why this reduction was observed was unclear but could 
potentially be due to irreversible inhibition, leading to reduced transduction as 
nascent components were not sufficiently produced during the incubation period.  
Incubation with EGA over longer periods led to a time-dependent decrease in the 
number of GFP positive cells, with a decrease in GFP positive cells of 55%, 81% and 
88% for 24-, 48- and 72-hour drug incubation periods, respectively.  Introduction of 
EGA at later time points led to recovery of transduction relative to cells treated for 
the full 72-hour period.  When EGA was added from 24-72 hours post attachment a 
49% decrease in the number of GFP positive cells relative to control was observed, 
which following addition of EGA from 48-72 hours displayed a phenotype 
comparable to control with 99% relative GFP positive cells.  Taken together this 
suggested that NH4Cl and EGA were inhibiting comparable stages of MCPyV entry 
and are most likely related to acidification.  Given the reported mechanisms of action 











































































































Figure 4.7: NH4Cl and EGA effects upon MCPyV transduction are time 
dependent.  293TT cells were infected with MCPyV GFP PsVs in the 
presence of 10 mM NH4Cl (A) or 10 µM EGA (B) for varying periods of 
time to determine whether infection was time dependent. Unless a 
time range is indicated (24-72 and 48-72 hours), 293TT cells were pre-
treated with drugs for 1 hour prior to a 2-hour incubation with MCPyV 
GFP PsVs in the presence of drug if applicable.  Fresh medium was then 
added before incubation for the indicated period of time, with 
introduction or removal of drugs performed in fresh growth medium 
as required.  Visualisation of GFP-positive cells was performed after 72 
hours using an Incucyte ZOOM instrument.  Predetermined analysis 
parameters were used to identify the number of GFP-positive cells for 





4.7 Endo/lysosomal network manipulation inhibits SV40 infection 
It had previously been reported that NH4Cl inhibits SV40 infection (Engel et al., 2011).  
However. no study has utilised EGA as an inhibitor and therefore it was investigated 
whether the observed inhibition of MCPyV was comparable to other members of the 
Polyomaviridae. 
As previously described, Vero cells were infected with SV40 in the presence of either 
10 mM NH4Cl or 25 µM EGA, with fixation and immunostaining for LT performed 24-
hours post infection.  Results showed that treatment with NH4Cl or EGA was 
detrimental to SV40 infection (Figure 4.8).  Treatment with 10 mM NH4Cl led to a 
54% decrease in the number of LT positive cells (Figure 4.8A).  25 µM EGA treatment 
led to a greater decrease in the number of LT positive cells by 78%, suggesting that it 
was a more potent inhibitor of SV40 infection, in comparison to 10 mM NH4Cl.  
Together these results supported that MCPyV traffics through the cell in a manner 













Figure 4.8: SV40 infection is perturbed by treatment with NH4Cl (A) 
and EGA (B).  Vero cells were pre-treated with drugs for 1 hour prior 
to a 2-hour incubation with SV40 at a MOI of 1, in the presence of drug.  
Fresh medium containing drug was then added before fixation 
following incubation for 24 hours.  Cells were permeabilised and 
immunostained for LT, with a species-specific secondary antibody 
conjugated to Alexa Fluor 488 used for visualisation.  Wells were then 
imaged using an Incucyte ZOOM instrument.  Predetermined analysis 
parameters were used to identify the number of LT cells for each 



















































































4.8 Broad spectrum ion channel inhibitor screen for MCPyV PsV 
transduction 
The ability of cells to regulate the functions of a maturing endosome is not just 
dependent upon H+, but also requires the flux of several ions including Cl-, K+, Na+, 
and Ca2+(Scott and Gruenberg, 2011). 
To establish whether ion channel inhibition is detrimental to MCPyV transduction, 
PsVs containing the GFP-reporter vector were utilised alongside broad-spectrum ion 
channel inhibitors (Table 2.1).  TEA mimics K+ ions in order to block K+ channels, 
verapamil inhibits both long lasting (L-type) and transient (T-type) Ca2+ channels, 
procainamide reversibly binds to and blocks voltage-gated Na+ channels and NPPB 
blocks Cl- channels via a currently unknown mechanism. 
Results showed that treatment with 10 mM TEA and 10 µM verapamil led to a 
reduction in the number of GFP positive cells by 62% and 57%, respectively, whilst 
treatment with 50 µM procainamide and 10 µM NPPB had little effect (Figure 4.9).  
This suggested that K+ and Ca 2+ channels were potentially important during MCPyV 




















4.9 K+ channel activity is important for MCPyV transduction 
K+ ion channel manipulation has previously been shown to be important during 
bunyamwera virus infection (Hover et al., 2016; Hover et al., 2018). Specifically, K+ 
ion flux into endosomes during post-penetration trafficking was required and 
inhibition of K+ channels led to a loss of infectivity. 
Following identification that manipulation of endosomal acidification and treatment 
of cells with the broad-spectrum K+ channel inhibitor TEA reduced MCPyV 
transduction, it was plausible that a similar mechanism is required during 
polyomavirus entry.  MCPyV PsV assays were therefore performed using a larger 
panel of K+ channel inhibitors to target a wider range of K+ channels. 
Figure 4.9: Effect of broad-spectrum ion channel inhibitors upon 
MCPyV transduction.  293TT cells were pre-treated with drugs for 1 
hour prior to a 2-hour incubation with MCPyV GFP PsVs in the 
presence of drug.  Fresh medium was then added before incubation 
and visualisation of GFP-positive cells after 72 hours using an Incucyte 
ZOOM instrument.  Predetermined analysis parameters were used to 
identify the number of GFP-positive cells for each sample before 







































































Results showed that 10 mM TEA, 50 mM KCl, 1 mM BaCl2 and 1 mM 4AP reduced the 
number of GFP positive cells in comparison to untreated controls (Figure 4.10).  
Quinidine HCl was also used in these experiments, however due to cytotoxicity it was 
not included in results. 
Treatment of cells with 10 mM KCl had no consistent effect upon transduction, whilst 
treatment with 50 mM led to a 55% reduction in GFP positive cells.  K2SO4, used at 
25 mM to introduce an equivalent number of K+ ions as 50 mM KCl, had little effect, 
suggesting that the presence of K+ ions alone was not sufficient to abrogate 
transduction and that KCl effects were potentially also reliant upon imbalances 
created through the additional presence of Cl- ions or that KCl was specifically 
manipulating a cellular mechanism not affected by K2SO4.  
4AP, which is a broad KV channel inhibitor, reduced the number of GFP positive cells 
by 67% when used at 1 mM, suggesting that voltage-gated channels were potentially 
important during entry.  Previous studies had identified that Kv1.3 channels are the 
most active in HEK293 cell lines, therefore margatoxin, which is a Kv1.3 specific 
inhibitor was used.  Results showed that 20 nM margatoxin had no inhibitory effect, 
which suggested that MCPyV may potentially affect channels during entry or that 
basal channel activity with respect to Kv1.3 was not important during initial MCPyV 
entry. 
Treatment with BaCl2, which inhibits inward rectifier potassium channels (KIR) 
through blockage by Ba2+ ions, led to an average reduction in GFP positive cells of 
57%.  There is evidence that some KIR channels may be internalised with vesicles that 
enter the endocytic network, however whether these channels have functionality 
during endosomal acidification remains unknown (Zylbergold et al., 2010). 
The mechanism of action of Qn has not yet been identified, in part due to 
promiscuous inhibition of K+ channels and no clearly defined target family.  The 
unrestrained inhibitory effects of Qn are further exemplified by its use as an anti-
malarial drug which is believed to be toxic to the pathogen through effects upon the 
parasite’s ability to metabolise haemoglobin.  However, in relation to MCPyV, results 


















TRP channels are typically localised at the plasma membrane, however there are also 
examples of channels that are present in endosomal membranes.  Treatment of cells 
with 50 µM RR, a broad spectrum TRP channel inhibitor, had no detrimental effect 
upon MCPyV transduction, suggesting this channel family was not important during 
initial entry events. 
To confirm that K+ channel inhibitors were not directly affecting penetration, cells 
were treated with 10 mM TEA before transduction using EdU-labelled PsVs (Figure 
4.11A).  Results showed that MCPyV PsV were still able to penetrate into the cell, as 
seen by puncta forming around nuclei and that at least for TEA, drug treatment did 
not affect penetration.  Drugs that had an inhibitory effect upon MCPyV transduction 
were also tested to confirm that GFP expression was not perturbed (Figure 4.11B).  
Treatment with 10 mM TEA, 1 mM 4AP and 50 mM KCl led to a non-significant 
reduction of 17%, 4% and 2% in comparison to an untreated control, respectively.  
Whilst a decrease of 17% for TEA treatment was greater than desired, this was 
Figure 4.10: Effect of K+ ion channel inhibitors upon MCPyV 
transduction.  293TT cells were pre-treated with drugs for 1 hour prior 
to a 2-hour incubation with MCPyV GFP PsVs in the presence of drug.  
Fresh medium was then added before incubation and visualisation of 
GFP-positive cells after 72 hours using an Incucyte ZOOM instrument.  
Predetermined analysis parameters were used to identify the number 





















































































believed to be a product of a repeat that had a lower confluence in comparison to 
untreated cells and this subsequently skewed the data (not shown).  Effects of 1 mM 
BaCl2 upon GFP expression was not determined due to lack of reagent availability.  
Due to time restrictions it was not possible to perform further experimentation to 






















Figure 4.11: K+ channel inhibitors do not affect penetration or 
expression of GFP.  (A) 293TT cells were transduced with EdU-labelled 
MCPyV PsVs with fixation after a 48-hour incubation.  Cells were 
permeabilised before a click reaction was performed to label PsVs with 
Alexa Fluor 488.  Cells were visualised using a ZEISS LSM880 upright 
confocal microscope and DAPI staining was used to identify nuclei.  
Scale bar 20 µm.  (B) 293TT cells were incubated with GFP containing 
transfection complexes for 6 hours.  Fresh growth medium containing 
drug was then added for a further 18 hours before evaluation of GFP-
positive cells using an Incucyte using predetermined analysis 
parameters. 


































































4.10 Effects of broad-spectrum ion channel inhibitors upon early events 
during SV40 infection 
 To investigate whether ion channel inhibitor effects were conserved between 
different polyomavirus species, drugs were incubated with Vero cells during infection 
with SV40 (Figure 4.12).  Results showed that similar to MCPyV, 50 µM procainamide 
had no inhibitory effect.  10 mM TEA also had no inhibitory effect which was in 
contrast to data obtained for MCPyV and suggested that K+ channel activity may not 
be required during entry events for all polyomaviruses.  Interestingly, treatment with 
10 µM verapamil led to a 57% reduction in the number of LT-positive cells and 
therefore suggested that Ca2+ channel activity may represent a conserved 
requirement for polyomaviruses given that the same observation was made in 
relation to MCPyV.  Due to reagent availability, NPPB, which had no inhibitory effect 















Figure 4.12: Effect of broad-spectrum ion channel inhibitors upon 
early events during SV40 infection.  Vero cells were pre-treated with 
drugs for 1 hour prior to a 2-hour incubation with SV40 at a MOI of 1, 
in the presence of drug.  Fresh medium containing drug was then 
added before fixation following incubation for 24 hours.  Cells were 
permeabilised and immunostained for LT, with a species-specific 
secondary antibody conjugated to Alexa Fluor 488 used for 
visualisation.  Wells were then imaged using an Incucyte ZOOM 
instrument.  Predetermined analysis parameters were used to identify 


























































4.11 K+ channel inhibition does not impede SV40 infection 
To establish whether K+ channel requirements are conserved between a wide range 
of polyomaviruses, drugs in addition to TEA were used to test whether treatment 
would perturb SV40 infection of Vero cells. 
Results showed that 10 mM TEA, 1 mM 4AP and 100 µM Qn had no inhibitory effect 
upon SV40 infection (Figure 4.13).  Results for KCl and K2SO4 were discarded due to 
significant cytotoxicity for Vero cells at comparable concentrations to those used in 
293TT cell based MCPyV experimentation.  RR and BaCl2 were not tested due to lack 
of reagent availability. 
The fact that no inhibition of SV40 was observed could have been attributed to two 
alternative hypotheses.  Firstly, it may have been that the requirement of K+ channel 
activity was unique to MCPyV or that SV40 was a member of a group of 
polyomaviruses that does not require manipulation of K+.  Alternatively, the observed 
effects may have been cell-type specific.  It may be that when using monkey cell 
lineages there are additional factors that could overcome inhibitors, which are not 
conserved with human lineages.  Unfortunately, the limited range of cells that may 
be infected using MCPyV did not include Vero cells and therefore MCPyV PsVs could 
not be used to test drug effects in this cell line.  Given that SV40 was more permissive 
to infection, it was more likely this virus could have been tested in 293TT cells.  
However, detection of T antigen following infection could not be applied to 293TT 
cells due to already expressing high amounts of both SV40 LT and ST.  Due to time 

























4.12 L-type Ca2+ channel activity is not required for MCPyV 
transduction 
Given that MCPyV and SV40 displayed conserved and comparable phenotype when 
treated with the broad spectrum Ca2+ inhibitor verapamil, it was explored whether a 
specific type of channel was required during entry.  Verapamil has been shown to 
inhibit both L- and T-type Ca2+ channels.  Available within the laboratory were Nif and 
Nit, both of which specifically inhibit L-type channels. 
Results showed that treatment with 10 µM Nif and 10 µM Nit had no effect upon the 
number of GFP positive cells in comparison to the control, which suggested that L-
type Ca2+ channels were not essential during MCPyV transduction (Figure 4.14).  
Large error bars were observed due to one repeat that had a very low number of 
positive cells for untreated, which in turn amplified errors, whilst results compared 
to DMSO remained consistently similar. 
Figure 4.13: SV40 infection does not require K+ ion channels. Vero 
cells were pre-treated with drugs for 1 hour prior to a 2-hour 
incubation with SV40 at a MOI of 1, in the presence of drug.  Fresh 
medium containing drug was then added before fixation following 
incubation for 24 hours.  Cells were permeabilised and immunostained 
for LT, with a species-specific secondary antibody conjugated to Alexa 
Fluor 488 used for visualisation.  Wells were then imaged using an 
Incucyte ZOOM instrument.  Predetermined analysis parameters were 
used to identify the number of LT cells for each sample before 































































4.13 L-type channel activity is not required for SV40 infection  
Given that MCPyV did not require L-type channels it was expected that SV40 would 
follow the same trend since verapamil effects were similar.  Nif and Nit were used to 
determine whether SV40 infection would be perturbed by the L-type Ca2+ channel 
inhibitors. 
Comparably to MCPyV, results showed that 10 µM Nif and 10 µM Nit had no 
detrimental effect upon SV40 infection, with a reduction in LT positive cells of 8% and 
16%, respectively (Figure 4.15).  Taken together, results for MCPyV and SV40 showed 
that verapamil inhibited infection of both polyomaviruses, suggesting broad Ca2+ 
channel inhibition could potentially be detrimental to a variety, if not all, 
polyomaviruses.  However, targeting of L-type channels had little inhibitory effect. 
 
Figure 4.14: Effect of T-type Ca2+ channel inhibitors upon MCPyV 
transduction.  293TT cells were pre-treated with drugs for 1 hour prior 
to a 2-hour incubation with MCPyV GFP PsVs in the presence of drug.  
Fresh growth medium was then added before incubation and 
visualisation of GFP-positive cells after 72 hours using an Incucyte 
ZOOM instrument.  Predetermined analysis parameters were used to 
identify the number of GFP positive cells for each sample before 































































4.14 MCPyV but not SV40 infection is sensitive to T-type Ca2+ inhibitors 
Given that two L-type channel inhibitors had no effect, this suggested that T-type 
channels were possibly required for efficient polyomavirus infection.  Therefore the 
T-type specific inhibitors mibefradil and flunarizine were used in MCPyV transduction 
and SV40 infection assays.  Both inhibitors displayed dose-dependent inhibition for 
MCPyV (Figure 4.16A) but had no significant effect upon SV40 infection (Figure 
4.16B), suggesting that T-type Ca2+ activity was required for entry of MCPyV but not 
SV40.  For SV40, 10 µM flunarizine was omitted due to cytotoxicity. 
Treatment of 293TT cells with mibefradil during MCPyV transduction led to a 
reduction in GFP-positive cells of 26%, 41% and 99% at 2.5 µM, 5 µM and 10 µM, 
respectively.  Flunarizine showed increased potency at lower concentrations with a 
Figure 4.15: Effect of T-type Ca2+ channel inhibitors upon SV40 
infection.  Vero cells were pre-treated with drugs for 1 hour prior to a 
2-hour incubation with SV40 at a MOI of 1, in the presence of drug.  
Fresh medium containing drug was then added before fixation 
following incubation for 24 hours.  Cells were permeabilised and 
immunostained for LT, with a species-specific secondary antibody 
conjugated to Alexa Fluor 488 used for visualisation.  Wells were then 
imaged using an Incucyte ZOOM instrument.  Predetermined analysis 
parameters were used to identify the number of LT cells for each 



















































52% and 83% reduction in GFP positive cells when treated with 2 µM and 5 µM, 
respectively. 
Interestingly this requirement was not conserved during SV40 infection, as treatment 
with 5 µM mibefradil and 5 µM flunarizine led to a reduction in LT positive cells of 
16% and 22%, respectively.  Treatment with 10 µM mibefradil, which completely 
abolished transduction of MCPyV, led to a 16% reduction in SV40 LT positive cells, 
further confirming that SV40 did not display the same sensitivity to T-type Ca2+ 
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M ib e fr a d i l F lu n a r iz in e
A – MCPyV 
B – SV40 
Figure 4.16: T-type Ca2+ channels are required for entry of MCPyV (A) 
but not SV40 (B).  (A) 293TT cells were pre-treated with drugs for 1 
hour prior to a 2-hour incubation with MCPyV GFP PsVs in the 
presence of drug.  Fresh growth medium was then added before 
incubation and visualisation of GFP-positive cells after 72 hours using 
an Incucyte ZOOM instrument.  Predetermined analysis parameters 
were used to identify the number of GFP positive cells for each sample 
before comparison to an untreated control.  (B) Vero cells were pre-
treated with drugs for 1 hour prior to a 2-hour incubation with SV40 at 
a MOI of 1, in the presence of drug.  Fresh medium containing drug 
was then added before fixation following incubation for 24 hours.  
Cells were permeabilised and immunostained for LT, with a species-
specific secondary antibody conjugated to Alexa Fluor 488 used for 
visualisation.  Wells were then imaged using an Incucyte ZOOM 
instrument.  Predetermined analysis parameters were used to identify 







To date there are limited studies available with regards to early events in the lifecycle 
of polyomaviruses.  At the beginning of this study there had been no published data 
regarding MCPyV trafficking events, with confirmation that sequential binding of 
GAGs and sialylated glycans to permit entry, the extent of existing knowledge. 
Given that other polyomaviruses traffic through the endo/lysosomal system and 
successful infection requires an acidified environment, it was firstly confirmed that 
this was the case for MCPyV.  EdU labelled MCPyV PsVs showed discrete puncta 
within the cell which were confirmed to be within vesicles that were coated with the 
late endosomal and lysosomal associated protein LAMP2.  Furthermore, treatment 
with 10 mM NH4Cl, a drug that has been well established to deprotonate acidic 
environments within the cell, led to significant impairment of MCPyV transduction in 
a time dependent manner.  Taken together these results confirmed that MCPyV like 
other polyomaviruses were present within the endo/lysosomal network and that 
acidification was required during entry.  The requirement of acidification has also 
been independently verified by Becker et al., with their results comparably showing 
that NH4Cl perturbed MCPyV transduction. 
Whilst trafficking and acidification was not a novel discovery in relation to 
polyomaviruses, it has never been established as to how far into the endo/lysosomal 
network virions travel, with suggestions that observations of virions contained within 
lysosomes have potentially entered an environment that is too acidic for viable 
infection and merely represents an artefact with detection of virions that have 
missed a proposed window of opportunity for release from endosomes.  EGA, a drug 
that leads to clustering of acidified lysosomes and in turn prevents cargo release, was 
therefore utilised during transduction and infection assays for MCPyV and SV40, 
respectively.  Results showed that treatment with EGA severely perturbed both 
viruses, and that for SV40 it was more effective than NH4Cl at the tested 
concentrations (78% vs 54%).  This suggested that prior to ER fusion, SV40 virions 
enter lysosomes that are of a low pH and do not exit the endo/lysosomal network at 




Acidification of endo/lysosomes requires the flux of ions in order to translocate H+ 
ions across the membrane.  This is achieved through the activity of ion channels, 
which whilst the field is still in its infancy, has been well characterised to require 
imbalances in several ions including K+, Ca2+, Na+ and Cl-.  Following the use of broad-
spectrum inhibitors against each of the aforementioned ion channels, results showed 
that treatment with TEA (K+ channel inhibitor) was detrimental to MCPyV 
transduction and that treatment with verapamil (Ca2+ channel inhibitor) led to 
restriction of both MCPyV and SV40 infection. 
In relation to MCPyV and K+ channels, results showed that when a larger screen was 
performed KCl, 4AP and BaCl2 all had inhibitory effects.  Interestingly, inclusive of 
TEA, all four drugs led to comparable reduction and whilst this may be coincidental, 
there was also the possibility that targeting of the same inhibitory event may have 
occurred.  TEA and 4AP both are primarily associated with the blockage of KV 
channels, whereas BaCl2 is an inhibitor of KIR channels.  Despite BaCl2 deemed specific 
for KIR channels, there were conflicting reports that suggested that outside of M 
range the drug could also inhibit some KV channels.  Given that BaCl2 was used at 1 
mM there was therefore the potential that alongside TEA and 4AP, inhibition of 
MCPyV transduction by BaCl2 was through blockage of KV channels.  To definitively 
confirm whether KIR channel activity was required, assays that introduce caesium 
ions (Cs+), another inhibitor of KIR channels would be required. 
The inhibition of MCPyV transduction associated with KCl treatment was less 
obvious.  Results suggested that K+ ion addition alone was not enough to cause 
inhibition, as treatment with 50 mM KCl would introduce an equivalent amount of K+ 
ions as 25 mM K2SO4 which had no inhibitory effect.  Therefore, this potentially 
suggested that Cl- ions were solely responsible or required in addition to K+ in order 
to perturb transduction.  It was also plausible that treatment with 50 mM KCl 
disrupted ionic balances that were detrimental to an alternative viral requirement, 
as altering the overall concentration of K+ and Cl- ions would likely have 
consequences upon a larger range of ions and in turn pathways. 
In contrast to MCPyV transduction assays, treatment of Vero cells during SV40 




cells.  This suggested that K+ channels were either only required for MCPyV 
transduction or that it was a requirement for polyomavirus infection of human cell 
lines.  In order to determine whether this was cell line specific, SV40 could be used 
to infect human cell lines.  Given that 293TT cells stably express high amount of SV40 
LT and ST it was not possible to use this cell line.  Had more time been available, 
alternative assays to detect SV40 infection could have been performed to further 
identify whether this was cell line specific.  Infection of HEK293 cells, that were not 
additionally transformed using SV40 T antigens were a viable option, as would have 
been moving into Renal Proximal Tubular Epithelial Cells (RPTECs).  RPTECs are a 
primary human renal cell line that has been identified as the natural host cell 
reservoir during persistent human infection of BKPyV and is also permissive to SV40 
infection.  Alongside SV40 infection, BKPyV could have also been used to determine 
whether different human polyomaviruses are also sensitive to K+ channel inhibition 
or whether observations were MCPyV specific. 
Results showed that both MCPyV and SV40 were inhibited by treatment with 
verapamil, a clinically available L- and T-type Ca2+ inhibitor.  Further screening 
showed that for both viruses the L-type inhibitors Nif and Nit had no inhibitory effect.  
This therefore suggested that T-type Ca2+channel activity may be of importance to 
polyomavirus infection.   Preliminary data suggested that this was the case for MCPyV 
but not SV40, with mibefradil and flunarizine treatment abolishing the ability of 
MCPyV to successfully enter the cell. 
There was also the potential that effects observed following verapamil treatment, 
beyond T-type inhibition for MCPyV, could follow a similar mechanism of inhibition 
that has been shown for Ebola, whereby verapamil was shown to prevent TPC-
mediated fusion of endosomes to the ER.  SV40 has been shown to traffic through 
the ER on route to the nucleus.  It is therefore plausible that polyomaviruses may 
employ a similar mechanism.  If this is the case, or other polyomaviruses require T-
type Ca2+ channel activity similarly to MCPyV, there is the potential that repurposing 
of clinically available drugs may represent a valid option in the therapeutic 
intervention of a range of polyomavirus-induced diseases, including BKPyV-mediated 














Chapter 5  
p38 MAPK drives ST-mediated cellular 






MCPyV is known to be the causative agent in the majority of MCC cases (Feng et al., 
2008).  Clonal integration and mutation of the viral genome leads to truncation of LT 
resulting in a non-replicative virus.  Full length LT is responsible for driving 
progression of later stages of the replicative cycle, such as genome replication and 
capsid protein production (Decaprio and Garcea, 2013).  This is implemented by the 
formation of two opposed LT hexameric complexes which form a helicase, opening 
the viral genome for replication, providing RNA polymerase access to the late coding 
promoter and suppressing early gene expression.  It is therefore unsurprising that in 
all studied cases of MCPyV-positive MCC, there is a loss of the helicase domain, which 
lies downstream of early stop codon mutations (Shuda et al., 2008).  However, LT 
truncated forms arising in MCC always retain the ability to bind pRb.  Despite the 
requirement for LT to bind pRb and the loss of the helicase domain in the progression 
of disease, ST has been implicated as the major oncogene.  This is reinforced by 
depletion studies, where loss of ST expression leads to growth arrest in MCC cell lines 
(Shuda et al., 2014). 
A hallmark of cancer is the ability to metastasise, and the highly migratory 
phenotypes associated with MCCs contributes in part to the aggressive nature of 
disease (Nieto et al., 2016).  Metastasis is a complex multistep process and it has 
been well characterised that the MCPyV oncogene ST manipulates the host cell to 
enhance migratory phenotypes.  In order for a cell to migrate, an essential step is the 
disruption of cell to cell junctions and breakdown of the surrounding extracellular 
matrix to enhance cellular dissociation (Knights et al., 2012).  MCPyV ST induces the 
expression of A disintegrin and metalloproteinase (ADAM) proteins 10 and 17, which 
when inhibited ablate ST-mediated dissociation and motility (Nwogu et al., 2018).  
Differential expression of several proteins required for cytoskeletal rearrangements 
and microtubule destabilisation is also facilitated by ST (Knight et al., 2015).  In 
particular, the microtubule-associated protein stathmin was highlighted as a key 
regulator in promoting motility and migration.  Furthermore, ST has been identified 
to induce actin cytoskeleton rearrangements to enhance filopodia formation via the 




Impairment of MCPyV induced manipulation of both microtubule and actin 
cytoskeletons has been attributed to the protein phosphatase PP4, in particular the 
interaction of ST with its catalytic subunit, PP4C.  By inhibiting the activity of PP4C or 
prevention of ST binding, ST-induced migratory phenotypes can be severely 
hindered.  Given that PP4 is a phosphatase, it is not surprising that the ST interaction 
causes alteration in the phosphorylation status of proteins.  Whilst ST mutants that 
lack the ability to bind to PP2A A or PP4C could both induce overexpression of 
stathmin, results showed that dephosphorylation of stathmin and subsequent 
deacetylation and destabilisation of tubulin required an interaction with PP4C.  
Similarly, the activation – through phosphorylation – of Rho-GTPases was shown to 
be dependent upon ST-mediated manipulation of PP4C. 
Despite the knowledge that signalling cascades are likely to be important in the 
phosphorylation and subsequent alteration of protein activities following ST 
expression, there has been little investigation into how this occurs.  This chapter 
describes an investigation into kinase pathways that are dysregulated by expression 
of MCPyV ST and subsequent evaluation to confirm that the p38 MAPK pathway is 
an essential mechanism required to promote the metastatic phenotypes 
synonymous with MCC. 
5.2 Screening the phosphorylation status of MAPKs following MCPyV 
ST expression 
In order to identify kinases that displayed altered phosphorylation status in the 
presence of MCPyV ST, a kinase immunoblot array assay was performed.  HEK293 
cells were transfected with GFP or ST-GFP and incubated for 24 hours.  A 22-hour 
serum depletion was performed before a 2-hour boost with 10% (v/v) serum and 
subsequent lysis using a kit specific buffer.  Lysed samples were standardised by BCA 
assay before incubation with membranes presenting immobilised phosphorylated 
MAPK proteins.  Following washes, the amount of phosphorylated protein was 
determined by chemiluminescent detection and densitometry.  A series of exposure 
times were taken so that each dot could be visualised whilst saturation was avoided, 




determined relative to mock and duplicates were averaged (Figure 5.1B).  Results 
showed that most kinases displayed little to no increase in the amount of signal 
detected. 
SV40 ST has previously been shown to bind to and inhibit PP2A, suppressing 
dephosphorylation of Akt which contributes to cellular transformation.  In contrast, 
MCPyV ST does not activate Akt and it has further been shown that shRNA-mediated 
depletion of ST in the MCPyV-positive MCC cell line MKL-1 led to increased Akt 
phosphorylation and activation (Shuda et al., 2011).  In the case of MCPyV ST, the 
loss of Akt activation is overcome by preventing hyperphosphorylated 4E-BP1 
turnover, which contributes to cellular transformation by promoting cap-dependent 
protein translation.  Similarly, the kinase screen suggested that no isoform of Akt 
showed substantially increased hyperphosphorylation following ST expression 
(Figure 5.1B).   
The screen suggested that JNK2 displayed the largest increase in phosphorylation, 
whilst JNK1 and JNK3 remained unaffected.  This was further supported by 
observation that a pan-JNK antibody also displayed increased phosphorylation and 
therefore implied that JNK2 could be activated by ST. 
The p38 MAPK family also displayed increased phosphorylation of isoforms  and , 
whilst  and  showed some but relatively lower levels of increase.  This was 
somewhat unexpected, as what could be seen by eye suggested that all four isoforms 
highlighted in Figure 5.1A showed increased phosphorylation following ST 
expression.  p38 is the most highly and ubiquitously expressed isoform of p38 
throughout all human cells and results showed that the signal produced was 
significantly higher than the other isoforms in the array.  Whilst variation in detection 
may be attributed to antibody binding kinetics, there was also the potential that high 
basal activation may have prevented the determination of differential 
































Figure 5.1: Evaluation of MAPK phosphorylation following the 
expression of MCPyV ST.  HEK293 cells were transfected with GFP or 
ST-GFP and incubated for 22-hours in serum-free medium before a 2-
hour serum addition.  Lysis was performed using kinase array lysis 
buffer.  BCA assays were performed to standardise protein 
concentrations before the kinase array assay was performed as per 
manufacturer specifications with detection using chemiluminescence 
detection and light sensitive film. (A) Short and long chemiluminescent 
exposures of ST-GFP and GFP (control) membranes.  Red box highlights 
p38 MAPK isoforms. (B) Analysis of detection by densitometry of each 
kinase in ST-GFP expressing cells compared with GFP control.  
Highlighted in red are the four p38 isoforms and in blue JNK2 and JNK 





























































































































































5.3 MCPyV ST expression leads to p38 hyperphosphorylation 
Based upon initial kinase array data, it was investigated whether expression of ST led 
to p38 phosphorylation.  HEK293 cells were transfected with empty vector or ST 
before lysis after 48-hours.  Western blotting was then performed to determine the 
phosphorylation status of MAPKs. 
Results showed that p38 was hyperphosphorylated in the presence of ST (Figure 5.2).  
Given that increased phosphorylation was observed, total p38 expression was also 
evaluated.  Given that there was no change in the total amount of p38, this confirmed 
that ST expression induced hyperphosphorylation of p38 and that this was not an 
artefact of differential protein expression.  Phosphorylation of ERK was also 
evaluated and Results showed that consistent with the kinase array data (Figure 5.1) 
there was no change in ERK phosphorylation status, which suggested that the 















Figure 5.2: Expression of MCPyV ST induces hyperphosphorylation of 
p38.  HEK293 cells were transfected with empty vector or ST with lysis 
using Leeds lysis buffer performed following a 48-hour incubation.  
Antibodies were used to detect phosphorylated ERK1/2 and p38 that 
corresponded to activated protein.  p38 and GAPDH antibodies were 









5.4 MCPyV ST induced p38 phosphorylation is due to activation 
A current issue facing pharmaceutical production of therapeutics targeting p38 are 
negative feedback loops which activate upstream kinases in response to inhibition.  
Therefore, increased phosphorylation of p38 was not necessarily due to activation 
and could have instead been attributed to inhibition of the pathway.  To determine 
whether p38 was activated, the phosphorylation status of downstream substrates 
was investigated. 
To determine whether expression of ST induced p38 pathway activation, Western 
blotting was performed to detect three substrates of p38.  MSK1 is a kinase 
downstream of p38 and ERK pathways that is responsible for further phosphorylation 
and activation of a range of transcription factors and may post-translationally modify 
histones and related proteins.  ATF2 is a transcription factor that is activated by p38 
and/or JNK, which is a member of the ATF/CREB family of leucine zipper proteins and 
primarily binds to both AP-1 and CRE DNA response elements.  MK2 is a kinase that 
is solely activated by p38 and is responsible for a range of activities relating to TNF 
biosynthesis, cytokine-induced mRNA stability and polymerisation of actin, the latter 
of which is mediated by phosphorylation and activation of HSP27. 
Results showed that MK2, MSK1 and ATF2 all displayed increased phosphorylation 
following ST expression (Figure 5.3).  This suggested that ST activated p38 and 
























5.5 Inhibition of p38 ablates downstream target phosphorylation 
To evaluate whether inhibition of p38 was sufficient to ablate ST-induced pathway 
activation, chemical inhibitors were utilised.  Whilst the previously described kinase 
screen suggested that p38 isoforms  and  were the most upregulated, 
phosphorylation of MK2 is attributed solely to p38 activity.  Despite the screen 
suggesting that p38 was not activated, the phosphorylation of MK2 and significant 
increase in pan-p38 phosphorylation most likely suggested that p38 was also 
activated.  SB202190 is a potent, selective inhibitor of p38 isoforms  and .    
SB202474, a structural analogue of SB202190 that has no inhibitory effect, was also 
used as a negative control.  Before use, viability assays were performed to evaluate 
the toxicity of both compounds.  The literature suggested that 10 M SB202190 was 
sufficient to inhibit p38  and  and both drugs were not toxic at this concentration 
(Figure 5.4) (Hirasawa et al., 2003; Schwartz et al., 2018).  In both cases results 
showed that viability appeared to be increased following drug treatment compared 
to an untreated control, particularly at concentrations of 5 M and 10 M.  The 
Figure 5.3: MCPyV ST leads to phosphorylation of p38 substrates.  
HEK293 cells were transfected with empty vector or ST with lysis using 
Leeds lysis buffer performed following a 48-hour incubation.  
Antibodies were used to detect phosphorylated MK2, MSK1 and ATF2 
that corresponded to activated protein.  GAPDH was used as a loading 









concentrations used for the MTS assay confirmed that SB202190 and SB202474 were 
not toxic up to concentrations of 25 M and 50 M, respectively, which were both 
higher than the intended 10 M to be used. 
Given that the inhibitors did not have a detrimental effect upon cellular viability, 
HEK293 cells expressing ST were treated with SB202190 and SB202474 for 24 hours 
before lysis.  Visualisation of MK2 phosphorylation showed that DMSO and 10 M 
SB202474 negative controls had no influence upon phosphorylation of MK2 following 
ST expression (Figure 5.5).  However, treatment with 10 M SB202190, the p38 
inhibitor, completely ablated MK2 phosphorylation.  This therefore suggested that 














































Figure 5.4: MTS viability assays to determine p38 compound toxicity 
in HEK293 cells.  To determine whether SB202190 (A) or SB202474 (B) 
displayed cytotoxicity MTS assays were performed.  5x104 HEK293 
cells were seeded into wells of a 96-well plate.  Following overnight 
incubation to allow cells to adhere 100 L fresh growth medium 
containing a range of drug concentrations were applied to wells.  
Following a further 48-hour incubation 20 L of MTS reagent was 
added to each well.  Following a 1-hour incubation absorbance at 490 
nm was determined using an automatic plate reader.  Wells containing 
medium only were used to subtract background absorbance before 
comparison of each concentration to an untreated equivalent.  Each 
























































































5.6 ERK activity does not affect ST induced MSK1 activation 
MK2 is phosphorylated only by p38, however other downstream targets, such as 
MSK1, may be activated by multiple kinases.  It was therefore investigated whether 
MSK1 was solely activated by p38 or whether ERK could compensate for the 
inhibition. 
Unlike p38 which may be targeted by MKK3/6 and MKK4, ERK1/2 are solely activated 
by MEK1/2, therefore the MEK1/2 inhibitor U0126 was used alongside the p38 
inhibitor SB202190. To confirm that U0126 had no cytotoxic effects MTS assays were 
performed.  Results indicated that at the working concentration of 20 µM, U0126 







Figure 5.5: p38 activity is essential for ST induced MAPK pathway 
activation.  HEK293 cells were transfected with empty vector or ST for 
6 hours before aspiration of transfection complexes and replacement 
with fresh growth medium containing drug as described.  Following a 
48-hour incubation lysis using Leeds lysis buffer performed.  An 
antibody was used to detect phosphorylated MK2, which 
corresponded to activated protein.  GAPDH was used as a loading 



















As previously described, inhibitors were added for the final 24 hours before lysis and 
Western blotting performed for MSK1 and MK2 phosphorylation (Figure 5.7).  
Treatment with the p38 inhibitor SB202190 led to a loss of MK2 phosphorylation as 
previously noted at 10 M.  As would be expected, given that MK2 is not a substrate 
of ERK, no decrease in phosphorylation was observed when cells were treated with 
20 M U0126.  Results showed that MSK1 retained some phosphorylation when cells 
were treated with 20 M U0126, whilst no signal was detected in the presence of 10 































Figure 5.6: MTS viability assays to determine U0126 compound 
toxicity in HEK293 cells.  To determine whether U0126 displayed 
cytotoxicity MTS assays were performed.  5x104 HEK293 cells were 
seeded into wells of a 96-well plate.  Following overnight incubation 
to allow cells to adhere 100 L fresh growth medium containing a 
range of drug concentrations were applied to wells.  Following a 
further 48-hour incubation 20 L of MTS reagent was added to each 
well.  Following a 1-hour incubation absorbance at 490 nm was 
determined using an automatic plate reader.  Wells containing 
medium only were used to subtract background absorbance before 


















5.7 p38 inhibition abrogates ST-induced cellular motility 
MCPyV ST manipulates the cellular cytoskeleton to enhance migration and motility.  
Research previously published by our laboratory showed that manipulation of 
cellular protein phosphorylation was essential for both microtubule destabilisation 
and actin polymerisation which led to enhanced filopodia formation.  In both 
instances ST interaction with cellular protein phosphatases was required, however a 
mechanistic link between phosphatases and phenotypic alterations was never fully 
elucidated.  It was therefore investigated whether p38 activity was important for 
cellular motility by performing a scratch assay utilising a monoclonal HEK293 FlpIn 
cell line with tetracycline-inducible ST expression.  Scratches were performed 24-
hours after ST-expression was induced by treatment with 2 g/mL doxycycline 





Figure 5.7: Inhibition of ERK activity does not affect MAPK substrate 
phosphorylation.  HEK293 cells were transfected with empty vector or 
ST for 6 hours before aspiration of transfection complexes and 
replacement with fresh growth medium containing drug as described.  
Following a 48-hour incubation lysis using Leeds lysis buffer 
performed.  Antibodies were used to detect phosphorylated MK2 and 
MSK1 that corresponded to activated protein.  GAPDH was used as a 




before scratching was performed and maintained for the duration of the time course.  
Images were taken 1- and 48-hours post-scratch to determine wound closure. 
Results were similar to previous publications, with induction of ST expression 
significantly increasing the speed at which the wound closed (Figure 5.8A).  Through 
comparison of the initial scratch (dashed blue line) with the distance closed (dashed 
red line), results showed that the induced sample was almost fully closed, whilst the 
uninduced cells displayed much less wound closure suggesting that ST promoted 
cellular motility.  Interestingly, treatment with 10 M SB202190 led to a reduction in 
the rate of wound closure that was comparable with uninduced cells. 
Measurements of the width of each scratch were performed for each image to 
determine the speed at which wounds closed.  Given that across all scratches there 
was not complete closure this was calculated as m/hour.  Results showed that cells 
not expressing ST displayed wound closure speeds of 5 m/hour, whilst ST expressing 
cells displayed significantly increased closure of 12 m/hour (Figure 5.8B).  
Treatment with SB202190 reduced wound closure to 5 m/hour which was 
comparable with uninduced cells.  This therefore suggested that inhibition of p38 








































Figure 5.8: Scratch assay to determine the effect of p38 inhibition upon ST-induced 
cellular motility and migration.  (A) Representative images of wound closure at 1- and 
48-hours post scratch.  (B) Analysis of wound closure of three biological repeats.  ST-
inducible HEK293 cells were seeded into wells of a 12-well poly-l-lysine treated plate.  
Growth medium +/- c 2 g/mL doxycycline hyclate was added to wells and incubated 
for 24-hours to allow wells to reach 100% confluence.  Growth medium was changed to 
fresh medium containing drug for 1-hour before a scratch was performed using a 
Thermo Fisher 100 L ClipTip™.  Cells were washed once with PBS to remove dislodged 
cells before addition of fresh growth medium containing drugs as applicable.  Wells were 
then imaged 1- and 48-hours post scratch using an EVOS II FL Auto.  Wound closure 
analysis was performed using ImageJ and blue and red dashed lines are indicative of 




5.8 p38 inhibition restricts migration of MCPyV-positive MCC 
Given that results suggested that p38 inhibition prevented ST-induced cellular 
motility, it was investigated whether the same restriction would be observed in 
MCPyV-positive MCC cell lines. 
The MCPyV-positive PeTa and WaGa cell lines were available within the laboratory.  
The effects of p38 inhibition upon the cell lines was determined by MTS assay (Figure 
5.9).  Results indicated that SB202190 and SB202474 had little effect upon cellular 
viability, suggesting that the drugs were not cytotoxic or displayed any effects upon 















Given that the available cell lines grew in suspension, it was not possible to perform 
scratch/wound healing assays.  As an alternative, a transwell migration assay was 
performed using PeTa cells.  Cells were incubated in reduced serum growth medium 
(containing 0.5% (v/v) FBS) and inhibitors where applicable for 24 hours.  Cells were 
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Figure 5.9: MTS assays to determine whether p38 inhibitors display 
cytotoxicity or affect proliferation of MCPyV-positive MCC cell lines 
PeTa (A) and WaGa (B).   2x105 PeTa and WaGa cells were plated in 
wells of a 96-well plates containing 1 or 10 M of SB202190 or 
SB202474.  Following a 48-hour incubation 20 L of MTS reagent was 
added to the wells before a further 1-hour incubation. Absorbance at 
490 nm was determined using an automatic plate reader.  Wells 
containing medium only were used to subtract background 
absorbance before comparison of each concentration to an untreated 






transferred to the upper chamber of the transwell, with serum enriched growth 
medium (containing 20% (v/v) FBS) added into the lower chamber as a 
chemoattractant.  Following a further 48-hour incubation the number of cells in the 
upper and lower chambers were counted and the percentage of cells migrated in 
each condition calculated, with untreated cells assumed to represent unrestricted 
migration (Figure 5.10).  Results showed that the DMSO control and treatment with 
10 M SB202474 displayed no significant decrease in the number of migrated cells.  
In contrast, treatment with 10 M SB202190 led to a significant loss of migration, 
with a 62% reduction in the number of migratory cells compared to untreated.  This 
confirmed that p38 activity was essential to promote migratory phenotypes 
associated with MCC and that inhibition of p38 was sufficient to restrict the migration 

































































Figure 5.10: Effect of p38 inhibition upon the migration of MCPyV-
positive MCC PeTa cells.  1x106 PeTa cells were seeded in serum 
depleted medium (containing 0.5% (v/v) FBS) containing drug if 
applicable in wells of a 12-well plate.  Following a 24-hour incubation 
300 L of serum depleted medium containing cells was added to the 
top chamber of a transwell.  Serum enriched medium (containing 20% 
(v/v) FBS) was added to the bottom chamber before an incubation for 
48-hours to allow cells to migrate.  Medium was taken from both the 
top and bottom chambers and cell counts performed using a Countess 
II FL Automated cell counter.  The percentage of migrated cells for each 




5.9 ST-mediated p38 activation is via MKK4 signalling not canonical 
MKK3/6 
Activation of the MAPKs typically follow well characterised cascades in response to 
stress stimuli.  In the case of p38, activation is typically initiated by the MAP2Ks, 
MKK3 and MKK6.  The kinase screen previously performed in Figure 5.1 suggested 
that there was potentially upregulation of MKK3/6 phosphorylation. 
To elucidate whether upstream kinases are activated or whether ST directly targets 
p38, ST was expressed in cells before Western blotting for phosphorylated MKK3/6.  
Results showed that following expression of ST, the phosphorylation status of 
MKK3/6 remained unchanged (Figure 5.11).  
Whilst this result was surprising, given that MKK3/6 is attributed to p38 activation in 
most cases, a more debatable and alternative mechanism of activation relies upon 
phosphorylation of MKK4.  Results showed that MKK4 showed significantly increased 
phosphorylation compared to mock transfected cells (Figure 5.11).  This therefore 
suggested that ST-induced activation was via the non-canonical MKK4 cascade, 
potentially independently of MKK3/6.  Observed differences in ST-induced MKK3/6 
phosphorylation for the kinase screen were believed to be due to amplification of 











Figure 5.11: ST-mediated activation of p38 is via MKK4 signalling, 
independent of MKK3/6. HEK293 cells were transfected with empty 
vector or ST before a 48-hour incubation.  Lysis using Leeds lysis buffer 
was performed.  Antibodies were used to detect phosphorylated 
MKK4 and MKK3/6 that corresponded to activated protein.  GAPDH 








5.10 Activation of p38 is independent of extracellular stimuli 
Activation of MAPKs is associated with extracellular stress stimuli.  Due to the fact 
that ST activated the p38 pathway via a non-canonical MKK4 mechanism, it was 
investigated whether extracellular stimuli were required, or if activation was due to 
manipulation of cascades through protein-protein interactions, independent of 
stimuli. 
HEK293 cells were transfected with ST before lysis after 48 hours.  To evaluate the 
requirement of extracellular stimuli, medium was either unchanged or changed with 
fresh serum free-medium for the final two hours before lysis.  As previously shown, 
results indicated that when the medium was not changed a small amount of basal 
MKK4 phosphorylation was observed in mock transfected cells, which was 
significantly increased upon ST expression (Figure 5.12).  Following incubation with 
serum-free medium, basal phosphorylation of MKK4 was lost in cells that were mock 
transfected.  In contrast, ST-expressing cells maintained phosphorylation of MKK4, 
which suggested that ST activated the p38 pathway independent of extracellular 
stimuli. 
To determine whether p38 was active both with and without medium change, the 
phosphorylation status of MK2 was investigated.  Results showed that in both 
conditions upregulated phosphorylation of MK2 was maintained upon ST expression.  
There was however detection of basal MK2 phosphorylation in mock transfected 
samples under both conditions.  As such, further investigation would be required to 
determine whether this activation was due to basal MKK3/6 activation or whether 
the kinetics of p38 and/or MK2 dephosphorylation would require longer incubation 























5.11 p38 cascade activation is dependent upon a ST-PP4C interaction 
Due to continued MKK4 phosphorylation independent of extracellular stimuli, 
potential mechanisms through which ST could dysregulate the p38 signalling cascade 
were explored.  ST has been shown to interact with protein phosphatases to 
manipulate the host cellular environment and due to the link between cellular 
phosphatases and protein phosphorylation, the possibility that ST interactions with 
phosphatases led to p38 dysregulation was investigated. 
ST has previously been identified to interact with several protein phosphatase 
subunits including PP2A A, PP2A A and PP4C.  ST mutants have previously been 
generated to prevent interaction with different protein phosphatase subunits, which 
are summarised in Table 5.1.  The 100-103 mutant, which cannot bind to any 
phosphatase subunit was produced through substitution to alanine at each residue.  
The R7A mutant provided loss of PP2A A binding and the R102A mutant led to loss 
Figure 5.12: ST activates the p38 cascade independent of 
extracellular stimuli.  HEK293 cells were transfected with empty 
vector or ST before a 46-hour incubation.  Cells were then washed 
twice with PBS before replacement with fresh growth medium or 
medium containing no serum for 2 hours.  Lysis using Leeds lysis buffer 
was then performed.  Antibodies were used to detect phosphorylated 
MK2 and MKK4 that corresponded to activated protein.  GAPDH was 








of PP4C binding.  The F103A mutant led to loss of PP4C and PP2A A binding and 
therefore if this mutant showed a change in phenotype whilst the R102A mutant 
retained wild-type phenotypes, this would have suggested that PP2A A interaction 




The described mutants were available within the laboratory as GFP-tagged 
constructs, which were utilised in order to determine whether protein phosphatase 
interactions were important for manipulation of the p38 cascade.  HEK293 cells were 
transfected with the ST-GFP mutants before Western blotting for phosphorylated 
MK2.  Results showed that all constructs led to a similar amount of GFP-tagged 
mutant ST protein expression, which was confirmed by detection of GFP (Figure 
5.13).  The R7A mutant retained phosphorylation relative to WT, however all other 
mutants showed phosphorylation comparable to the GFP control.  This suggested 
that PP4C was important for ST mediated p38 activation, given that all mutants that 






ST mutant Maintains interaction with Does not interact with 
R7A PP2A Aβ + PP4C PP2A Aα 
Δ100-103 None PP2A Aα, PP2A Aβ + PP4C 
R102A PP2A Aα + PP2A Aβ  PP4C 
F103A PP2A Aα PP2A Aβ + PP4C 





























Figure 5.13: MK2 phosphorylation requires the interaction of ST with 
PP4C (A) and analysis by densitometry (B).  HEK293 cells were 
transfected with GFP or an ST-GFP mutant before a 48-hour 
incubation.  Lysis using Leeds lysis buffer was performed.  An antibody 
was used to detect phosphorylated MK2, which corresponded to 
activated protein.  GAPDH was used as a loading control and GFP to 
detect the expression of ST mutants.  Densitometry was performed to 
determine MK2 phosphorylation using GAPDH as a control for 
















































5.12 ST interacts with PP4C to perturb wild-type activities 
Following identification that an interaction between ST and PP4C was essential for 
activation of the p38 pathway, the requirement of PP4C was further investigated.  In 
order to determine whether the activity of PP4C was essential, WT and trans-
dominant negative (TDN) PP4C constructs were co-transfected into HEK293 cells, in 
the presence of ST. 
Results showed that expression of a TDN PP4C had no effect upon ST-induced 
hyperphosphorylation of MK2 (Figure 5.14A).  Analysis by densitometry further 
confirmed that overexpression of the TDN PP4C had no phenotypic consequences in 
regard to MK2 phosphorylation, with results consistent to that of cells transfected 
with ST only (Figure 5.14B).  Conversely, results indicated that co-transfection with 
WT PP4C led to reduced MK2 phosphorylation (Figure 5.14A+B).   Overexpression of 
WT PP4C likely increased the total number of protein subunits compared to the 
normal cellular environment.  Therefore, ST would be unable to bind all PP4C 
subunits to prevent the normal formation and functions of PP4, which could have a 
regulatory role upon ST-induced p38 activation.  Taken together these results 
suggested that the interaction of ST with PP4C is required to perturb regulatory 
































Previous studies within our group have identified that MCPyV ST induces phenotypic 
alterations in a range of cytoskeletal proteins to enhance cellular motility.  It has 
previously been demonstrated that the phosphorylation status of stathmin is 
manipulated by ST to promote microtubule destabilisation and ST-mediated Rho-
GTPase activities are required to induce filopodia formation. 
Despite clear evidence that phosphorylation-regulated protein activities are essential 
for ST-induced cellular motility, the mechanisms through which these phenotypes 
are brought about has not been fully elucidated.  Given the requirement of 
Figure 5.14: Dysregulation of PP4C is required for MCPyV ST induced 
hyperphosphorylation of MK2 (A) and analysis by densitometry (B).  
HEK293 cells were co-transfected with empty vector or ST +/- WT/TDN 
PP4C before a 48-hour incubation.  Lysis using Leeds lysis buffer was 
performed.  An antibody was used to detect phosphorylated MK2, 
which corresponded to activated protein.  Flag and HA antibodies 
were used to detect WT and TDN PP4C, respectively.  GAPDH and MK2 
were used as a loading control and 2T2 hybridoma to detect ST.  
Densitometry was performed to determine MK2 phosphorylation 


























































phosphorylation, coupled with the implication of protein phosphatase interactions 
in both studies, a kinase screen was performed to identify pathways that showed 
differential phosphorylation following ST expression.  Results suggested that JNK2 
and p38 isoforms displayed increased phosphorylation, which are members of the 
MAPK family.  In this study a focus was placed upon the p38 pathway and ST-induced 
activation was confirmed using antibodies targeting p38 and activated downstream 
markers MK2, MSK1 and ATF2.  Through the use of chemical inhibitors, it was further 
confirmed that MK2 and MSK1 were specifically phosphorylated by p38. 
Scratch assays using ST-inducible HEK293 cells confirmed that p38 activity was 
required for ST-induced cellular motility.  This was further confirmed using the 
MCPyV-positive MCC cell line PeTa in transwell assays, which again showed that p38 
inhibition significantly restricted the migratory potential of cells. 
Interestingly, results suggested that canonical MKK3/6 activation was not observed 
and that instead the lesser studied MKK4 potentially led to pathway activation.  
Results further indicated that p38 activation was independent of extracellular 
stimuli, as serum depletion did not prevent pathway activation.  This suggested that 
ST-induced pathway activation was potentially mediated through pathway 
disruption within the cell. 
ST has been well characterised to interact with and manipulate a range of protein 
phosphatases, therefore a panel of protein phosphatase binding mutants were 
utilised.  Results suggested that interaction with PP4C was essential for p38 pathway 
activation and that PP2A A and PP2A A interactions were dispensable.  This was 
further confirmed using PP4C mutants, which showed that overexpression of WT 
PP4C reduced the ability of ST to phosphorylate MK2, whilst overexpression of a TDN 
PP4C has no consequences towards activation. 
This study, in support of previously published data, has further highlighted that 
interaction of ST with PP4C is essential for enhancement of motility and migratory 
phenotypes that are associated with MCPyV-positive MCC.  Here, a novel 
requirement of p38 pathway activity has been implicated in motility and 




Given that p38 phosphorylation can be directly linked to microtubule destabilisation 
via Tau mediated stathmin dephosphorylation, actin polymerisation through HSP27 
phosphorylation, and vimentin stabilisation mediated by MK2 phosphorylation, 
there is the potential that p38 could represent a master regulator of ST-induced 
motility and migration. 
Despite intense pharmaceutical interest in p38 as a therapeutic target, due to 
negative feedback and subsequent alternate pathway activation there are currently 
no suitable drugs that may be used for therapeutic intervention.  Whilst there is still 
the potential that drugs may be developed in the future that specifically inhibit p38, 
given the currently low number of MCC cases in comparison to other diseases 
repurposing of available therapeutics may represent the most economic method of 
treatment.  To this extent, complete mapping of how ST activates the p38 pathway 
may yield new proteins that could be targeted to restrict MCPyV-positive MCC. 
In this study it was identified that ST-mediated activation is independent of 
extracellular stimuli and MKK3/6, which is not representative of classical p38 
pathway activation.  The identification of PP4C interaction as an essential mediator 
further highlights that ST manipulation is via intracellular mechanisms. 
Previous data has recognised that ST interaction with PP4C is required for activation 
of the Rho-GTPases cdc42 and RhoA, which in turn induce filopodia formation and 
cell motility (Stakaitytė et al., 2017).  Cdc42 and RhoA are typically associated with 
activation of MAPKs in response to TNF to promote inflammatory responses via 
MKK4 activation of p38 and JNK.  Whilst TNF has been demonstrated to inhibit viral 
replication, there are several examples of viruses hijacking the response to enhance 
their lifecycles, such as during infection with BKPyV (Ribeiro et al., 2016).  In the case 
of MCPyV it has previously been demonstrated that the LXCXE domain of LT can 
enhance expression of genes relating to cell cycle, DNA replication and cellular 
movement (Richards et al., 2015).  The study reported that expression of several 
genes was enhanced when ST was co-expressed.  Therefore ST-mediated activation 
of cdc42 and RhoA may increase gene expression or stabilise mRNAs through MAPK 




Perturbing Rho-GTPase activity may therefore represent a potential target for 
inhibitors to prevent ST-mediated activation of p38 and ultimately restrict several 
metastatic phenotypes.  Activity of cdc42 and RhoA depend upon (p21-activated 
kinases) PAKs to act as a scaffold and unpublished data from the laboratory 
demonstrated that siRNA mediated knock-out of PAK1 and PAK2 severely restricted 
migration and dissociation of ST-inducible cells.  Disrupting PAK interaction with Rho-
GTPases may possibly provide a novel approach in limiting MCPyV-positive MCC 
metastasis, however further investigation is currently required to link Rho-GTPases 
with p38 activation. 
This study provides evidence that ST interaction with PP4C mediates p38 activation 
and by understanding the mechanisms, this may yield new potential targets in order 






















The Polyomaviridae represents a diverse family of viruses that infect a wide range of 
mammals, birds and fish.  Polyomaviruses ubiquitously infect the human population, 
maintaining a persistent asymptomatic infection in an immunocompetent host.  
BKPyV and JCPyV were identified as the causative agents of disease in 
immunocompromised humans in the early 1970s, however in contrast to the 
polyoma name, human polyomaviruses for a long time were not identified as the 
cause of cancer.  This changed in 2008, when technological advances facilitated the 
identification of MCPyV as the causative agent of MCC (Feng et al., 2008). 
The progression from MCPyV infection to MCC is the culmination of a series of events 
(Shuda et al., 2008; Schrama et al., 2019).  Following expression of TAgs, UV-
mediated mutation leads to rolling circle DNA replication of genomes containing a 
premature stop codon that truncates LT, resulting in loss of C-terminal activities 
including the helicase domain.  With degradation over time of WT LT, the virus is 
unable to produce new progeny and complete its lifecycle.  Instead, the mutated 
genome becomes integrated into the host, where expression of tLT, alongside the 
oncoprotein ST, promotes transformation of the host cell and ultimately MCC. 
Despite obvious focus upon the association of MCPyV with MCC, the virus is also an 
example of a VP3-less polyomavirus.  Most polyomaviruses can express and 
incorporate two minor capsid proteins, VP2 and VP3, into the capsid (Decaprio and 
Garcea, 2013).  However, MCPyV lacks the ability to express a second minor capsid 
protein and therefore packages only one type of minor capsid protein (Schowalter 
and Buck, 2013).  This uncommon feature makes MCPyV an attractive species to 
study, as comparison with other polyomaviruses could permit the identification of 
conserved requirements and development of therapeutics that are applicable to a 
range of diseases that are caused by continuous polyomavirus infection. 
6.2 Creating systems to study polyomaviruses 
A significant challenge to studying early events in human polyomavirus infection is a 
lack of cell systems in which the polyomavirus replicates.  MCPyV is prime example, 




productive infection of human dermal fibroblasts (Liu et al., 2016).  To date there is 
little evidence of alternative cell lines that are permissive to MCPyV infection.  Host 
range however, is not likely restricted by entry events, as other cell lines have been 
shown to permit transduction of PsVs containing reporter vectors, suggesting that a 
lack of replicative ability confines host range (Schowalter and Buck, 2013). 
Due to the simplistic architecture of small non-enveloped DNA viruses, production of 
virus-like particles (VLPs) and PsVs is a plausible alternative to study polyoma and 
papillomaviruses (Pastrana et al., 2004; Buck and Thompson, 2007; Schowalter and 
Buck, 2013; Gee et al., 2013; Zhang et al., 2018; Becker et al., 2019)  Whilst a VLP, 
which is an empty viral capsid, provides a useful tool to identify structural features 
of viruses, their application in functional studies is limited, due to lack of end-point 
analysis.  An exploitable feature of polyoma and papillomaviruses is that they 
promiscuously package dsDNA.  Therefore, reporter vectors that efficiently express 
proteins such as GFP or luciferase can be packaged into the capsid to mimic infection, 
with endpoint analysis of reporter features such as fluorescence and luminescence 
to determine early lifecycle events and requirements. 
Despite protocols detailing the overall method to produce MCPyV PsVs being publicly 
available, at the start of this study there had been little investigation into early events 
in the lifecycle of MCPyV.  The dual mechanism of how MCPyV binds to and enters 
the host cell had been characterised however, beyond this, information was limited 
(Schowalter et al., 2011).  We therefore optimised the production of PsVs containing 
two different reporters.  Firstly, PsVs were produced that contained either a GFP 
reporter or a secreted luciferase reporter in which EdU was incorporated to permit 
evaluation of successful trafficking and subcellular localisation, respectively.  
Previous use of GFP PsVs has relied upon flow cytometry to quantify the number of 
GFP-positive cells, which has presented challenges leading to limited studies.  
Therefore, the development of Incucyte-based detection provided a new, rapid and 
high-throughput method to study not only MCPyV or polyomaviruses, but any 





In contrast to MCPyV, SV40 infection is highly efficient and requires no artificial 
manipulation of the host cell.  Therefore, rather than producing PsVs to provide 
comparison for any phenotypic changes seen during drug screening, infection with 
SV40 represents a more physiologically relevant system.  Analysis of SV40 infection 
had previously been performed by Western blotting or flow cytometry using 
antibodies to detect the expression of viral proteins.  Similar to systems that use 
PsVs, these methods have several limitations when factoring time and reagent 
consumption.  We therefore investigated whether a 96-well plate format could be 
coupled with Incucyte analysis to reduce the amount of reagent required and 
processing time during SV40 experimentation. 
Methods to quantify SV40 titres have seen little improvement since the optimisation 
of plaque assays in 1983 (Fendrick and Hallick, 1983).  Whilst the plaque assay 
remains a routine and robust method of quantification, assays can take several 
weeks and can lack sensitivity.  A more recent titration protocol coupled 
immunofluorescence with analysis by flow cytometry, reducing assay time to 2 days 
but increased the amount of reagents consumed (Drayman et al., 2010).  Incucyte 
detection provided a new approach to the protocol used for flow cytometry, with a 
rapid and accurate method, which had the added benefit of using little virus stock or 
reagents to determine titre.  Given that polyomaviruses have a relatively slow 
lifecycle and many do not exhibit lytic release required for plaque formation, 
quantification of other polyomavirus titres is typically performed by 
haemagglutination assay (Sinibaldi et al., 1987; Knowles et al., 1995; Hamilton et al., 
2000; Knowles and Sasnauskas, 2003).  As is found with PsVs, polyomaviruses may 
package non-viral DNA and there is a growing understanding that a significant 
proportion (approximately 30%) of virions may in fact package DNA that is not virus 
genomes (personal communications with Dr Christopher Buck).  These viruses are 
likely to impact upon the reliability of titration by haemagglutination assay.  
Detection of infected cells by Incucyte analysis therefore could offer a more accurate 





6.3 Ion channels and polyomavirus infection, novel therapeutic 
targets? 
Polyomaviruses are well established to traffic through the endo/lysosomal network 
following penetration and to require an acidified environment for initial proteolytic 
capsid rearrangements (Pelkmans et al., 2001; Querbes et al., 2006; Liebl et al., 2006; 
Jiang et al., 2009; Becker et al., 2019).  Despite knowledge that polyomaviruses 
require an acidified environment, how far the virions enter the endo/lysosomal 
network had not been established.  We therefore utilised EGA to determine whether 
virions were entering late endo/lysosomes or if there was a molecular cue to trigger 
earlier release from endosomes at a higher pH.  Results indicated that MCPyV and 
SV40 could not infect the cell following treatment with EGA, confirming that 
polyomaviruses entered into acidified endosomes.  The pH requirement for EGA 
action is currently unknown, therefore environmental acidity would have to be 
determined by another mechanism, such as using pH-sensitive dyes alongside 
infection with the viruses.  Pre-treatment of virions in buffers with a range of pH prior 
to incubation with cells exposed to NH4Cl could provide an alternative approach to 
determine pH requirements.  However, experiments of this nature using BUNV 
showed that incubating the virus in a low pH buffer alone was not sufficient to 
enhance virus infectivity, with the presence of K+ also essential (Hover et al., 2018).  
Results indicated that MCPyV required K+ channel activity, with several channel 
inhibitors leading to a reduction in GFP-positive cells.  This could provide evidence 
that a similar mechanism to BUNV is required for initial entry events, and it would be 
interesting to see whether similar treatment with low pH and high K+ could enhance 
MCPyV transduction. 
This mechanism would likely not be conserved for all polyomaviruses, since K+ 
channel inhibition showed no effect upon the infection of SV40.  While this was not 
consistent with the hypothesis of a universal requirement, there are several reasons 
that this may be the case.  Firstly, experiments using SV40 were performed using a 
monkey cell line and MCPyV used a human line, therefore the requirement of K+ 
channel activity may be specific to infection of human cells.  Given that MCPyV can 




lines may represent a better opportunity to further investigate whether effects are 
specific for host species.  Alternatively it may be that K+ channels constitute a 
requirement for infection of cells for human polyomaviruses and not simian 
polyomaviruses.  Investigation as to whether viruses including BKPyV and JCPyV 
display similar requirements for K+ channels could reveal if this is conserved or 
represents a unique condition for infection with a VP3-less polyomavirus.  BKPyV is 
also able to infect Vero cells, therefore this virus represents an ideal candidate to 
further investigate polyomavirus requirements of K+ channels (Eash et al., 2004). 
Treatment using the T- and L-type Ca2+ channel inhibitor verapamil reduced MCPyV 
transduction and SV40 infection.  Further investigation identified that L-type channel 
inhibition alone was not sufficient to inhibit infection by either virus.  Whilst data was 
preliminary, treatment with the T-type Ca2+ channel inhibitors mibefradil and 
flunarizine showed dose-dependent results, with 10 M of each compound 
abolishing MCPyV transduction.  Neither drug however reduced SV40 infection, 
suggesting that T-type channel activity, similar to K+ channels, may be cell line or 
polyomavirus species dependent and further investigation would be required to 
establish if that is the case. 
It was however intriguing that SV40 infection could be inhibited by verapamil, but 
not by T- or L-type specific inhibitors.  Whilst there was the potential that SV40 could 
activate both subfamilies of Ca2+ channel, given that polyomaviruses traffic through 
the endo/lysosomal network before fusion with the ER, it was also possible that a 
mechanism comparable to EBOV could have been inhibited.  EBOV requires the 
activity of TPC1/2 to lower Ca2+ concentration within the endosomal compartment 
to facilitate fusion with endosomes, a process that can be prevented by verapamil-
mediated NAADP signalling inhibition (Sakurai et al., 2015).  Therefore, the inhibitory 
effect of verapamil upon SV40 infection may be due to loss of TPC activity and Ca2+ 
release.  This requirement may be conserved between polyomaviruses and in the 
case of MCPyV is masked by an additional requirement of T-type channel activity.  To 
further investigate whether TPC activity is required, the NAADP-signalling inhibitor 
tetrandrine or RNAi-mediated knock out of TPCs could be used.  Given that EBOV has 




identification of comparable sensitivity to loss of TPC channel activity may reveal an 
essential check point for a wider range of viruses that traffic through the ER. 
In this study, verapamil was shown to inhibit both SV40 infection and MCPyV 
transduction and may represent a potential therapeutic for the treatment of diseases 
related to polyomavirus infection, as the drug is already in clinical use and could 
therefore be repurposed without many of the stringent tests required prior to a drug 
reaching market.  Similarly, mibefradil and flunarizine are available therapeutics and 
by identifying whether these inhibitors have an effect upon other human 
polyomaviruses, they may yield new avenues in the treatment, restriction and 
prevention of polyomavirus-associated disease. 
In a wider context, this study has identified Ca2+ channels that are important in the 
sorting of a virus whilst transiting through the endo/lysosomal network.  Whilst the 
roles of such ion channels remain elusive in the context of normal endo/lysosomal 
functions, this study highlights potential therapeutics that could be used for the 
treatment of channelopathies relating to Ca2+ channels in non-excitable cells. 
6.4 p38 MAPK drives ST-mediated cellular motility and migration 
MCC is a highly aggressive and metastatic form of skin cancer that originates from 
Merkel cells found around hair follicles and in the touch-sensitive basal layers of the 
epidermis (Morrison et al., 2009; Spurgeon and Lambert, 2013).  In a minority of 
cases, UV exposure leads to extremely high mutational burden and non-viral MCC, 
however it is more common that clonal integration of a replication-defective MCPyV 
genome drives tumorigenesis, compensating for tens of thousands of somatic 
mutations (Starrett et al., 2017).  Despite truncation of the LT. gene being an essential 
prerequisite for MCPyV-positive MCC, ST is the major oncogene.  ST alone is sufficient 
to promote anchorage- and contact-independent growth of rodent fibroblasts and 
RNAi targeting of ST leads to growth arrest of MCPyV-positive MCCs (Shuda et al., 
2011; Shuda et al., 2014). 
Previous publications from the Whitehouse laboratory have identified that ST is 
responsible for driving cellular motility, migration and invasion, with cytoskeletal 




phosphatase, PP4C.  This interaction facilitates dephosphorylation of stathmin to 
prevent acetylation as well as promoting destabilisation of microtubules and actin 
polymerisation through activation of the Rho family GTPases cdc42 and RhoA (Knight 
et al., 2015; Stakaitytė et al., 2017).  Despite evidence that signalling pathways were 
modulated to promote migratory phenotypes, there had been little study into the 
molecular mechanisms by which ST facilitates such alterations.  We therefore 
investigated whether signalling pathways were dysregulated by ST to promote 
migratory phenotypes. 
Initial screening of kinases that were differentially phosphorylated at activation-
associated residues following ST expression suggested that the level of p38 isoforms 
was upregulated.  Subsequent analysis confirmed that p38 was hyperphosphorylated 
in its activation loop and three substrates, MK2, MSK1 and ATF2, all displayed 
increased phosphorylation.  Further characterisation determined that p38 activation 
was essential for ST-induced enhanced migratory phenotypes in cells overexpressing 
ST and in MCC cell lines. 
This study provides evidence that MCPyV-induced activation of p38 MAPK signalling 
is mediated by ST interaction with PP4C which dysregulates regulatory functions of 
phosphatase targeting, or upstream of, MKK4.  This novel finding highlights how 
PP4C acts as a regulator of MAPK signalling and potentially implicates it as a target 
for modulation of diseases associated with p38 dysregulation. 
Whilst ST expression enhances migratory phenotypes, further investigation is 
required to link p38 activity with microtubule destabilisation and actin filament 
formation.  Heat shock protein 27 (HSP27) activity is directly related to the 
polymerisation of actin, accumulation of F-actin structures and promotion of cell 
migration (Mounier and Arrigo, 2002).  p38 activation of the kinase MK2, which is 
hyperphosphorylated following ST expression, can in turn phosphorylate and 
activate HSP27 leading to actin polymerisation (Larsen et al., 1997; Guay et al., 1997; 
Sébastien et al., 2004).  This may therefore represent the axis through which ST 
enhances F-actin, however a link between PP4C, RhoGTPases and p38 signalling is 




PP4C dephosphorylation of stathmin has not been shown to be a direct interaction.  
Therefore, ST may induce dephosphorylation through signalling pathways.  Tau is a 
protein that is predominantly associated with Alzheimer’s disease, however it also 
regulates microtubule stability, with hyperphosphorylation of Tau leading to 
dissociation from microtubule filaments to promote destabilisation (Kadavath et al., 
2015).  p38 activity is required for hyperphosphorylation of Tau, therefore p38 
activation by ST may also contribute to the destabilisation of microtubules in addition 
to the effects of stathmin (Maphis et al., 2016).  Unpublished data from the 
Whitehouse laboratory has also shown that, following ST expression, vimentin (a 
cytoskeletal intermediate filament protein and marker of EMT), is increased at the 
protein, but not at the RNA level (data not shown).  Vimentin is a substrate of MK2 
and therefore phosphorylation may lead to stabilisation, EMT and ultimately 
metastasis (Cheng et al., 2003; Powell et al., 2003; Wang et al., 2018). 
Whilst immunotherapy targeting the PD1/PDL1 checkpoint is showing promise in the 
treatment of MCC, given the advanced age of patients and relatively low number of 
cases, it would be naïve to believe that pharmaceutical interest in MCC would be 
economically viable and management of disease to prolong life may represent a 
more viable option.  With life expectancy increasing, incidence of such diseases is 
increasing, and it is therefore important to have a better understanding of the 
mechanisms by which viruses transform host cells and identify potential therapeutic 
targets.  This chapter described a novel mechanism whereby ST interaction with PP4C 
mediates p38 pathway activation and promotion of phenotypes that are associated 
with metastasis.  Whilst direct pharmaceutical interest in MCC is unlikely, the 
association of p38 activation with a range of diseases has led to a large body of 
investigation (Fisk et al., 2014; Xing, 2016; Patnaik et al., 2016; Scheltens et al., 2018).  
Issues with negative feedback causing unwanted side effects are a current stumbling 
block, however in the future it may be that modulation of p38 by targeting upstream 
factors can be used in clinic to restrict the metastatic potential of MCPyV-positive 





6.5 Concluding remarks 
In summary, work described in this thesis provides two approaches that identify 
potential therapeutic targets for restriction of polyomavirus infections in general and 
metastasis of MCPyV-positive MCC. 
Firstly, novel systems to study early events in the lifecycle of MCPyV and SV40 were 
described, with subsequent identification of the clinically available Ca2+ channel 
inhibitor verapamil that restricted the ability of both viruses to enter the cell.  
Furthermore, T-type Ca2+ channel and K+ channel inhibitors limited transduction of 
MCPyV.  Continued investigation will find if MCPyV requirements are conserved 
among other human polyomaviruses.  This study highlights the potential of 
repurposing clinically available drugs in the intervention and prevention of diseases 
related to polyomavirus infection. 
Secondly, the highly metastatic phenotypes associated with MCPyV-positive MCC 
and expression of ST were shown to require activity of the p38 MAPK pathway.  With 
intense pharmaceutical interest in this pathway, there is the potential that future 
identification of potent inhibitors could be used to restrict MCC metastasis and 
improve the prognosis of patients. 
Taken together, the findings presented in this thesis advance the current 
understanding of entry requirements of polyomaviruses and pathways manipulated 
by MCPyV ST to promote metastasis.  Elucidation of these events provides new 
insights into the molecular mechanisms for which polyomaviruses cause disease and 
emphasise the potential of repurposing available drugs to restrict disease and 
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